Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

A0A6G7K2L4 (A0A6G7K2L4_SARS2) Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)

Spike glycoprotein UniProtKBInterProInteractive Modelling

1273 aa; Sequence (Fasta) ; 2 identical sequences: Severe acute respiratory syndrome coronavirus 2: P0DTC2, A0A679G9E9

Available Structures

1722 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Cryo-EM structure of the SARS-CoV-2 spike protein (2-up RBD) bound to neutralizing nanobodies P86 Heteromer
P0DTC2;
14-1162
17×NAG;NAG;NAG; 30×NAG;
Assess
SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv289 Heteromer
P0DTC2;
14-1162
15×NAG;NAG; 27×NAG;
Assess
SARS-CoV-2 Omicron variant spike protein in complex with two XGv347 binding to one close state RBD … Heteromer
P0DTC2;
14-1162
15×NAG;NAG; 29×NAG;
Assess
SARS-CoV-2 Omicron variant spike in complex with Fab 9A8 (State 1) Heteromer
P0DTC2;
14-1162
NAG;NAG; 41×NAG;
Assess
Neutral Omicron Spike Trimer in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1162
16×NAG;NAG; 34×NAG;
Assess
SARS-CoV-2 Omicron variant spike protein with three XGv347 Fabs binding to three closed state RBDs Heteromer
P0DTC2;
14-1162
16×NAG;NAG; 31×NAG;
Assess
17b10 fab in complex with full-length SARS-CoV-2 Spike G614 trimer Heteromer
P0DTC2;
14-1162
24×NAG;NAG;NAG; 25×NAG;
Assess
SARS-CoV-2 Omicron variant spike in complex with Fab XGv051 Heteromer
P0DTC2;
14-1162
15×NAG;NAG; 30×NAG;
Assess
SARS-CoV-2 Omicron variant spike in complex with Fab XGv286 Heteromer
P0DTC2;
14-1162
12×NAG;NAG; 28×NAG;
Assess
SARS-CoV-2 Omicron variant spike in complex with Fab 9A8 (State 2) Heteromer
P0DTC2;
14-1162
16×NAG; 31×NAG;
Assess
SARS-CoV-2 Omicron variant spike in complex with Fab XGv264 Heteromer
P0DTC2;
14-1162
36×NAG;
Assess
SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv282 Heteromer
P0DTC2;
14-1162
16×NAG;NAG; 27×NAG;
Assess
SARS-CoV-2 Omicron variant spike protein with two XGv347 binding to two open state RBDs Heteromer
P0DTC2;
14-1162
15×NAG;NAG; 29×NAG;
Assess
SARS-CoV-2 Omicron variant spike protein in complex with Fab XGv265 Heteromer
P0DTC2;
14-1162
14×NAG;NAG; 26×NAG;
Assess
Three RBD-down state of SARS-CoV-2 D614G spike in complex with the SP1-77 neutralizing antibody Fab… Heteromer
P0DTC2;
14-1162
NAG; 24×NAG;NAG; 21×NAG;
Assess
An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5… Heteromer
P0DTC2;
14-1162
16×NAG; 12×NAG;NAG; 23×NAG;
Assess
SARS-CoV-2 Beta spike in complex with three S3H3 Fabs Heteromer
P0DTC2;
14-1161
Assess
SARS-CoV-2 Beta spike in complex with two S5D2 Fabs Heteromer
P0DTC2;
14-1161
Assess
SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2B state Heteromer
P0DTC2; Q9BYF1;
14-1161
Assess
SARS-CoV-2 Beta spike in complex with one S5D2 Fab Heteromer
P0DTC2;
14-1161
Assess
SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C3 state Heteromer
P0DTC2; Q9BYF1;
14-1161
Assess
SARS-CoV-2 Beta spike in complex with two S3H3 Fabs Heteromer
P0DTC2;
14-1161
Assess
SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C1 state Heteromer
P0DTC2; Q9BYF1;
14-1161
Assess
SARS-CoV-2 Beta spike in complex with three S5D2 Fabs Heteromer
P0DTC2;
14-1161
Assess
SARS-CoV-2 spike protein in complex with ACE2, Beta variant, C2A state Heteromer
P0DTC2; Q9BYF1;
14-1161
Assess
Camel nanobodies 7A3 and 8A2 broadly neutralize SARS-CoV-2 variants Heteromer
P0DTC2;
15-1159
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets t… Heteromer
P0DTC2;
14-1149
13×NAG;NAG; 27×NAG;
Assess
SARS-CoV-2 spike protein complexed with two nanobodies Heteromer
P0DTC2;
14-1149
NAG; 25×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets t… Heteromer
P0DTC2;
14-1149
NAG; 15×NAG;NAG; 27×NAG;
Assess
SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-S21F2 Heteromer
P0DTC2;
14-1149
NAG; 22×NAG;
Assess
SARS-CoV-2 spike protein trimer (down conformation) bound with a nanobody Heteromer
P0DTC2;
14-1149
NAG; 25×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with antibodies B1-182.1 and A19-61.1 Heteromer
P0DTC2;
14-1149
NAG; 25×NAG;
Assess
SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-13 Heteromer
P0DTC2;
14-1149
15×NAG; 29×NAG;
Assess
SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-02 Heteromer
P0DTC2;
14-1149
14×NAG;NAG; 23×NAG;
Assess
SARS-CoV-2 spike protein bound with a nanobody Heteromer
P0DTC2;
14-1149
NAG; 24×NAG;
Assess
SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 034_32 Heteromer
P0DTC2;
14-1149
12×NAG; 23×NAG;
Assess
SARS-Cov2 S protein structure in complex with neutralizing monoclonal antibody 002-S21B10 Heteromer
P0DTC2;
14-1149
NAG; 28×NAG;
Assess
Beta-43 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
P0DTC2;
13-1147
12×NAG; 29×NAG;
Assess
SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-8 Heteromer
P0DTC2;
13-1147
NAG;NAG;NAG;NAG;NAG;NAG;NAG; 32×NAG;AH2;
Assess
OMI-42 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN Heteromer
P0DTC2;
13-1147
12×NAG; 30×NAG;
Assess
OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE Heteromer
P0DTC2;
13-1147
12×NAG; 28×NAG;
Assess
SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 Heteromer
P0DTC2;
13-1147
Assess
OMI-2 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE GLYCOPROTEIN Heteromer
P0DTC2;
13-1147
12×NAG; 30×NAG;
Assess
COVOX-222 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
P0DTC2;
13-1147
12×NAG; 28×NAG;
Assess
Beta-06 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
P0DTC2;
13-1147
12×NAG; 28×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodo… Heteromer
P0DTC2; Q9BYF1;
14-1147
23×NAG; 24×NAG;ZN;
Assess
SARS-CoV-2 Spike in complex with IgG 553-15 (S-553-15 trimer) Heteromer
P0DTC2;
14-1147
45×NAG;
Assess
S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab Heteromer
P0DTC2;
14-1147
Assess
Cryo-EM structure of Omicron S-ACE2, C2 state Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 33×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 Heteromer
P0DTC2;
14-1147
18×NAG; 24×NAG;
Assess
SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (3 RBD down) Heteromer
P0DTC2;
14-1147
12×NAG; 30×NAG;
Assess
The state 3 complex structure of Omicron spike with Bn03 (2-up RBD, 5 nanobodies) Heteromer
P0DTC2;
14-1147
28×NAG;
Assess
SARS-CoV-2 Omicron open state spike protein in complex with S3H3 Fab Heteromer
P0DTC2;
14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2 Heteromer
P0DTC2; Q8R0I0;
14-1147
18×NAG; 26×NAG;
Assess
SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail Heteromer
P0DTC2;
14-1147
15×NAG; 16×NAG;
Assess
EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159 Heteromer
P0DTC2;
14-1147
15×NAG; 24×NAG;
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike Heteromer
P0DTC2;
14-1147
28×NAG;
Assess
The state 2 complex structure of Omicron spike with Bn03 (2-up RBD, 4 nanobodies) Heteromer
P0DTC2;
14-1147
36×NAG;
Assess
CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (non-uniform refinement) Heteromer
P0DTC2;
14-1147
NAG;NAG; 29×NAG;
Assess
S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab. Heteromer
P0DTC2;
14-1147
Assess
SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 1 YB9-258 Fab (1 RBD up) Heteromer
P0DTC2;
14-1147
12×NAG; 30×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C3 state Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 42×NAG;
Assess
SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail Heteromer
P0DTC2;
14-1147
15×NAG; 16×NAG;
Assess
Cryo-EM structure of RBD-directed neutralizing antibody P2B4 in complex with prefusion SARS-CoV-2 s… Heteromer
P0DTC2;
14-1147
44×NAG;
Assess
S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab. Heteromer
P0DTC2;
14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with mouse ACE2 Heteromer
P0DTC2; Q8R0I0;
14-1147
18×NAG; 25×NAG;
Assess
SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail Heteromer
P0DTC2;
14-1147
14×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectod… Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 26×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 26×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 28×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 28×NAG;
Assess
The state 1 complex structure of Omicron spike with Bn03 (1-up RBD, 3 nanobodies) Heteromer
P0DTC2;
14-1147
40×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1) Heteromer
P0DTC2;
14-1147
18×NAG; 24×NAG;
Assess
Furin Site deletion of SARS-CoV-2 spike Heteromer
P0DTC2;
14-1147
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the macrocyclic peptide S1B3inL1 Heteromer
P0DTC2;
14-1147
13×NAG; 23×NAG;
Assess
S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with… Heteromer
P0DTC2;
14-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159 Heteromer
P0DTC2;
14-1147
15×NAG; 24×NAG;
Assess
Cryo-EM structure of hACE2-bound SARS-CoV-2 Omicron spike protein with L371S, P373S and F375S mutat… Heteromer
P0DTC2; Q9BYF1;
14-1147
15×NAG; 33×NAG;ZN;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2;
14-1147
14×NAG; 10×NAG;
Assess
CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (non-uniform refinemen… Heteromer
P0DTC2;
14-1147
10×NAG; 20×NAG;
Assess
SARS-CoV-2 S-ACE2 complex Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 36×NAG;
Assess
SARS-CoV-2 Kappa variant spike protein in complex with ACE2, state C2a Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab. Heteromer
P0DTC2;
14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike protein with ACE2, C1 state Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectod… Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 32×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 26×NAG;
Assess
Cryo-EM structure of NTD-directed neutralizing antibody LP5 Fab in complex with SARS-CoV-2 S2P spike Heteromer
P0DTC2;
14-1147
NAG;NAG;NAG; 28×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron Spike protein with human ACE2 receptor, C2 state Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycopro… Heteromer
P0DTC2;
14-1147
NAG; 18×NAG; 30×NAG;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2; Q9BYF1;
14-1147
14×NAG; 12×NAG;
Assess
S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab Heteromer
P0DTC2;
14-1147
Assess
SARS-CoV-2 Delta S-ACE2-C1 Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with human ACE2 ectodo… Heteromer
P0DTC2; Q9BYF1;
14-1147
22×NAG; 23×NAG;ZN;
Assess
SARS-CoV-2 Spike in complex with IgG 553-60 (1-up trimer) Heteromer
P0DTC2;
14-1147
39×NAG;
Assess
SARS-CoV-2 Omicron closed state spike protein in complex with S3H3 Fab Heteromer
P0DTC2;
14-1147
Assess
Cryo-EM structure of NTD-directed non-neutralizing antibody 4-33 in complex with prefusion SARS-CoV… Heteromer
P0DTC2;
14-1147
NAG; 33×NAG;
Assess
SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state Heteromer
P0DTC2;
14-1147
27×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2) Heteromer
P0DTC2;
14-1147
18×NAG; 24×NAG;
Assess
P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein Heteromer
P0DTC2;
14-1147
15×NAG; 16×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the 87G7 antibody Fab fragment Heteromer
P0DTC2;
14-1147
12×NAG; 27×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 26×NAG;
Assess
SARS-CoV-2 Delta S-ACE2-C2a Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
Cryo-EM structure of mink variant Y453F trimeric spike protein bound to one mink ACE2 receptors Heteromer
A0A7T0Q2W2; P0DTC2;
14-1147
Assess
Cryo-EM structure of SARS-CoV-2 prototype spike protein in complex with white-tailed deer ACE2 Heteromer
A0A6J0Z472; P0DTC2;
14-1147
21×NAG; 23×NAG;ZN;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound t… Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 28×NAG;
Assess
S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab. Heteromer
P0DTC2;
14-1147
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 1-87 in complex with prefusion SARS-CoV-2 s… Heteromer
P0DTC2;
14-1147
17×NAG;NAG; 34×NAG;
Assess
Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed st… Heteromer
P0DTC2;
14-1147
14×NAG; 16×NAG;
Assess
SARS-CoV-2 Spike in complex with IgG 553-60 (2-up trimer) Heteromer
P0DTC2;
14-1147
38×NAG;
Assess
SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (1 RBD up) Heteromer
P0DTC2;
14-1147
12×NAG; 30×NAG;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2; Q9BYF1;
14-1147
14×NAG; 20×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 26×NAG;
Assess
S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab. Heteromer
P0DTC2;
14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with white-tailed deer ACE2 Heteromer
A0A6J0Z472; P0DTC2;
14-1147
17×NAG;NAG; 31×NAG;ZN;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with Fab 4A8 Heteromer
P0DTC2;
14-1147
18×NAG; 21×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 D614G spike protein in complex with VH ab6 Heteromer
P0DTC2;
14-1147
18×NAG; 21×NAG;
Assess
Omicron Spike bitrimer with 6m6 antibody Heteromer
P0DTC2;
14-1147
49×NAG;
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 s… Heteromer
P0DTC2;
14-1147
24×NAG; 30×NAG;
Assess
SARS-CoV-2 Delta S-8D3 Heteromer
P0DTC2;
14-1147
Assess
XG005-bound SARS-CoV-2 S Heteromer
P0DTC2;
14-1147
45×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound t… Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 42×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike protein (S-6P-RRAR) in complex with S309 fab Heteromer
P0DTC2;
14-1147
19×NAG; 25×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 36×NAG;
Assess
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… Heteromer
P0DTC2;
14-1147
14×NAG; 10×NAG;
Assess
SARS-CoV-2 Spike in complex with IgG 553-15 (S-553-15 dimer trimer ) Heteromer
P0DTC2;
14-1147
90×NAG;
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spi… Heteromer
P0DTC2;
14-1147
26×NAG;
Assess
SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 2 YB9-258 Fabs (2 RBD up) Heteromer
P0DTC2;
14-1147
12×NAG; 30×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with VH ab6 Heteromer
P0DTC2;
14-1147
18×NAG; 23×NAG;
Assess
SARS-CoV-2 Delta S-ACE2-C2b Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with 3 YB13-292 Fabs (2 RBD up) Heteromer
P0DTC2;
14-1147
12×NAG; 30×NAG;
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 s… Heteromer
P0DTC2;
14-1147
16×NAG;NAG; 36×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 34×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2… Heteromer
P0DTC2; Q9BYF1;
14-1147
18×NAG; 28×NAG;
Assess
SARS-CoV-2 Delta S-ACE2-C3 Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
SARS-CoV-2 spike/Nb3 complex with 1 RBD up and 2 Nb3 Heteromer
P0DTC2;
14-1147
11×NAG; 25×NAG;
Assess
SARS-CoV-2 spike/Nb4 complex with 2 RBDs up and 3 Nb4 bound Heteromer
P0DTC2;
14-1147
11×NAG; 25×NAG;
Assess
SARS-CoV-2 spike/Nb3 complex with 2 RBDs up and 3 Nb3 bound at 2.5 A Heteromer
P0DTC2;
14-1147
11×NAG; 25×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron Prototype S-trimer in complex with fab L4.65 and L5.34 Heteromer
P0DTC2;
14-1147
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.4 S-trimer in complex with fab L4.65 and L5.34 Heteromer
P0DTC2;
14-1147
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 S-trimer in complex with fab L4.65 and L5.34 Heteromer
P0DTC2;
14-1147
32×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1147
24×NAG; 33×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with mouse ACE2 (conformation 2) Heteromer
P0DTC2; Q8R0I0;
14-1147
20×NAG;NAG; 21×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with mouse ACE2 (conformation 1) Heteromer
P0DTC2; Q8R0I0;
14-1147
19×NAG;NAG; 21×NAG;
Assess
SARS-CoV-2 spike/nanobody mixture complex Heteromer
P0DTC2;
14-1147
12×NAG; 45×NAG;
Assess
SARS-CoV-2 spike/Nb6 complex Heteromer
P0DTC2;
14-1147
11×NAG; 39×NAG;
Assess
SARS-CoV-2 spike/Nb5 complex Heteromer
P0DTC2;
14-1147
10×NAG; 33×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 prototype spike protein in complex with hippopotamus ACE2 Heteromer
P0DTC2;
14-1147
12×NAG; 25×NAG;ZN;
Assess
Nanobody C5 bound to Spike Heteromer
P0DTC2;
14-1147
15×NAG; 36×NAG;
Assess
SARS-CoV-2 S trimer with four-antibody cocktail complex Heteromer
P0DTC2;
14-1147
12×NAG;
Assess
SARS-CoV-2 S trimer with three-antibody cocktail complex Heteromer
P0DTC2;
14-1147
15×NAG;
Assess
SARS-CoV-2 Kappa variant spike protein in C2b state Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
SARS-CoV-2 Kappa variant spike protein in C3 state Heteromer
P0DTC2; Q9BYF1;
14-1147
Assess
VAS5 Spike (1 RBD up) Heteromer
P0DTC2;
14-1147
13×NAG; 31×NAG;
Assess
SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 IgG. Heteromer
P0DTC2;
15-1147
15×NAG; 14×NAG;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2;
15-1147
18×NAG; 30×NAG;
Assess
SARS CoV2 Spike in the 2-up state in complex with Fab47. Heteromer
P0DTC2;
14-1146
NAG; 43×NAG;
Assess
SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound Heteromer
P0DTC2; Q9BYF1;
14-1146
23×NAG;ZN;
Assess
SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs Heteromer
P0DTC2;
14-1146
NAG; 24×NAG;
Assess
J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut2 S protein (conformation 1) Heteromer
P0DTC2;
15-1147
NAG; 15×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab H4 Heteromer
P0DTC2;
14-1146
NAG; 33×NAG;
Assess
SARS-CoV-2 Spike (dimers) in complex with six Fu2 nanobodies Heteromer
P0DTC2;
14-1146
NAG; 46×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with non-neutralizing NTD-directed CV3-13 Fab isol… Heteromer
P0DTC2;
15-1147
NAG; 36×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … Heteromer
P0DTC2; Q9BYF1;
14-1146
31×NAG; 13×NAG;
Assess
SARS Cov2 Spike RBD in complex with Fab47 Heteromer
P0DTC2;
14-1146
NAG; 45×NAG;
Assess
SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Clockwise Direction Heteromer
P0DTC2; Q9BYF1;
14-1146
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with K202.B bispecific antibody Heteromer
P0DTC2;
16-1148
32×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… Heteromer
P0DTC2;
14-1146
20×NAG;NAG; 21×NAG;
Assess
SARS-CoV-2 spike glycoprotein:Fab 3D11 complex Heteromer
P0DTC2;
14-1146
Assess
CryoEM structure of SARS-CoV-2 spike protein (S-6P, 2-up) in complex with sybodies (Sb45) Heteromer
P0DTC2;
14-1146
17×NAG; 30×NAG;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2;
15-1147
15×NAG; 24×NAG;
Assess
Beta-26 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
P0DTC2;
15-1147
13×NAG; 31×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) 2-up confor… Heteromer
P0DTC2;
14-1146
NAG; 45×NAG;
Assess
SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-57 (three down conformation) Heteromer
P0DTC2;
14-1146
28×NAG; 25×NAG;
Assess
Trimeric SARS-CoV-2 spike ectodomain bound to P008_056 Fab Heteromer
P0DTC2;
14-1146
25×NAG;BLA; 29×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with FSR22, an anti-SARS-CoV-2 DARPin Heteromer
P0DTC2;
14-1146
NAG;NAG;NAG; 18×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014 Heteromer
P0DTC2;
14-1146
Assess
SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-22 Heteromer
P0DTC2;
15-1147
Assess
SARS-CoV-2 Spike trimer in complex with RmAb 9H1 Fab in the class 2 conformation Heteromer
P0DTC2;
15-1147
17×NAG; 27×NAG;
Assess
SARS-CoV-2 Spike Glycoprotein with 2 ACE2 Bound Heteromer
P0DTC2; Q9BYF1;
14-1146
Assess
SARS-CoV-2 wildtype spike trimer (6P) in complex with 3 YB9-258 Fabs and 3 R1-32 Fabs (3 RBD up) Heteromer
P0DTC2;
14-1146
12×NAG; 30×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2 Heteromer
P0DTC2; Q8R0I0;
15-1147
22×NAG; 23×NAG;ZN;
Assess
SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-67 Heteromer
P0DTC2;
15-1147
14×NAG;NAG;NAG; 32×NAG;
Assess
CryoEM structure of del68-76/del679-688 prefusion-stabilized spike in complex with the Fab of N12-9 Heteromer
P0DTC2;
14-1146
10×NAG; 28×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … Heteromer
P0DTC2; Q9BYF1;
14-1146
37×NAG; 15×NAG;
Assess
SARS-CoV-2 Spike Glycoprotein with 3 ACE2 Bound Heteromer
P0DTC2; Q9BYF1;
14-1146
Assess
SARS-CoV-2 Spike (6P) in complex with 1 R1-32 Fab Heteromer
P0DTC2;
14-1146
NAG; 24×NAG;
Assess
SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-65 Heteromer
P0DTC2;
15-1147
Assess
Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351) in complex with Angiotensin-converting enz… Heteromer
P0DTC2; Q9BYF1;
14-1146
31×NAG; 17×NAG;
Assess
SARS-CoV-2 Omicron Variant SPIKE trimer complexed with ACE2 Heteromer
P0DTC2; Q9BYF1;
15-1147
12×NAG; 21×NAG;CL;ZN;
Assess
Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing nanobodies (Ty1) Heteromer
P0DTC2;
14-1146
12×NAG; 39×NAG;
Assess
SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-57 Heteromer
P0DTC2;
15-1147
30×NAG;
Assess
SARS-CoV-2 Spike (6P) in complex with 2 R1-32 Fabs Heteromer
P0DTC2;
14-1146
NAG; 24×NAG;
Assess
SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in th… Heteromer
P0DTC2;
15-1147
15×NAG; 15×NAG;
Assess
The SARS-CoV-2 spike in complex with the 1.29 neutralizing nanobody Heteromer
P0DTC2;
14-1146
NAG; 33×NAG;
Assess
CryoEm structure of SARS-CoV-2 spike protein (S-6P, 1-up) in complex with sybodies (Sb45) Heteromer
P0DTC2;
14-1146
19×NAG; 35×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … Heteromer
P0DTC2; Q9BYF1;
14-1146
43×NAG; 14×NAG;
Assess
SARS Cov2 Spike in 1-up conformation complex with Fab47 Heteromer
P0DTC2;
14-1146
NAG; 44×NAG;
Assess
SARS-CoV-spike bound to two neutralising nanobodies Heteromer
P0DTC2;
14-1146
NAG; 42×NAG;
Assess
S protein of SARS-CoV-2 in complex with 2G1 Heteromer
P0DTC2;
14-1146
24×NAG; 30×NAG;EIC;
Assess
SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 1 conformation Heteromer
P0DTC2;
15-1147
14×NAG; 15×NAG;
Assess
SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 2 conformation Heteromer
P0DTC2;
15-1147
14×NAG; 15×NAG;
Assess
A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses including all major Omicro… Heteromer
P0DTC2;
15-1147
10×NAG; 28×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) Heteromer
P0DTC2;
14-1146
NAG; 45×NAG;
Assess
SARS-CoV-2 spike glycoprotein:Fab 5A6 complex I Heteromer
P0DTC2;
14-1146
23×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2) in complex with Angiotensin-converting … Heteromer
P0DTC2; Q9BYF1;
14-1146
38×NAG; 16×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… Heteromer
P0DTC2; Q9BYF1;
14-1146
30×NAG;NAG; 19×NAG;
Assess
SARS-CoV-2 Spike in complex with PVI.V6-14 Fab Heteromer
P0DTC2;
14-1146
15×NAG;NAG;NAG;NAG; 18×NAG;
Assess
SARS-CoV-2 spike in complex with nanobodies E Heteromer
P0DTC2;
14-1146
51×NAG;
Assess
SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-45 Heteromer
P0DTC2;
15-1147
Assess
Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… Heteromer
P0DTC2; Q9BYF1;
14-1146
29×NAG; 26×NAG;
Assess
The SARS-CoV-2 spike in complex with the 1.10 neutralizing nanobody Heteromer
P0DTC2;
14-1146
NAG; 33×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… Heteromer
P0DTC2;
14-1146
NAG; 12×NAG; 18×NAG;
Assess
SARS-CoV-2 Spike Glycoprotein with 1 ACE2 Bound and 1 RBD Erect in Anticlockwise Direction Heteromer
P0DTC2; Q9BYF1;
14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1) in complex with Angiotensin-converting … Heteromer
P0DTC2; Q9BYF1;
14-1146
37×NAG; 13×NAG;
Assess
SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal antibody 1H1 Fab in cl… Heteromer
P0DTC2;
15-1147
15×NAG; 14×NAG;
Assess
SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment Heteromer
P0DTC2;
15-1147
12×NAG;NAG; 36×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1) in complex with Angiotensin-converting enzyme… Heteromer
P0DTC2; Q9BYF1;
14-1146
30×NAG; 29×NAG;
Assess
SARS-CoV-2 Spike trimer in complex with RmAb 9H1 Fab in the class 1 conformation Heteromer
P0DTC2;
15-1147
18×NAG; 27×NAG;
Assess
SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-23 Heteromer
P0DTC2;
15-1147
Assess
SARS-CoV-2 Kappa variant spike protein in complex wth ACE2, state C1 Heteromer
P0DTC2; Q9BYF1;
14-1146
Assess
SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab in the class 2 conformation Heteromer
P0DTC2;
15-1147
15×NAG; 15×NAG;
Assess
The SARS-CoV-2 spike in complex with the 2.15 neutralizing nanobody Heteromer
P0DTC2;
14-1146
NAG; 33×NAG;
Assess
SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1146
NAG; 36×NAG;ZN;
Assess
J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut2 S protein (conformation 2) Heteromer
P0DTC2;
15-1147
12×NAG; 21×NAG;
Assess
SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab in the class 1 conformation Heteromer
P0DTC2;
15-1147
14×NAG; 15×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113… Heteromer
P0DTC2;
14-1146
16×NAG; 20×NAG;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2;
15-1147
18×NAG; 30×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with 4A8 Heteromer
P0DTC2;
14-1146
NAG; 23×NAG; 25×NAG;
Assess
SARS-CoV-2 S-6P in complex with 9 Fabs Heteromer
P0DTC2;
14-1146
Assess
SARS-CoV-2 S/S2M11/S2M28 Global Refinement Heteromer
P0DTC2;
14-1145
NAG;NAG; 45×NAG;
Assess
Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 sp… Heteromer
P0DTC2;
14-1145
NAG; 48×NAG;
Assess
SARS-CoV-2 S B.1.617.1 kappa variant + S2X303 Global Refinement Heteromer
P0DTC2;
14-1145
NAG; 51×NAG;
Assess
SARS-CoV-2 S B.1.1.529 Omicron variant + S309 + S2L20 Global Refinement Heteromer
P0DTC2;
14-1145
NAG; 50×NAG;
Assess
SARS-CoV-2 S ectodomain trimer in complex with neutralizing antibody 10-5B Heteromer
P0DTC2;
14-1145
Assess
SARS-CoV-2 Omicron BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fa… Heteromer
P0DTC2;
14-1145
NAG; 48×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with VHH21 Heteromer
P0DTC2;
14-1145
40×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike in complex with antibodies A19-46.1 and B1-182.1 Heteromer
P0DTC2;
14-1145
13×NAG; 15×NAG;
Assess
Delta SARS-CoV-2 spike protein in complex with REGN10987 Fab homologue. Heteromer
P0DTC2;
15-1146
Assess
SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement Heteromer
P0DTC2;
14-1145
NAG; 45×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with VHH14 Heteromer
P0DTC2;
14-1145
38×NAG;
Assess
SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement Heteromer
P0DTC2;
14-1145
51×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike in complex with antibody A19-46.1 Heteromer
P0DTC2;
14-1145
14×NAG; 28×NAG;
Assess
SARS-CoV-2 S/S2M11/S2X333 Global Refinement Heteromer
P0DTC2;
14-1145
NAG;NAG; 45×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the neutralizing antibody Fab fragment, C15… Heteromer
P0DTC2;
14-1145
12×NAG; 35×NAG;
Assess
SD1-3 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein Heteromer
P0DTC2;
16-1147
30×NAG;
Assess
SARS-CoV-2 S (C.37 Lambda variant) plus S309, S2L20, and S2X303 Fabs Heteromer
P0DTC2;
14-1145
57×NAG;
Assess
SARS-CoV-2 S/S2M11/S2L28 Global Refinement Heteromer
P0DTC2;
14-1144
NAG;NAG;NAG; 39×NAG;
Assess
Structure of the SARS-CoV-2 Spike trimer with one RBD down in complex with the Fab fragment of huma… Heteromer
P0DTC2;
15-1145
29×NAG; 25×NAG;
Assess
Structure of the SARS-CoV-2 Spike trimer with three RBDs up in complex with the Fab fragment of hum… Heteromer
P0DTC2;
15-1145
33×NAG; 21×NAG;
Assess
cryo-EM structure of omicron spike in complex with de novo designed binder, full map Heteromer
P0DTC2; Q9VKJ9;
19-1147
18×NAG; 12×NAG; 16×NAG;
Assess
SARS-CoV-2 BA.2 variant spike protein in complex with Fab BD55-5840 Heteromer
P0DTC2;
22-1150
Assess
Structure of SARS-CoV-2 Omicron BA.1.1.529 Spike trimer with two RBDs down in complex with the Fab … Heteromer
P0DTC2;
19-1147
27×NAG; 19×NAG;
Assess
SARS-CoV-2 S Omicron Spike B.1.1.529 - 3-P2G3 and 1-P5C3 Fabs (Global) Heteromer
P0DTC2;
19-1147
14×NAG;NAG;NAG; 26×NAG;
Assess
Structure of SARS-CoV-2 Omicron BA.1.1.529 Spike trimer with one RBD down in complex with the Fab f… Heteromer
P0DTC2;
19-1147
20×NAG; 23×NAG;
Assess
SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations… Heteromer
P0DTC2;
20-1147
10×NAG; 27×NAG;
Assess
CryoEM structure of neutralizing nanobody Nb12 in complex with SARS-CoV2 spike Heteromer
P0DTC2;
23-1150
NAG; 13×NAG; 22×NAG;
Assess
Beta-50 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
P0DTC2;
21-1147
NAG; 14×NAG;NAG; 25×NAG;
Assess
cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound Heteromer
P0DTC2;
14-1140
21×NAG;NAG; 18×NAG;
Assess
XBB.1.5 spike protein in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1140
Assess
XBB.1.5.10 spike protein in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1140
Assess
XBB.1.5.70 spike protein in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
14-1140
Assess
Cryo-EM Structure of SARS-CoV-2 BA.2 Spike protein in complex with BA7535 Heteromer
P0DTC2;
18-1143
12×NAG; 12×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-3 Heteromer
P0DTC2;
22-1147
NAG; 45×NAG;
Assess
S728-1157 IgG in complex with SARS-CoV-2-6P-Mut7 Spike protein (focused refinement) Heteromer
P0DTC2;
22-1147
11×NAG;
Assess
BA.2-07 FAB IN COMPLEX WITH SARS-COV-2 BA.2.12.1 SPIKE GLYCOPROTEIN Heteromer
P0DTC2;
22-1147
12×NAG; 24×NAG;
Assess
SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment Heteromer
P0DTC2;
15-1140
18×NAG;NAG; 30×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051 Heteromer
P0DTC2;
15-1140
NAG; 27×NAG;
Assess
LM18/Nb136 bispecific tetra-nanobody immunoglobulin in complex with SARS-CoV-2-6P-Mut7 S protein (f… Heteromer
P0DTC2;
22-1147
13×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with Fab S2M11 Heteromer
P0DTC2;
15-1140
18×NAG;NAG; 30×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
15-1140
NAG; 32×NAG;
Assess
Beta049 fab in complex with SARS-CoV2 beta-Spike glycoprotein, The Beta mAb response underscores th… Heteromer
P0DTC2;
22-1147
NAG; 14×NAG;NAG; 26×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548 Heteromer
P0DTC2;
15-1140
NAG;NAG;NAG;NAG; 26×NAG;
Assess
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… Heteromer
P0DTC2;
23-1148
Assess
BA.2(S375) Spike (S6P)/hACE2 complex Heteromer
P0DTC2; Q9BYF1;
22-1147
NAG; 51×NAG;
Assess
SD1-2 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein Heteromer
P0DTC2;
22-1147
30×NAG;
Assess
cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound Heteromer
P0DTC2;
14-1138
NAG;NAG; 25×NAG;
Assess
Omicron spike trimer with 6m6 antibody Heteromer
P0DTC2;
23-1147
24×NAG;
Assess
The state 4 of Omicron Spike with bispecific antibody FD01 Heteromer
P0DTC2;
24-1147
23×NAG;
Assess
The state 5 of Omicron Spike with bispecific antibody FD01 Heteromer
P0DTC2;
24-1147
18×NAG;
Assess
Cryo-EM Structure of Double ACE2-Bound SARS-CoV-2 Trimer Spike at pH 5.5 Heteromer
P0DTC2; Q9BYF1;
26-1149
NAG; 48×NAG;
Assess
CryoEM structure of neutralizing nanobody Nb30 in complex with SARS-CoV2 spike Heteromer
P0DTC2;
26-1149
11×NAG;NAG;NAG; 29×NAG;
Assess
SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 1up/1up-out/1down conformation Heteromer
P0DTC2;
26-1149
11×NAG;NAG;NAG; 19×NAG;
Assess
The state 2 of Omicron Spike with bispecific antibody FD01 Heteromer
P0DTC2;
24-1147
23×NAG;
Assess
SARS-CoV-2 Omicron 1-RBD up spike trimer complexed with two XG005 Fab Heteromer
P0DTC2;
24-1147
Assess
Cryo-EM structure of SARS-CoV-2 Spike protein in complex with A6 repebody Heteromer
P0DTC2;
26-1149
NAG; 24×NAG;
Assess
The state 1 of Omicron Spike with bispecific antibody FD01 Heteromer
P0DTC2;
24-1147
28×NAG;
Assess
SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 3up conformation Heteromer
P0DTC2;
26-1149
10×NAG;NAG;NAG;NAG; 29×NAG;
Assess
SARS-CoV-2 Omicron 1-RBD up Spike trimer complexed with three XG005 molecules Heteromer
P0DTC2;
24-1147
Assess
Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike … Heteromer
P0DTC2;
24-1147
16×NAG;NAG;
Assess
SARS-CoV-2 spike protein in complex with sybodyb#15 in a 1up/1up-out/1down conformation. Heteromer
P0DTC2;
26-1149
NAG;NAG;NAG;NAG; 19×NAG;
Assess
SARS-CoV-2 Omicron 2-RBD up Spike trimer complexed with three XG005 molecules Heteromer
P0DTC2;
24-1147
Assess
SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-"up", asymmetric Heteromer
P0DTC2;
14-1137
NAG;NAG;NAG;
Assess
Cryo-EM structure of Triple ACE2-bound SARS-CoV-2 Trimer Spike at pH 5.5 Heteromer
P0DTC2; Q9BYF1;
26-1149
NAG; 56×NAG;
Assess
3D model of the 3-RBD up single trimeric spike protein of SARS-CoV2 in the presence of synthetic pe… Heteromer
P0DTC2;
26-1149
39×NAG;
Assess
SARS-CoV-2 spike in complex with LCB1 (2RBDs open) Heteromer
P0DTC2;
27-1150
13×NAG; 33×NAG;
Assess
SARS-CoV-2 spike protein in complex with sybody#68 in a 2up/1flexible conformation Heteromer
P0DTC2;
26-1149
10×NAG;NAG;NAG;NAG; 28×NAG;
Assess
Cryo-EM structure of double ACE2-bound SARS-CoV-2 trimer Spike at pH 7.4 Heteromer
P0DTC2; Q9BYF1;
26-1149
NAG; 53×NAG;
Assess
SARS-CoV-2 S (Spike Glycoprotein) D614G with Three (3) RBDs Up, Bound to Antibody 2-7 scFv, composi… Heteromer
P0DTC2;
26-1149
NAG; 45×NAG;
Assess
SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-"up"-1-"down" conformation Heteromer
P0DTC2;
14-1137
12×NAG;NAG; 16×NAG;
Assess
The state 6 of Omicron Spike with bispecific antibody FD01 Heteromer
P0DTC2;
24-1147
Assess
Cryo-EM structure of triple ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 Heteromer
P0DTC2; Q9BYF1;
26-1149
NAG; 55×NAG;
Assess
The state 3 of Omicron Spike with bispecific antibody FD01 Heteromer
P0DTC2;
24-1147
21×NAG;
Assess
SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab Heteromer
P0DTC2;
25-1147
15×NAG; 30×NAG;
Assess
Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 5.5 Heteromer
P0DTC2; Q9BYF1;
26-1148
NAG; 44×NAG;
Assess
Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27 Heteromer
P0DTC2;
25-1147
15×NAG; 29×NAG;
Assess
SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 Heteromer
P0DTC2;
25-1147
12×NAG; 50×NAG;
Assess
Cryo-EM structure of single ACE2-bound SARS-CoV-2 trimer spike at pH 7.4 Heteromer
P0DTC2; Q9BYF1;
26-1148
NAG; 46×NAG;
Assess
CryoEM structure of SARS-CoV-2 Spike in complex with Nb17 Heteromer
P0DTC2;
25-1147
Assess
SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab Heteromer
P0DTC2;
25-1147
15×NAG; 30×NAG;
Assess
SARS-CoV-2 S trimer with one RBD in the open state and complexed with one H014 Fab. Heteromer
P0DTC2;
25-1147
15×NAG; 30×NAG;
Assess
SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state1) Heteromer
P0DTC2; Q9BYF1;
22-1144
NAG;ZN;CL; 49×NAG;
Assess
SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(state2) Heteromer
P0DTC2; Q9BYF1;
22-1144
NAG; 53×NAG;ZN;CL;
Assess
SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state1) Heteromer
P0DTC2;
22-1144
NAG;NAG; 45×NAG;
Assess
SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state2) Heteromer
P0DTC2;
22-1144
NAG;NAG; 45×NAG;
Assess
SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (state3) Heteromer
P0DTC2;
22-1144
NAG; 45×NAG;
Assess
cryo-EM structure of Omicron BA.5 S protein in complex with S2L20 Heteromer
P0DTC2;
25-1146
NAG; 18×NAG; 30×NAG;
Assess
cryo-EM structure of Omicron BA.5 S protein in complex with XGv289 Heteromer
P0DTC2;
25-1146
18×NAG; 33×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, HSW-1 Heteromer
P0DTC2;
26-1147
NAG; 34×NAG;
Assess
cryo-EM structure of Omicron BA.5 S protein in complex with XGv282 Heteromer
P0DTC2;
25-1146
18×NAG; 33×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-31 Heteromer
P0DTC2;
26-1147
NAG; 39×NAG;
Assess
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… Heteromer
P0DTC2;
27-1148
Assess
A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses including all major Omicro… Heteromer
P0DTC2;
29-1150
12×NAG; 25×NAG;
Assess
SARS-CoV-2 spike in prefusion state Heteromer
P0DTC2;
27-1148
16×NAG;NAG;NAG; 18×NAG;MAN;DMS;
Assess
Cryo-EM structure of SARS-CoV-2 spike glycoprotein in complex with three F61 Fab Heteromer
P0DTC2;
26-1147
24×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-34 Heteromer
P0DTC2;
26-1147
42×NAG;
Assess
A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses including all major Omicro… Heteromer
P0DTC2;
29-1150
13×NAG; 24×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-28 Heteromer
P0DTC2;
26-1147
39×NAG;
Assess
CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H4 Q98R H100E nanobody complex in 2Up1Down conformation Heteromer
P0DTC2;
26-1147
20×NAG; 26×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
45×NAG;
Assess
SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab Heteromer
P0DTC2;
27-1147
13×NAG; 23×NAG;
Assess
Complex structure of BD-218 and Spike protein Heteromer
P0DTC2;
27-1147
NAG; 32×NAG;
Assess
EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-253H55L Fab Heteromer
P0DTC2;
27-1147
10×NAG;NAG; 27×NAG;
Assess
SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab Heteromer
P0DTC2;
27-1147
Assess
CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-B5 nanobody complex Heteromer
P0DTC2;
27-1147
20×NAG; 26×NAG;
Assess
SARS CoV2 Spike ectodomain with engineered trimerized VH binder Heteromer
P0DTC2;
27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-253H55L Fab Heteromer
P0DTC2;
27-1147
14×NAG;NAG; 32×NAG;
Assess
SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation) Heteromer
P0DTC2;
27-1147
12×NAG; 21×NAG;NAG;NAG;NAG;NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7) in complex with Angiotensin-converting enzym… Heteromer
P0DTC2; Q9BYF1;
27-1147
29×NAG; 26×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… Heteromer
P0DTC2;
27-1147
NAG;NAG;NAG; 24×NAG;
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein(S-GSAS-D614G-delFV) missing the S1 subunit and S… Heteromer
P0DTC2;
27-1147
NAG; 27×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound domain-swapped antibody 2G12 from masked 3D r… Heteromer
P0DTC2;
27-1147
10×NAG;NAG;NAG;NAG; 32×NAG;
Assess
Structure of the SARS-CoV-2 Omicron BA.1 S 6P trimer in complex with the mouse antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
NAG; 27×NAG;
Assess
Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2 Heteromer
P0DTC2;
27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab Heteromer
P0DTC2;
27-1147
11×NAG; 27×NAG;
Assess
SARS-CoV-2 Spike Glycoprotein with two ACE2 Bound Heteromer
P0DTC2; Q9BYF1;
27-1147
20×NAG; 40×NAG;
Assess
SARS-CoV-2 Spike ectodomain with Fab FI3A Heteromer
P0DTC2;
27-1147
11×NAG; 27×NAG;
Assess
SARS-CoV-2 spike glycoprotein in complex with the ICO-hu23 neutralizing antibody Fab fragment Heteromer
P0DTC2;
27-1147
12×NAG; 30×NAG;
Assess
Cryo-EM structure of South African (B.1.351) SARS-CoV-2 spike glycoprotein in complex with two T6 F… Heteromer
P0DTC2;
27-1147
25×NAG;
Assess
Cryo-EM structure of South African (B.1.351) SARS-CoV-2 spike glycoprotein in complex with three T6… Heteromer
P0DTC2;
27-1147
25×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to one copy of domain-swapped antibody 2G12 Heteromer
P0DTC2;
27-1147
10×NAG;NAG;NAG;NAG; 31×NAG;
Assess
Cryo-EM structure of mink variant Y453F trimeric spike protein bound to one mink ACE2 receptors at … Heteromer
A0A7T0Q2W2; P0DTC2;
27-1147
Assess
Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490 Heteromer
P0DTC2;
27-1147
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab Heteromer
P0DTC2;
27-1147
15×NAG;NAG;NAG; 30×NAG;
Assess
SARS-CoV-2 Spike in complex with neutralizing nanobody mNb6 Heteromer
P0DTC2;
27-1147
18×NAG; 27×NAG;
Assess
SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-38 (three down conformation) Heteromer
P0DTC2;
27-1147
15×NAG; 33×NAG;
Assess
Cryo-EM structure of Antibody 12-16 in complex with prefusion SARS-CoV-2 Spike glycoprotein Heteromer
P0DTC2;
27-1147
48×NAG;
Assess
SARS-Cov2 Omicron varient S protein structure in complex with neutralizing monoclonal antibody 002-… Heteromer
P0DTC2;
27-1147
13×NAG; 28×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the M1 conformation, D4 Heteromer
P0DTC2;
27-1147
12×NAG; 22×NAG;
Assess
SARS-CoV-2 Spike Glycoprotein with three ACE2 Bound Heteromer
P0DTC2; Q9BYF1;
27-1147
24×NAG; 42×NAG;
Assess
Cryo-EM structure of Antibody 12-19 in complex with prefusion SARS-CoV-2 Spike glycoprotein Heteromer
P0DTC2;
27-1147
47×NAG;
Assess
Cryo-EM Structure of SARS-CoV-2 Spike : H11-D4 Nanobody Complex Heteromer
P0DTC2;
27-1147
20×NAG; 26×NAG;
Assess
Cryo-EM structure of prefusion SARS-CoV-2 spike glycoprotein in complex with 910-30 Fab Heteromer
P0DTC2;
27-1147
12×NAG; 35×NAG;
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
13×NAG; 34×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
NAG;NAG;
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab Heteromer
P0DTC2;
27-1147
15×NAG; 30×NAG;
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
13×NAG;NAG;NAG; 33×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the 47D11 neutralizing antibody Fab … Heteromer
P0DTC2;
27-1147
10×NAG;NAG;NAG;NAG;NAG;MAN; 28×NAG;FUC;MAN;
Assess
SARS-CoV-2 Spike in complex with neutralizing nanobody Nb6 Heteromer
P0DTC2;
27-1147
12×NAG; 30×NAG;
Assess
Structure of the SARS-CoV-2 BA.1 spike with UT28-RD Heteromer
P0DTC2;
27-1147
NAG; 34×NAG;
Assess
SARS-CoV-2 Spike in complex with neutralizing Fab 2B04 (one up, two down conformation) Heteromer
P0DTC2;
27-1147
14×NAG; 21×NAG;NAG;NAG;NAG;
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
28×NAG;
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab Heteromer
P0DTC2;
27-1147
11×NAG; 27×NAG;
Assess
Cryo-EM structure of mink variant Y453F trimeric spike protein bound to two mink ACE2 receptors Heteromer
A0A7T0Q2W2; P0DTC2;
27-1147
Assess
SARS-CoV-2 Spike Glycoprotein with one ACE2 Bound Heteromer
P0DTC2; Q9BYF1;
27-1147
17×NAG; 36×NAG;
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
15×NAG; 27×NAG;
Assess
SARS-CoV-2 S-trimer (3 RBDs up) bound to TriSb92, fitted into cryo-EM map Heteromer
P0DTC2;
26-1146
NAG; 39×NAG;
Assess
SARS-CoV-2 Delta Spike in complex with IS-9A Heteromer
P0DTC2;
27-1147
NAG; 24×NAG;
Assess
CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H6 nanobody complex Heteromer
P0DTC2;
27-1147
20×NAG; 26×NAG;
Assess
SARS-CoV-2 Spike protein in complex with the single chain fragment scFv76 Heteromer
P0DTC2;
27-1147
12×NAG; 27×NAG;
Assess
SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C Heteromer
P0DTC2;
26-1146
NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(1 down RBD, state1) Heteromer
P0DTC2;
27-1147
27×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(1 out RBD, state3) Heteromer
P0DTC2;
27-1147
27×NAG;
Assess
Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1041 Heteromer
P0DTC2;
27-1147
11×NAG;NAG; 17×NAG;
Assess
SARS-CoV-2 spike glycoprotein trimer complexed with Fab fragment of anti-RBD antibody E7 Heteromer
P0DTC2;
26-1146
NAG; 14×NAG;
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
10×NAG; 21×NAG;
Assess
CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11 nanobody complex Heteromer
P0DTC2;
27-1147
19×NAG; 28×NAG;
Assess
Cryo-EM structure of the Omicron S in complex with 35B5 Fab(1 down- and 2 up RBDs) Heteromer
P0DTC2;
27-1147
NAG; 27×NAG;
Assess
Structure of human SARS-CoV-2 spike glycoprotein trimer bound by neutralizing antibody C1C-A3 Fab (… Heteromer
P0DTC2;
27-1147
NAG; 45×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike glycoprotein in complex with three D2 Fab Heteromer
P0DTC2;
26-1146
32×NAG;
Assess
Cryo-EM structure of the Omicron S in complex with 35B5 Fab(1 down-, 1 up- and 1 invisible RBDs) Heteromer
P0DTC2;
27-1147
27×NAG;
Assess
SARS-CoV-2 Spike in complex with Fab of m31A7 Heteromer
P0DTC2;
20-1140
NAG;NAG;NAG;NAG;NAG;NAG;NAG;NAG;NAG; 19×NAG;
Assess
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… Heteromer
P0DTC2;
27-1147
22×NAG;
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab Heteromer
P0DTC2;
27-1147
15×NAG;NAG; 25×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12 Heteromer
P0DTC2;
27-1147
NAG;NAG;NAG;NAG; 25×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(3 up RBDs, state2) Heteromer
P0DTC2;
27-1147
27×NAG;
Assess
SARS-CoV-2 WT Spike in complex with R15 Fab and P14 Nanobody Heteromer
P0DTC2;
27-1147
15×NAG; 33×NAG;
Assess
CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-H4 Q98R H100E nanobody complex in 1Up2Down conformation Heteromer
P0DTC2;
27-1147
20×NAG; 26×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
15×NAG; 30×NAG;
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab Heteromer
P0DTC2;
27-1147
11×NAG; 27×NAG;
Assess
EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-253H165L Fab Heteromer
P0DTC2;
27-1147
10×NAG;NAG; 27×NAG;
Assess
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… Heteromer
P0DTC2;
27-1147
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
NAG;NAG;NAG; 26×NAG;
Assess
Beta-32 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
P0DTC2;
27-1147
15×NAG; 30×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab f… Heteromer
P0DTC2;
27-1147
NAG;NAG;NAG;NAG; 30×NAG;
Assess
Beta-53 fab in complex with SARS-CoV-2 beta-Spike glycoprotein Heteromer
P0DTC2;
27-1147
NAG; 11×NAG; 15×NAG;
Assess
SARS-CoV-2 B.1.1.7 S-ACE2 complex Heteromer
P0DTC2; Q9BYF1;
27-1147
16×NAG; 27×NAG;
Assess
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutat… Heteromer
P0DTC2;
27-1147
20×NAG;
Assess
J08 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (conformation 3) Heteromer
P0DTC2;
27-1147
NAG; 16×NAG;
Assess
Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052 Heteromer
P0DTC2;
27-1147
14×NAG; 31×NAG;
Assess
Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1 Heteromer
P0DTC2;
27-1147
15×NAG; 33×NAG;
Assess
Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047 Heteromer
P0DTC2;
27-1147
13×NAG;NAG; 24×NAG;
Assess
CryoEM structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1042 Heteromer
P0DTC2;
27-1147
NAG; 12×NAG; 33×NAG;
Assess
CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE : H11-A10 nanobody complex Heteromer
P0DTC2;
27-1147
20×NAG; 26×NAG;
Assess
H11-H4 bound to Spike Heteromer
P0DTC2;
27-1147
20×NAG; 26×NAG;
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
28×NAG;
Assess
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1147
23×NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S in complex with TH003 Fab Heteromer
P0DTC2;
27-1146
37×NAG;
Assess
overall structure of hu33 and spike Heteromer
P0DTC2;
27-1146
NAG; 10×NAG; 26×NAG;
Assess
CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWA9 Fab Heteromer
P0DTC2;
27-1146
Assess
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs Heteromer
P0DTC2;
27-1146
NAG; 31×NAG;
Assess
SARS-CoV-2 Omicron BA.1 Variant Spike Trimer with one mouse ACE2 Bound Heteromer
P0DTC2; Q8R0I0;
27-1146
37×NAG;ZN;
Assess
S protein of SARS-CoV-2 in complex with GW01 Heteromer
P0DTC2;
27-1146
23×NAG; 25×NAG;
Assess
CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWC11 Fab Heteromer
P0DTC2;
27-1146
Assess
cryo-EM structure of D614 spike in complex with de novo designed binder Heteromer
P0DTC2; Q9VKJ9;
27-1146
NAG; 32×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1146
11×NAG; 26×NAG;
Assess
SARS-CoV-2 Omicron Variant S Trimer complexed with two JMB2002 Fab Heteromer
P0DTC2;
27-1146
NAG; 36×NAG;
Assess
Cryo EM structure of SARS-CoV-2 spike in complex with TAU-2212 mAbs in conformation 4 Heteromer
P0DTC2;
27-1146
33×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with Fab30 Heteromer
P0DTC2;
27-1146
13×NAG; 27×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike glycoprotein in complex with three F61 Fab and three … Heteromer
P0DTC2;
27-1146
31×NAG;
Assess
Conformation 1 of S-ACE2-B0AT1 ternary complex Heteromer
P0DTC2; Q695T7; Q9BYF1;
27-1146
58×NAG; 64×NAG;LEU;ZN;
Assess
SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with two human ACE2 Bound Heteromer
P0DTC2; Q9BYF1;
27-1146
39×NAG;CL;ZN;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B Heteromer
A0A5C2G1U0; P01834; P0DP01; P0DTC2; V9HW68;
27-1146
22×NAG;NAG; 27×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-3C12_2B Heteromer
P0DTC2;
27-1146
22×NAG; 26×NAG;
Assess
SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (3U) Heteromer
P0DTC2;
27-1146
18×NAG; 18×NAG;
Assess
Furin Cleaved Alpha Variant SARS-CoV-2 Spike in complex with 3 ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
NAG; 48×NAG;ZN;
Assess
SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with three human ACE2 Bound Heteromer
P0DTC2; Q9BYF1;
27-1146
39×NAG;CL;ZN;
Assess
S protein of SARS-CoV-2 in complex bound with P36-5D2 (state1) Heteromer
P0DTC2;
27-1146
Assess
BD23-Fab in complex with the S ectodomain trimer Heteromer
P0DTC2;
27-1146
NAG;NAG; 32×NAG;
Assess
S-ECD (Omicron BA.2) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
38×NAG; 28×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1146
33×NAG;
Assess
S-ECD (Omicron BA.3) in complex with three PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
38×NAG; 28×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B Heteromer
A0A5C2G1U0; P01834; P0DP01; P0DTC2; V9HW68;
27-1146
21×NAG;NAG; 28×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with T-ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
35×NAG; 34×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-3C12_1B Heteromer
P0DTC2;
27-1146
21×NAG; 27×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25 Heteromer
P0DTC2;
27-1146
27×NAG; 21×NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S in complex with TH272/281 Fab Heteromer
P0DTC2;
27-1146
37×NAG;
Assess
S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (2 up RBD and 1 PD bound) Heteromer
P0DTC2; Q9BYF1;
27-1146
27×NAG; 28×NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S in complex with TH027 Fab Heteromer
P0DTC2;
27-1146
37×NAG;
Assess
S-ECD (Omicron) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
23×NAG; 45×NAG;
Assess
SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (2u1d) Heteromer
P0DTC2;
27-1146
17×NAG; 20×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-3A1 Heteromer
P0DTC2;
27-1146
22×NAG; 26×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-017 Heteromer
P0DTC2;
27-1146
NAG; 19×NAG;
Assess
SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with one mouse ACE2 Bound Heteromer
P0DTC2; Q8R0I0;
27-1146
34×NAG;ZN;
Assess
Omicron BA.4/5 SARS-CoV-2 S in complex with TH281 Fab Heteromer
P0DTC2;
27-1146
36×NAG;
Assess
SARS-CoV-2 spike in complex with LCB3 (2RBDs open) Heteromer
P0DTC2;
27-1146
13×NAG; 33×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15… Heteromer
P0DTC2;
27-1146
27×NAG; 21×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45 Heteromer
P0DTC2;
27-1146
24×NAG; 24×NAG;
Assess
SARS-CoV-2 Omicron Variant S Trimer complexed with three JMB2002 Fab Heteromer
P0DTC2;
27-1146
NAG; 35×NAG;
Assess
S-ECD (Omicron BA.3) in complex with two PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
33×NAG; 27×NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S in complex with TH027/132 Fab Heteromer
P0DTC2;
27-1146
37×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4 Heteromer
A0A5C2GJG2; P0DTC2;
27-1146
NAG;NAG;NAG; 36×NAG;
Assess
Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 1 (1 up RBD and … Heteromer
P0DTC2; Q9BYF1;
27-1146
27×NAG; 28×NAG;
Assess
S protein of Delta variant in complex with ZWD12 Heteromer
P0DTC2;
27-1146
23×NAG; 25×NAG;
Assess
S protein of Delta variant in complex with ZWC6 Heteromer
P0DTC2;
27-1146
23×NAG; 25×NAG;
Assess
SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with two mouse ACE2 Bound Heteromer
P0DTC2; Q8R0I0;
27-1146
37×NAG;ZN;
Assess
S-ECD (Omicron BA.5) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
38×NAG; 28×NAG;
Assess
Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (2 up RBD and … Heteromer
P0DTC2; Q9BYF1;
27-1146
32×NAG; 29×NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S in complex with TH132 Fab Heteromer
P0DTC2;
27-1146
36×NAG;
Assess
SARS-CoV-2 Omicron BA.1 Spike in complex with IY-2A Heteromer
P0DTC2;
27-1146
Assess
S protein of SARS-CoV-2 in complex bound with P36-5D2(state2) Heteromer
P0DTC2;
27-1146
17×NAG; 28×NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S in complex with TH236 Fab Heteromer
P0DTC2;
27-1146
37×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032 Heteromer
P0DTC2;
27-1146
NAG;NAG; 22×NAG;
Assess
S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 2 (1 up RBD and 1 PD bound) Heteromer
P0DTC2; Q9BYF1;
27-1146
26×NAG; 30×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the mouse antibody Fab fragment, M8a-6 Heteromer
P0DTC2;
28-1147
48×NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S in complex with TH272 Fab Heteromer
P0DTC2;
27-1146
36×NAG;
Assess
SARS-CoV 2 Spike Protein bound to LY-CoV555 Heteromer
P0DTC2;
27-1146
NAG; 16×NAG;
Assess
S-ECD (Omicron) in complex with STS165 Heteromer
P0DTC2;
27-1146
19×NAG; 33×NAG;
Assess
SARS-CoV-2 Omicron BA.1 Variant Spike Trimer with two mouse ACE2 Bound Heteromer
P0DTC2; Q8R0I0;
27-1146
39×NAG;ZN;
Assess
Trypsin-digested S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 3 (3 up RBD and … Heteromer
P0DTC2; Q9BYF1;
27-1146
32×NAG; 29×NAG;
Assess
SARS-CoV-2 Omicron Variant S Trimer complexed with one JMB2002 Fab Heteromer
P0DTC2;
27-1146
NAG; 33×NAG;
Assess
SARS-CoV-2 Omicron BA.2 Variant Spike Trimer with three JMB2002 Fab Bound Heteromer
P0DTC2;
27-1146
NAG; 35×NAG;
Assess
S-ECD (Omicron XBB.1) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
38×NAG; 28×NAG;
Assess
S-ECD (Omicron BF.7) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
38×NAG; 28×NAG;
Assess
S-ECD (Omicron BA.2.75) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
27-1146
37×NAG; 29×NAG;
Assess
BA.4/5-5 FAB IN COMPLEX WITH SARS-COV-2 BA.4 SPIKE GLYCOPROTEIN Heteromer
P0DTC2;
28-1147
12×NAG; 27×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B Heteromer
P01594; P0DOX5; P0DP02; P0DTC2; Q8TCD0;
27-1146
20×NAG; 31×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B Heteromer
A0A5C2GCZ2; A0A5C2GG81; P0DTC2; Q6GMX6; Q8TCD0;
27-1146
20×NAG; 30×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B Heteromer
A0A5C2GCZ2; A0A5C2GG81; P0DTC2; Q6GMX6; Q8TCD0;
27-1146
20×NAG; 31×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with FabP5A-1B8 Heteromer
A0A5C2GCZ2; A0A5C2GF00; P0DTC2; Q6GMX6; Q8TCD0;
27-1146
21×NAG; 28×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P2B-1A1 Heteromer
A0A5C2GM57; P01825; P0DTC2; Q5EFE5; Q8N5F4;
27-1146
23×NAG; 28×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with FabP5A-2G7 Heteromer
A0A0C4DH41; A0A5C2G2G8; P0DTC2; Q6IPQ0; V9HW68;
27-1146
20×NAG; 29×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B9 Heteromer
A0A5C2G1U0; P01825; P0DTC2; Q6GMX6; Q8TCD0;
27-1146
19×NAG; 33×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-2G9 Heteromer
A0A5C2GMM2; P01772; P0DOX5; P0DTC2; Q8N5F4;
27-1146
21×NAG; 28×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-2G7 Heteromer
A0A0C4DH41; A0A5C2G2G8; P0DTC2; Q6IPQ0; V9HW68;
27-1146
21×NAG; 28×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B Heteromer
P01594; P0DOX5; P0DP02; P0DTC2; Q8TCD0;
27-1146
21×NAG; 28×NAG;
Assess
S protein of SARS-CoV-2 in complex bound with P2B-1A10 Heteromer
A0A5C2GF00; P01594; P0DOX5; P0DTC2; Q8TCD0;
27-1146
21×NAG; 28×NAG;
Assess
SARS-CoV-2 Spike trimer in complex with XG014 Fab Heteromer
P0DTC2;
27-1146
24×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the neutralizing antibody Fab fragment, C17… Heteromer
P0DTC2;
27-1146
NAG;NAG; 27×NAG;
Assess
SARS-CoV-2 S trimer in complex with 1F Fab Heteromer
P0DTC2;
27-1146
15×NAG; 26×NAG;
Assess
Structure of SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state) Heteromer
P0DTC2; Q9BYF1;
21-1139
NAG;NAG;NAG; 36×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1) Heteromer
P0DTC2;
27-1145
39×NAG;
Assess
Structure of the SARS-CoV-2 Spike trimer with all RBDs down in complex with the Fab fragment of hum… Heteromer
P0DTC2;
27-1145
21×NAG; 30×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the ACE2 protein decoy, CTC-445.2 (State 4) Heteromer
P0DTC2;
27-1145
NAG; 27×NAG;
Assess
Structure of the SARS-CoV-2 Spike trimer with two RBDs down in complex with the Fab fragment of hum… Heteromer
P0DTC2;
27-1145
21×NAG; 30×NAG;
Assess
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open) Heteromer
P0DTC2;
27-1145
11×NAG; 36×NAG;
Assess
Structure of the SARS-CoV-2 Spike trimer with one RBD down in complex with the Fab fragment of huma… Heteromer
P0DTC2;
27-1145
23×NAG; 28×NAG;
Assess
SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment Heteromer
P0DTC2;
27-1145
12×NAG;NAG; 33×NAG;
Assess
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 Heteromer
P0DTC2;
27-1145
12×NAG; 36×NAG;
Assess
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragmen… Heteromer
P0DTC2;
27-1145
15×NAG; 33×NAG;
Assess
SARS-CoV-2 spike in complex with AHB2-2GS-SB175 Heteromer
P0DTC2;
27-1145
12×NAG; 36×NAG;
Assess
SARS-CoV-2 S glycoprotein in complex with S2X259 Fab Heteromer
P0DTC2;
27-1145
12×NAG; 30×NAG;
Assess
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation) Heteromer
P0DTC2;
27-1145
12×NAG; 36×NAG;
Assess
SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement Heteromer
P0DTC2;
27-1145
NAG;NAG; 39×NAG;
Assess
P5C3 is a potent fab neutralizer Heteromer
P0DTC2;
27-1145
Assess
SARS-CoV-2 BA.2.75 S Trimer in complex with XG2v024 Heteromer
P0DTC2;
22-1140
15×NAG;NAG; 24×NAG;
Assess
SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment Heteromer
P0DTC2;
27-1145
15×NAG; 33×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron Spike protein in complex with BA7208 fab Heteromer
P0DTC2;
26-1144
11×NAG; 16×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Delta Spike protein in complex with BA7054 and BA7125 fab Heteromer
P0DTC2;
26-1143
12×NAG; 12×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7 Heteromer
P0DTC2;
27-1144
NAG; 30×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 spike protein in complex with white-tailed deer ACE2 Heteromer
A0A6J0Z472; P0DTC2;
28-1145
14×NAG; 25×NAG;ZN;
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43 Heteromer
P0DTC2;
27-1144
NAG;NAG; 31×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-15 Heteromer
P0DTC2;
27-1144
NAG;NAG;NAG; 31×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Delta Spike protein in complex with BA7208 and BA7125 fab Heteromer
P0DTC2;
26-1143
12×NAG; 12×NAG;
Assess
SARS-CoV-2 Delta Spike in complex with FP-12A Heteromer
P0DTC2;
25-1140
NAG; 21×NAG;
Assess
SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (two receptor-bindin… Heteromer
P0DTC2;
26-1141
NAG; 37×NAG;
Assess
Cryo-EM structure of SARS-CoV2 Omicron BA.5 spike in complex with 8-9D Fabs Heteromer
P0DTC2;
27-1141
27×NAG;
Assess
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2) Heteromer
P0DTC2;
27-1141
NAG; 27×NAG;
Assess
SARS-CoV-2 BA.4 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C Heteromer
P0DTC2;
27-1141
NAG;
Assess
Structure of SARS-CoV-2 Omicron BA.1 spike in complex with antibody Fab 1C3 Heteromer
P0DTC2;
26-1139
NAG; 18×NAG;
Assess
Conformation 1 of SARS-CoV-2 Omicron BA.1 Variant Spike protein complexed with MO1 Fab Heteromer
P0DTC2;
27-1140
22×NAG;
Assess
Conformation 2 of SARS-CoV-2 Omicron BA.1 Variant Spike protein complexed with MO1 Fab Heteromer
P0DTC2;
27-1140
28×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… Heteromer
P0DTC2;
27-1140
12×NAG;NAG; 33×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab f… Heteromer
P0DTC2;
27-1140
10×NAG;NAG;NAG; 35×NAG;
Assess
Minor cryo-EM structure of S protein trimer of SARS-CoV2 with K-874A VHH, composite map Heteromer
P0DTC2;
27-1138
Assess
Major cryo-EM structure of S protein trimer of SARS-CoV2 with K-874, composite map Heteromer
P0DTC2;
27-1138
Assess
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (2-up state) Heteromer
P0DTC2; Q9BYF1;
28-1139
NAG;NAG;NAG; 42×NAG;
Assess
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (1-up state) Heteromer
P0DTC2; Q9BYF1;
28-1139
NAG;NAG;NAG; 35×NAG;
Assess
VFLIP Spike Trimer with GAR03 Heteromer
P0DTC2;
27-1135
Assess
SARS-CoV-2 S Omicron Spike B.1.1.529 - RBD and NTD (Local) Heteromer
P0DTC2;
19-1061
NAG;NAG;NAG;
Assess
Structure of the SARS-CoV-2 S1 subunit in complex with antibody N-612-004 Heteromer
P0DTC2;
12-700
Assess
Local refinement of SARS-CoV-2 spike/nanobody mixture complex around NTD Heteromer
P0DTC2;
14-700
35×NAG;
Assess
CryoEM structure of SARS-CoV-2 spike monomer in complex with neutralising antibody P008_60 Heteromer
P0DTC2;
14-697
NAG;3Q9;
Assess
Omicron spike variant BA.1 with Bn03 Heteromer
P0DTC2;
26-699
Assess
Omicron spike variant XBB with Bn03 Heteromer
P0DTC2;
28-699
Assess
Omicron spike variant XBB with n3130v-Fc Heteromer
P0DTC2;
28-699
Assess
Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2 Heteromer
P0DTC2; Q9BYF1;
14-676
ZN;NAG;
Assess
Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Unmasked Refinement) Heteromer
P0DTC2; Q9BYF1;
14-676
NAG;NAG;ZN;
Assess
Structure of the SARS-CoV-2 S S1 doamin in complex with the mouse antibody Fab fragment, HSW-2 Heteromer
P0DTC2;
24-676
NAG;
Assess
Omicron spike variant BQ.1.1 with n3130v-Fc Heteromer
P0DTC2;
28-677
Assess
SARS-CoV-2 wildtype S1 in complex with YB9-258 Fab and R1-32 Fab Heteromer
P0DTC2;
33-676
NAG;
Assess
Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement) Heteromer
P0DTC2;
33-676
NAG;
Assess
local refinement of SARS-CoV-2 spike/Nb4 complex with 2 RBDs up and 3 Nb4 bound Heteromer
P0DTC2;
14-620
12×NAG;
Assess
SARS-CoV-2 spike/Nb3 complex with 2 RBDs up and 3 Nb3 (local refinement) Heteromer
P0DTC2;
14-592
NAG;
Assess
SARS-CoV-2 spike/Nb3 complex with 1 RBD up and 2 Nb3 (local refinement) Heteromer
P0DTC2;
14-592
NAG;
Assess
SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB9-258 Fab, focused refinement of Fab re… Heteromer
P0DTC2;
14-588
NAG;
Assess
SARS-CoV-2 Omicron BA.1 spike trimer (6P) complex with YB9-258 Fab, focused refinement of RBD-dimer… Heteromer
P0DTC2;
14-588
NAG;
Assess
SARS-CoV-2 spike trimer RBD in complex with Fab NA8 Heteromer
P0DTC2;
27-590
NAG;
Assess
SARS-CoV-2 spike trimer RBD in complex with Fab NE12 Heteromer
P0DTC2;
32-590
NAG;
Assess
SARS-CoV-2 S protein bound to neutralising antibody UZGENT_A3 Heteromer
P0DTC2;
14-567
NAG;NAG;NAG;
Assess
SARS-CoV-2 S protein bound to human neutralising antibody UZGENT_G5 Heteromer
P0DTC2;
15-567
NAG;NAG;
Assess
Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement) Heteromer
P0DTC2;
33-579
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike (Omicron BA.1 variant) in complex with nanobody W25 (map 5, f… Heteromer
P0DTC2;
14-529
NAG;NAG;NAG;
Assess
SARS-CoV-2 Spike (2P) in complex with G32R7 Fab (RBD and NTD local reconstruction) Heteromer
P0DTC2;
14-528
NAG;NAG;NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike (HexaPro variant) in complex with nanobody W25 (map 3, focus … Heteromer
P0DTC2;
15-528
NAG;NAG;NAG;
Assess
SARS-CoV-2 NTD in complex with N9 Fab Heteromer
P0DTC2;
14-526
Assess
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab (state1, local refinement of the … Heteromer
P0DTC2;
27-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike protein in complex with nanobody C5G2 (localized refinement) Heteromer
P0DTC2;
27-517
NAG;
Assess
Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-804 Fab Heteromer
P0DTC2;
28-516
NAG;
Assess
Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-813 Fab and BD-744 Fab Heteromer
P0DTC2;
28-516
Assess
Local CryoEM of the SARS-CoV-2 S6PV2 in complex with BD-667 Heteromer
P0DTC2;
28-516
NAG;
Assess
Crystal structure of a chimeric protein mimic of SARS-CoV-2 Spike HR1 in complex with HR2 Heteromer
P0DTC2;
757-1203
Assess
Structure of the SARS-CoV-2 NTD in complex with C1520, local refinement Heteromer
P0DTC2;
14-322
NAG;NAG;
Assess
Structure of viral peptides IPB19/N52 Heteromer
P0DTC2;
908-1201
Assess
Crystal structure of the N-terminal domain of SARS-CoV-2 beta variant spike glycoprotein in complex… Heteromer
P0DTC2;
13-305
NAG;NAG;NAG;CL;PEG;GOL;PO4;NAG;PG4;
Assess
Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with Fab 4-8 (focused refineme… Heteromer
P0DTC2;
14-306
NAG;
Assess
SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement Heteromer
P0DTC2;
14-306
NAG;NAG;
Assess
SARS-CoV-2 S NTD B.1.1.529 Omicron variant + S309 Local Refinement Heteromer
P0DTC2;
14-306
NAG;
Assess
SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement Heteromer
P0DTC2;
14-306
NAG;NAG;
Assess
Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab Heteromer
P0DTC2;
14-305
NAG;NAG;NAG;NAG;UNX;XYL;SO4;
Assess
SARS-CoV-2 S NTD B.1.617.1 kappa variant S2X303 Local Refinement Heteromer
P0DTC2;
14-305
NAG;NAG;
Assess
SARS-CoV-2 S NTD (C.37 Lambda variant) plus S2L20 and S2X303 Fabs, local refinement Heteromer
P0DTC2;
14-305
NAG;NAG;NAG;
Assess
SARS-CoV-2 Spike NTD in complex with neutralizing Fab SARS2-57 (local refinement) Heteromer
P0DTC2;
14-304
NAG;NAG;
Assess
Crystallographic structure of neutralizing antibody 2-51 in complex with SARS-CoV-2 spike N-termina… Heteromer
P0DTC2;
14-303
NAG;NAG; 23×CA;ACT;PGE;
Assess
an engineered 5-helix bundle derived from SARS-CoV-2 S2 in complex with HR2P Heteromer
P0DTC2;
918-1204
Assess
Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with A942S mutation Heteromer
P0DTC2;
918-1200
Assess
Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with L938F mutation Heteromer
P0DTC2;
918-1200
Assess
Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with V1176F mutation Heteromer
P0DTC2;
918-1200
Assess
Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex Heteromer
P0DTC2;
918-1200
Assess
Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with S940F mutation Heteromer
P0DTC2;
918-1200
Assess
Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with D936Y mutation Heteromer
P0DTC2;
918-1200
Assess
Structure of the SARS-CoV-2 Omicron spike post-fusion bundle Heteromer
P0DTC2;
918-1200
Assess
Cryo-EM structure of the SARS-CoV-2 Omicron HR1-42G complex Heteromer
P0DTC2;
918-1200
Assess
Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with extended HR2 Heteromer
P0DTC2;
918-1200
Assess
SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20) Heteromer
P0DTC2;
27-306
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with Fab 4A8 (focused refinem… Heteromer
P0DTC2;
14-293
NAG;NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with Fab 4A8 (focused refineme… Heteromer
P0DTC2;
14-293
NAG;NAG;
Assess
SARS-CoV-2 Spike Protein N terminal domain in Complex with N11 Fab Heteromer
P0DTC2;
13-290
Assess
SARS-CoV-2 Spike in complex with PVI.V6-14 Fab Heteromer
A0A5C2FYK4; P0DTC2;
14-291
NAG;NAG;
Assess
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2 Heteromer
P0DTC2;
14-290
Assess
Local CryoEM structure of del68-76/del679-688 prefusion-stabilized spike in complex with the Fab of… Heteromer
P0DTC2;
14-290
Assess
SARS-CoV-2 Spike (2P) in complex with C12C9 Fab (NTD local reconstruction) Heteromer
P0DTC2;
14-290
NAG;
Assess
SARS-CoV-2 spike in complex with the ZB8 neutralizing antibody Fab (focused refinement on Fab-RBD) Heteromer
P0DTC2;
317-593
Assess
SARS-CoV-2 Beta spike SD1 in complex with S3H3 Fab Heteromer
P0DTC2;
318-593
Assess
SARS-CoV-2 Omicron spike protein SD1 in complex with S3H3 Fab Heteromer
P0DTC2;
318-593
Assess
sd1.040 Fab in complex with SARS-CoV-2 Spike 2P glycoprotein Heteromer
P0DTC2;
321-591
NAG;
Assess
SARS-CoV-2 spike/Nb2 complex with 1 RBD up (local refinement at 5.6 A) Heteromer
P0DTC2;
321-591
Assess
Cryo-EM structure of SARS-CoV-2 Omicron RBD in complex with S309 fab (local refinement) Heteromer
P0DTC2;
322-590
NAG;
Assess
Dissociated S1 domain of Mink Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) Heteromer
P0DTC2; Q9BYF1;
322-590
ZN;NAG;
Assess
Dissociated S1 domain of Alpha Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) Heteromer
P0DTC2; Q9BYF1;
322-590
ZN;NAG;
Assess
Dissociated S1 domain of SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) Heteromer
P0DTC2; Q9BYF1;
322-590
NAG;NAG;ZN;
Assess
Dissociated S1 domain of Beta Variant SARS-CoV-2 Spike bound to ACE2 (Non-Uniform Refinement) Heteromer
P0DTC2; Q9BYF1;
323-590
NAG;ZN;
Assess
SARS-CoV-2 RBD in complex with Omicron-neutralizing antibody 2A10 Heteromer
P0DTC2;
326-591
NAG;
Assess
Cryo-EM structure of spike binding to Fab of neutralizing antibody (locally refined) Heteromer
P0DTC2;
333-590
NAG;
Assess
SARS-CoV-2 S-NTD + Fab CM25 Heteromer
P0DTC2;
14-270
Assess
Antibody A7V3 bound to N-terminal domain of the spike Heteromer
P0DTC2;
14-270
NAG;
Assess
SARS-CoV-2 S/S2M11/S2M28 Local Refinement Heteromer
P0DTC2;
14-267
NAG;NAG;
Assess
SARS-CoV-2 S/S2M11/S2L28 Local Refinement Heteromer
P0DTC2;
14-265
NAG;NAG;
Assess
OMI-38 FAB IN COMPLEX WITH SARS-COV-2 BETA SPIKE RBD (local refinement) Heteromer
P0DTC2;
323-567
NAG;
Assess
SARS-CoV-2 S/S2M11/S2X333 Local Refinement Heteromer
P0DTC2;
14-251
NAG;NAG;
Assess
Structure of human SARS-CoV-2 neutralizing antibody C1C-A3 Fab Heteromer
P0DTC2;
319-541
NAG;NAG;
Assess
Crystallographic structure of two neutralizing nanobodies in complex with SARS-CoV-2 spike receptor… Heteromer
P0DTC2;
309-529
NAG;NAG;PEG;GOL;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2;
319-536
Assess
Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibo… Heteromer
P0DTC2;
321-537
NAG;
Assess
SARS-CoV-2 spike in complex with the 17T2 neutralizing antibody Fab fragment (local refinement of R… Heteromer
P0DTC2;
324-533
NAG;
Assess
SARS-CoV-2 Spike:Fab 3D11 complex focused refinement Heteromer
P0DTC2;
329-537
NAG;
Assess
SARS-CoV-2 Spike:5A6 Fab complex I focused refinement Heteromer
P0DTC2;
329-537
NAG;
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
325-532
NAG;
Assess
Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing… Heteromer
P0DTC2;
326-532
NAG;
Assess
CC6.33 IgG in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refinement) Heteromer
P0DTC2;
326-532
NAG;NAG;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2;
326-530
NAG;
Assess
SARS Cov2 Spike RBD in complex with Fab47 Heteromer
P0DTC2;
327-531
Assess
immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6 Heteromer
P0DTC2;
324-527
NAG;NAG;
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with a human single domain antibody n3113 Heteromer
P0DTC2;
328-531
NAG;
Assess
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immuni… Heteromer
P0DTC2; Q9BYF1;
329-531
NAG;CL;SO4;NA;PG5;ZN;NAG;PGE;
Assess
Structure of RBD directed antibody DH1047 in complex with SARS-CoV-2 spike: Local refinement of RBD… Heteromer
P0DTC2;
330-532
NAG;
Assess
Structure of sybody SR31 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) Heteromer
P0DTC2;
330-531
NAG; 13×FMT;GOL;ACT;
Assess
Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with human ACE2 (focused… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Local refinement of SARS-CoV-2 S-Gamma variant (P.1) RBD and Angiotensin-converting enzyme 2 (ACE2)… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;NAG;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomain bound to human ACE2… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike protein in complex with human ACE2 (focused refinemen… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Structure of the SARS-CoV-2 BA.1 RBD with UT28-RD Heteromer
P0DTC2;
329-529
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomain bound t… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomain bound to huma… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with mouse ACE2 (focused refi… Heteromer
P0DTC2; Q8R0I0;
330-530
NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectod… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with human ACE2 (focused re… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike protein in complex with human ACE2 (focused refin… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Neutral Omicron Spike Trimer in complex with ACE2. Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Local refinement of SARS-CoV-2 S-Beta variant (B.1.351) RBD and Angiotensin-converting enzyme 2 (AC… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomain bound to human ACE2 ectod… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Local refinement of SARS-CoV-2 S-Kappa variant (B.1.617.1) RBD and Angiotensin-converting enzyme 2 … Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;NAG;NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-45 (Focused refi… Heteromer
P0DTC2;
330-530
Assess
Local refinement of SARS-CoV-2 S-Delta variant (B.1.617.2) RBD and Angiotensin-converting enzyme 2 … Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;NAG;NAG;
Assess
SARS-CoV-2 Omicron variant spike RBD in complex with Fab 9A8 Heteromer
P0DTC2;
330-530
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomain bound t… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv347 Heteromer
P0DTC2;
330-530
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.1 spike protein in complex with mouse ACE2 (focused refi… Heteromer
P0DTC2; Q8R0I0;
330-530
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike protein in complex with human ACE2 (focused r… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 (focused… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to computationally engineered ACE2 mimetic CVD293 Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 (focused… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv265 Heteromer
P0DTC2;
330-530
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein in complex with human ACE2 (focused refi… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv051 Heteromer
P0DTC2;
330-530
Assess
SARS-CoV-2 Spike RBD in complex with the single chain fragment scFv76 (Focused Refinement) Heteromer
P0DTC2;
329-529
NAG;
Assess
SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv289 Heteromer
P0DTC2;
330-530
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refi… Heteromer
P0DTC2;
330-530
Assess
SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv282 Heteromer
P0DTC2;
330-530
Assess
SARS-CoV-2 S-RBD + Fab 54042-4 Heteromer
P0DTC2;
329-529
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomain bound to human ACE2… Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
329-529
NAG;NAG;NAG;
Assess
SARS-CoV-2 Wuhan-hu-1-Spike-RBD bound to linker variant of affinity matured ACE2 mimetic CVD432 Heteromer
P0DTC2; Q9BYF1;
330-530
NAG;
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab Heteromer
P0DTC2;
330-529
DMS;MLI;NAG;1PE;
Assess
SARS-CoV-2 Beta RBD in complex with human ACE2 and S304 Fab and S309 Fab Heteromer
P0DTC2; Q9BYF1;
330-529
NAG; 30×EDO; 22×CL;ZN; 13×NAG;
Assess
SARS-CoV-2 RBD in complex with Fab 15033-7 Heteromer
P0DTC2;
329-528
NAG;
Assess
SARS-CoV-2 RBD in complex with Fab 15033 Heteromer
P0DTC2;
329-528
NAG;
Assess
A human neutralizing antibody targeting SARS-CoV-2 RBD Heteromer
P0DTC2;
333-532
NAG;
Assess
A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2 Heteromer
P0DTC2;
333-532
NAG;
Assess
The SARS-CoV-2 receptor binding domain bound with an Fv-clasp form of a human neutralizing antibody… Heteromer
P0DTC2;
330-529
NAG;
Assess
Cryo-EM structure of S309-RBD-RBD-S309 in the S309-bound Omicron spike protein (local refinement) Heteromer
P0DTC2;
330-529
NAG;
Assess
Local refinement of the SARS-CoV-2 Spike trimer in complex with RmAb 9H1 Fab Heteromer
P0DTC2;
331-530
NAG;NAG;
Assess
SARS-CoV-2 S RBD B.1.617.1 kappa variant S309 Local Refinement Heteromer
P0DTC2;
329-528
NAG;NAG;
Assess
Structures of Omicron Spike complexes illuminate broad-spectrum neutralizing antibody development Heteromer
P0DTC2;
331-530
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3 Heteromer
P0DTC2;
334-532
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BQ.1.1 variant spike protein… Heteromer
P0DTC2; Q9BYF1;
329-527
NAG;NAG;NAG;ZN;NAG;
Assess
SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab Heteromer
P0DTC2;
330-528
NAG;CL;
Assess
Structure of the SARS-CoV-2 RBD in complex with the mouse antibody Fab fragment, HSW-2 Heteromer
P0DTC2;
333-531
NAG;
Assess
Structure of SARS-CoV-2 spike RBD in complex with cyclic peptide Heteromer
P0DTC2;
328-526
NAG;
Assess
The interface of JMB2002 Fab binds to SARS-CoV-2 Omicron Variant S Heteromer
P0DTC2;
331-529
Assess
Structure of SARS-CoV-2 XBB.1.5 spike RBD in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
331-529
NAG;NAG;NAG;NAG;
Assess
Local refinement of SARS-CoV-2 spike/nanobody mixture complex around RBD Heteromer
P0DTC2;
331-529
Assess
Structure of sybody MR17-SR31 fusion in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) Heteromer
P0DTC2;
334-531
NAG;GOL; 14×ACT;1PE;BU2; 17×CD;
Assess
Nanobody F2 bound to RBD Heteromer
P0DTC2;
331-528
NAG;
Assess
SARS-CoV-2 spike receptor-binding domain with a G485R mutation in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
333-530
NAG;NAG;EDO;ZN;
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with FP-12A Fab Heteromer
P0DTC2;
333-530
NAG;
Assess
Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by st… Heteromer
P0DTC2;
332-529
NAG;
Assess
Crystal structure of S43 bound to SARS-CoV-2 RBD Heteromer
P0DTC2;
333-530
NAG;NAG;
Assess
Crystal structure of a neutralizing monoclonal antibody (Ab08) in complex with SARS-CoV-2 receptor-… Heteromer
P0DTC2;
334-531
NAG;MPD;CA;CL;
Assess
SARS-CoV-2 Omicron RBD in complex with human ACE2 and S304 Fab and S309 Fab Heteromer
P0DTC2; Q9BYF1;
332-529
EDO; 11×CL;ZN;NAG;
Assess
Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizin… Heteromer
P0DTC2;
332-529
NAG;EDO; 11×SO4;
Assess
Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody N-612-056 Heteromer
P0DTC2;
331-528
NAG;
Assess
Crystal structure of SARS-CoV-2 omicron variant spike receptor-binding domain (RBD) in complex with… Heteromer
P0DTC2;
333-530
SO4;
Assess
Local refinement of SARS-CoV-2 Omicron S trimer complexed with XG005 Heteromer
P0DTC2;
331-528
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
331-528
NAG;
Assess
Three RBD-down state of SARS-CoV-2 D614G spike in complex with the SP1-77 neutralizing antibody Fab… Heteromer
P0DTC2;
332-529
NAG;
Assess
SIT1-ACE2-BA.2 RBD Heteromer
P0DTC2; Q9BYF1; Q9NP91;
333-530
16×NAG;NAG;3PH;ZN;
Assess
Local refinement of SARS-CoV-2 vaccine induced antibody DH1338 bound to SARS-CoV-2 HexaPro RBD Spik… Heteromer
P0DTC2;
333-530
NAG;
Assess
The second RBD of SARS-CoV-2 Omicron Variant in complexed with RBD-ACE2 Heteromer
P0DTC2; Q9BYF1;
331-528
NAG;CL;ZN;NAG;
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
332-529
NAG;
Assess
Omicron RBDs bound with P3E6 Fab (one up and one down) Heteromer
P0DTC2;
331-528
Assess
The local refined map of Omicron spike with bispecific antibody FD01 Heteromer
P0DTC2;
331-528
Assess
SARS-CoV-2 Omicron BA.2 Variant RBD complexed with human ACE2 Heteromer
P0DTC2; Q9BYF1;
331-528
CL;ZN;NAG;
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
332-529
NAG;NAG;
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
331-528
NAG;
Assess
SARS-CoV-2 Omicron Variant RBD complexed with ACE2 Heteromer
P0DTC2; Q9BYF1;
331-528
NAG;CL;ZN;
Assess
SIT1-ACE2-BA.5 RBD Heteromer
P0DTC2; Q9BYF1; Q9NP91;
333-530
16×NAG;NAG;3PH;ZN;
Assess
Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with human ACE2 (focused refinemen… Heteromer
P0DTC2; Q9BYF1;
330-527
NAG;NAG;
Assess
Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike protein in complex with mouse ACE2 (focused refinemen… Heteromer
P0DTC2; Q8R0I0;
330-527
NAG;NAG;NAG;
Assess
Local refinement of RBD-ACE2 Heteromer
P0DTC2; Q9BYF1;
332-529
NAG;NAG;ZN;
Assess
Nanobody H3 AND C1 bound to RBD with Kent mutation Heteromer
P0DTC2;
334-530
NAG;CIT;CL;
Assess
Crystal structure of synthetic nanobody (Sb14+Sb68) complexes with SARS-CoV-2 receptor binding doma… Heteromer
P0DTC2;
332-528
EDO;GOL;
Assess
Nanobody H3 AND C1 bound to RBD Heteromer
P0DTC2;
334-530
NAG;CIT;CL;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain (RBD) in complex with NCV2SG48 Fab Heteromer
P0DTC2;
334-530
NAG;SO4;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… Heteromer
P0DTC2;
331-527
NAG;
Assess
SARS-CoV-2 receptor binding domain in complex with WNb-2 Heteromer
P0DTC2;
331-527
NAG;PG4;
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab Heteromer
P0DTC2;
334-530
CIT;NAG;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv Heteromer
P0DTC2;
334-530
CA;NAG;
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutr… Heteromer
P0DTC2;
334-530
NAG;
Assess
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral … Heteromer
P0DTC2;
332-528
NAG;
Assess
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex Heteromer
P0DTC2;
332-528
NAG;
Assess
Crystal structure of BD55-1403 and SARS-CoV-2 Omicron RBD Heteromer
P0DTC2;
332-528
NAG;
Assess
Crystal structure of human ACE2 bound to the spike receptor-binding domain from a cave bat sarbecov… Heteromer
P0DTC2; Q9BYF1;
332-528
NAG;NAG;SO4;TRS;PEG;ZN;CL;GOL;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… Heteromer
P0DTC2;
331-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… Heteromer
P0DTC2;
331-527
NAG;
Assess
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A … Heteromer
P0DTC2;
333-529
NAG;PO4;
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal for… Heteromer
P0DTC2;
333-529
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
332-528
NAG;
Assess
SARS-CoV-2 BA.1 spike ectodomain trimer in complex with the S2X324 neutralizing antibody Fab fragme… Heteromer
P0DTC2;
334-530
NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (focused… Heteromer
P0DTC2;
332-528
NAG;
Assess
SARS-CoV-2 Omicron S monomer complexed with 553-49 Heteromer
P0DTC2;
332-528
Assess
SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv264 Heteromer
P0DTC2;
332-528
Assess
Cryo-EM structure of SARS-CoV-2 BA.2 RBD in complex with BA7535 fab (local refinement) Heteromer
P0DTC2;
332-528
Assess
SARS-CoV-2 Omicron variant spike RBD in complex with Fab XGv286 Heteromer
P0DTC2;
332-528
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with golden hamster ACE2 (local refinem… Heteromer
A0A1U7QTA1; P0DTC2;
332-528
ZN;NAG;
Assess
RBD-1 of SARS-CoV-2 Beta spike in complex with S5D2 Fab Heteromer
P0DTC2;
332-528
Assess
Nanobody C5 bound to RBD Heteromer
P0DTC2;
332-527
NAG;ACT;
Assess
The crystal structure of RBD-Nanobody complex, DL4 (SA4) Heteromer
P0DTC2;
334-529
NAG;GOL;ACT;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with aRBD5 Heteromer
P0DTC2;
333-528
NAG;
Assess
Crystal structure of nanobody 1-2C7 with SARS-CoV-2 RBD Heteromer
P0DTC2;
333-528
NAG;
Assess
Crystallographic structure of neutralizing antibody P14-44 in complex with SARS-CoV-2 spike recepto… Heteromer
P0DTC2;
333-528
NAG;GOL;
Assess
Nanobody H11-B5 and H11-F2 bound to RBD Heteromer
P0DTC2;
333-528
NAG;PEG;
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with VNAR 3B4 Heteromer
P0DTC2;
334-529
NAG;EDO;
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neu… Heteromer
P0DTC2;
334-529
NAG; 16×EDO;
Assess
Crystal structure of SARS-CoV-2 Receptor Binding Domain bound to A6 repebody Heteromer
P0DTC2;
333-528
NAG;
Assess
Crystal Structure of SARS-CoV-2 S delta variant receptor-binding domain (RBD) in complex CoV11 Fab … Heteromer
P0DTC2;
334-529
NAG;CIT;
Assess
Structure of the SARS-CoV-2 RBD in complex with the mouse antibody Fab fragment, M8a-34 Heteromer
P0DTC2;
333-528
NAG;
Assess
RBD domain of SARS-CoV2 in complex with neutralizing nanobody NM1226 Heteromer
P0DTC2;
332-527
NAG;PO4;PEG;
Assess
Crystal structure of synthetic nanobody (Sb45) complexes with SARS-CoV-2 receptor binding domain Heteromer
P0DTC2;
333-528
Assess
Nanobody H11-A10 and F2 bound to RBD Heteromer
P0DTC2;
333-528
NAG;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain (RBD) in complex with NCV2SG53 Fab Heteromer
P0DTC2;
333-528
SO4;NAG;
Assess
Fab arm of antibodies 4G1-C2 and 10G4 bound to CoV-2 receptor binding domain (RBD) Heteromer
P0DTC2; Q6GMX0;
333-528
GOL;NAG;
Assess
SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93 Heteromer
P0DTC2;
332-527
NAG;GOL;
Assess
Crystal structure of nanobody 3-2A2-4 with SARS-CoV-2 RBD Heteromer
P0DTC2;
333-528
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibodies CV0… Heteromer
P0DTC2;
334-529
EDO;NAG; 10×SO4;
Assess
Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibody AZD8895 Heteromer
P0DTC2;
334-529
GOL;NAG;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing … Heteromer
P0DTC2;
334-529
NAG;
Assess
Nanobody H11 and F2 bound to RBD Heteromer
P0DTC2;
333-528
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… Heteromer
P0DTC2;
333-528
NAG;IMD;CL;GLU;GLY;PGE;GOL;PG4;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing IGHV3-53-encoded antibody EH3 … Heteromer
P0DTC2;
334-529
NAG;
Assess
SARS-CoV-2-Beta-RBD and CB6-092-Fab complex Heteromer
P0DTC2;
333-528
Assess
Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing ant… Heteromer
P0DTC2;
332-527
NAG;NI;EDO;
Assess
Fab arms of antibodies GAR03 and 10G4 bound to the receptor binding domain of SARS-CoV-2 in a 1:1:1… Heteromer
P0DTC2;
333-528
NAG;CL;
Assess
SARS-CoV-2-prototyped-RBD and CB6-092-Fab complex Heteromer
P0DTC2;
333-528
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing nanobody 17F6 Heteromer
P0DTC2;
332-527
NAG;
Assess
SARS-CoV2 RBD bound to Fab06 Heteromer
P0DTC2;
333-528
NAG;
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with the ultrapotent antibody CV2.1169 and CR3022 Heteromer
P0DTC2;
333-528
NAG;SO4;
Assess
SARS-CoV-2-Beta-RBD and B38-GWP/P-VK antibody complex Heteromer
P0DTC2;
333-528
NAG;
Assess
The crystal structure of RBD-Nanobody complex, DL28 (SC4) Heteromer
P0DTC2;
334-529
NAG;GOL;
Assess
Soaking competent crystal form of the SARS-CoV-2 Receptor Binding Domain (RBD):CR3022 complex. Heteromer
P0DTC2;
333-528
NAG;
Assess
Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022 Heteromer
P0DTC2;
333-528
NAG;
Assess
Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody… Heteromer
P0DTC2;
333-528
NAG;
Assess
Structure of SARS-CoV-2 spike receptor-binding domain complexed with high affinity ACE2 mutant 3N39 Heteromer
P0DTC2; Q9BYF1;
332-527
NAG;NAG;NAG;NAG;ZN;SO4;
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab Heteromer
P0DTC2;
333-528
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with SARS-CoV-2 reactive human a… Heteromer
P0DTC2;
332-527
NAG;
Assess
SARS-CoV-2 BA.2.75 S Trimer in complex with S309 (interface) Heteromer
P0DTC2;
332-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets t… Heteromer
P0DTC2;
332-527
NAG;NAG;
Assess
Local refine of Omicron spike bitrimer with 6m6 antibody Heteromer
P0DTC2;
333-528
NAG;
Assess
The complex structure of Omicron BA.4 RBD with BD604, S309, and S304 Heteromer
P0DTC2;
333-528
NAG;
Assess
Local refinement of cryo-EM structure of the interface of the Omicron RBD in complex with antibodie… Heteromer
P0DTC2;
331-526
NAG;
Assess
17B10 fab in complex with up-RBD of SARS-CoV-2 Spike G614 trimer Heteromer
P0DTC2;
333-528
NAG;
Assess
Locally refined region of SARS-CoV-2 spike in complex with antibodies B1-182.1 and A19-61.1 Heteromer
P0DTC2;
332-527
NAG;
Assess
cryo-EM structure of omicron spike in complex with de novo designed binder, local Heteromer
P0DTC2; Q9VKJ9;
332-527
NAG;
Assess
XBB.1.5.10 RBD in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
334-529
NAG;
Assess
Local CryoEM structure of the SARS-CoV-2 S6P in complex with 14B1 Fab Heteromer
P0DTC2;
333-528
NAG;
Assess
SARS-CoV-2 XBB.1.5.70 in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
334-529
NAG;
Assess
SARS-CoV-2 Spike RBD (dimer) in complex with two Fu2 nanobodies Heteromer
P0DTC2;
333-528
NAG;
Assess
Local CryoEM structure of the SARS-CoV-2 S6P in complex with 7B3 Fab Heteromer
P0DTC2;
333-528
NAG;
Assess
XBB.1.5 RBD in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
334-529
NAG;
Assess
CryoEM structure of SARS CoV-2 RBD and Aptamer complex Heteromer
P0DTC2;
333-528
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Delta RBD in complex with BA7054 and BA7125 fab (local refinement) Heteromer
P0DTC2;
333-528
Assess
SARS-CoV-2 S B.1.1.529 Omicron variant (RBD + S309 Local Refinement) Heteromer
P0DTC2;
332-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets t… Heteromer
P0DTC2;
332-527
NAG;
Assess
The SARS-CoV-2 spike protein receptor binding domain bound to neutralizing nanobodies WNb 2 and WNb… Heteromer
P0DTC2;
333-528
Assess
CryoEM structure of SARS CoV-2 RBD and Aptamer complex Heteromer
P0DTC2;
333-528
NAG;
Assess
MaP OF P5C3RBD Interface Heteromer
P0DTC2;
332-527
Assess
XBB.1.5 RBD in complex with BD55-1205 Heteromer
P0DTC2;
334-529
Assess
RBD of SARS-CoV2 spike protein with ACE2 decoy Heteromer
P0DTC2; Q9BYF1;
332-527
NAG;NAG;NAG;NAG;ZN;SO4;
Assess
Crystal structure of neutralizing VHH P17 in complex with SARS-CoV-2 Alpha variant spike receptor-b… Heteromer
P0DTC2;
334-528
NAG; 12×EDO;
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutr… Heteromer
P0DTC2;
334-528
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 21B6 Heteromer
P0DTC2;
333-527
NAG;SO4;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
P0DTC2;
333-527
NAG; 19×EDO;NO3;PEG;SO4;CL;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC25.4 Heteromer
P0DTC2;
333-527
NAG;MPD;
Assess
THSC20.HVTR26 Fab bound to SARS-CoV-2 Receptor Binding Domain Heteromer
P0DTC2;
333-527
NAG;EPE;
Assess
H11-D4 complex with SARS-CoV-2 RBD Heteromer
P0DTC2;
334-528
NAG; 12×EDO;ACT;
Assess
SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab Heteromer
P0DTC2;
333-527
NAG; 23×SO4;GOL;CL;POL;
Assess
Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody Heteromer
P0DTC2;
334-528
NAG;
Assess
H11-H4 complex with SARS-CoV-2 Heteromer
P0DTC2;
334-528
NAG;SO4;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobodies VHH E and U Heteromer
P0DTC2;
334-528
NAG;EDO;
Assess
Fab arm of antibody 10G4 bound to CoV-2 receptor binding domain (RBD) Heteromer
P0DTC2;
334-528
NAG;NAG;MG;CL;
Assess
SARS-CoV-2 Omicron BA.4/5 RBD in complex with Beta-27 Fab and C1 nanobody Heteromer
P0DTC2;
333-527
10×GOL;IPA;NAG;PG4;
Assess
immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6 Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobodies VHH-F04 and VHH-G09 Heteromer
P0DTC2;
334-528
NAG;CL;
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with VNAR 2C02 Heteromer
P0DTC2;
334-528
EDO;NAG;CL;
Assess
Crystal structure of the SARS-CoV-2 neutralizing VHH 7A9 bound to the spike receptor binding domain Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing … Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD Heteromer
P0DTC2;
333-527
Assess
Crystal structure of SARS-CoV-2 antibody P2C-1F11 with mutated RBD Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with 6-2C Fab Heteromer
P0DTC2;
334-528
NAG;
Assess
SARS-CoV-2 receptor binding domain bound to Fab WCSL 119 Heteromer
P0DTC2;
333-527
NAG;
Assess
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab) Heteromer
P0DTC2;
334-528
NAG;
Assess
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab) Heteromer
P0DTC2;
334-528
NAG;
Assess
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab) Heteromer
P0DTC2;
334-528
NAG;
Assess
Fab arm of antibody GAR12 bound to the receptor binding domain of SARS-CoV-2. Heteromer
P0DTC2;
334-528
NAG;
Assess
Complex between the Fab arm of AB-3467 and the SARS-CoV-2 receptor binding domain (RBD) Heteromer
P0DTC2;
334-528
NAG;CL;SCN;
Assess
Crystal structure of antibody Ab246 in complex with SARS-CoV-2 receptor binding domain Heteromer
P0DTC2;
333-527
CL;GOL;NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
P0DTC2;
333-527
NAG;GOL;TRS;
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with the human antibody CV2.2325 Heteromer
P0DTC2;
334-528
NAG;NA;CL;
Assess
Crystal structure of SARS-CoV-2 BA.2 receptor binding domain in complex with neutralizing antibody … Heteromer
P0DTC2;
333-527
NAG;EDO;GOL;GLY;PEG;
Assess
Crystal structure of SARS-CoV-2 RBD binding to pangolin ACE2 Heteromer
P0DTC2;
333-527
NAG;ZN;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
P0DTC2;
333-527
NAG;GOL;CL;PG4;
Assess
Structure of SARS-CoV-2 spike receptor-binding domain Y453F mutation complexed with human ACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;ZN;
Assess
The receptor binding domain of SARS-CoV-2 Omicron variant spike glycoprotein in complex with Beta-5… Heteromer
P0DTC2;
333-527
NAG;GOL;ACT;CL;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with neutralizing nanobody… Heteromer
P0DTC2;
334-528
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
P0DTC2;
333-527
NAG;GOL;FMT;
Assess
SARS-CoV-2 S protein RBD in complex with A5-10 Fab Heteromer
P0DTC2;
333-527
NAG;
Assess
Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;ZN;
Assess
Crystal structure of SARS CoV-2 Spike Receptor Binding Domain in complex with shark neutralizing VN… Heteromer
P0DTC2;
333-527
NAG;GOL;
Assess
Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
P0DTC2;
333-527
NAG;NAG;GOL;CL;
Assess
Crystal structure of synthetic nanobody (Sb16) complexes with SARS-CoV-2 receptor binding domain Heteromer
P0DTC2;
333-527
Assess
Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022 Heteromer
P0DTC2;
334-528
NAG;
Assess
Structure of SARS-CoV-2 Beta variant spike receptor-binding domain complexed with human ACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;ZN;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022 Heteromer
P0DTC2;
334-528
NAG;
Assess
Crystal structure of Omicron BA.3 RBD complexed with hACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;NAG;ZN;NAG;
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic… Heteromer
P0DTC2;
334-528
NAG;
Assess
Structure of SARS-CoV-2 spike receptor-binding domain F486L mutation complexed with human ACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;ZN;
Assess
Structure of sybody MR17 in complex with the SARS-CoV-2 S receptor-binding domain (RBD) Heteromer
P0DTC2;
333-527
NAG;GOL;
Assess
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab) Heteromer
P0DTC2;
334-528
NAG;
Assess
Structure of SARS-CoV-2 Gamma variant spike receptor-binding domain complexed with human ACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;ZN;
Assess
Crystal structure of Nanobody nb112 and SARS-CoV-2 RBD Heteromer
P0DTC2;
334-528
NAG;
Assess
Structure of SARS-CoV-2 Alpha variant spike receptor-binding domain complexed with human ACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;ZN;
Assess
The crystal structure of SARS-CoV-2 Omicron BA.1 variant RBD in complex with equine ACE2 Heteromer
F6V9L3; P0DTC2;
333-527
ZN;BR;NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies eCR3022.20 and C… Heteromer
P0DTC2;
334-528
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Delta variant in complex with IMCAS7… Heteromer
P0DTC2;
333-527
NAG;
Assess
Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022 Heteromer
P0DTC2;
334-528
NAG;
Assess
SARS-CoV-2-Omicron-RBD and B38-GWP/P-VK antibody complex Heteromer
P0DTC2;
334-528
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutral… Heteromer
P0DTC2;
334-528
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD and horse ACE2 Heteromer
F6V9L3; P0DTC2;
334-528
NAG;
Assess
Crystal structure of Omicron BA.2 RBD complexed with hACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;ZN;NAG;
Assess
Structure of SARS-CoV-2 Omicron BA.2.75 RBD in complex with human ACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;ZN;NAG;
Assess
Crystal structure of T6 Fab bound to theSARS-CoV-2 RBD of B.1.351 Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing … Heteromer
P0DTC2;
334-528
NAG;
Assess
Structure of sybody MR17-K99Y in complex with the SARS-CoV-2 S Receptor-binding domain (RBD) Heteromer
P0DTC2;
333-527
NAG;GOL;
Assess
THSC20.HVTR04 Fab bound to SARS-CoV-2 Receptor Binding Domain Heteromer
P0DTC2;
333-527
NAG;SO4;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutra… Heteromer
P0DTC2;
333-527
NAG;
Assess
Fab HbnC3t1p1_C6 bound to SARS-CoV-2 RBD Heteromer
P0DTC2; Q6PIL8;
333-527
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD binding to dog ACE2 Heteromer
P0DTC2;
333-527
ZN;NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron variant spike glycoprotein i… Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;ZN;
Assess
Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of Omicron BA.1.1 RBD complexed with hACE2 Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;ZN;
Assess
Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and A… Heteromer
P0DTC2;
333-527
PO4;NAG;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing … Heteromer
P0DTC2;
334-528
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022 Heteromer
P0DTC2;
333-527
GOL;SO4;NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1 Heteromer
P0DTC2;
334-528
NAG;
Assess
Crystal structure of neutralizing antibody 80 in complex with SARS-CoV-2 receptor binding domain Heteromer
P0DTC2;
334-528
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in co… Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;
Assess
Structural basis for cross-species recognition of COVID-19 virus spike receptor binding domain to b… Heteromer
E2DHI3; P0DTC2;
333-527
ZN;
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with MW05 Fab Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-3B11 Fab Heteromer
P0DTC2;
334-528
Assess
Crystal structure of SARS-CoV-2 Receptor Binding Domain in complex with the monoclonal antibody m31… Heteromer
P0DTC2;
333-527
NAG;NAG;
Assess
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex Heteromer
P0DTC2;
334-528
NAG;
Assess
Crystal structure of SARS-CoV-2 Omicron spike receptor-binding domain in complex with civet ACE2 Heteromer
P0DTC2; Q56NL1;
333-527
NAG;NAG;ZN;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with broadly neutralizing … Heteromer
P0DTC2;
334-528
NAG;
Assess
Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2) Heteromer
P0DTC2;
334-528
Assess
Crystal structure of SARS-CoV-2 receptor-binding domain in complex with intermediate horseshoe bat … Heteromer
A0A7D7FA76; P0DTC2;
334-528
ZN;NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Delta variant spike glycoprotein in … Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;NAG;ZN;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 25F9 Heteromer
P0DTC2;
333-527
NAG;SO4;BCN;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BA.4/5 variant spike protein… Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;ZN;NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-… Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of antibody WRAIR-2123 in complex with SARS-CoV-2 receptor binding domain Heteromer
P0DTC2;
333-527
NAG;
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 210 Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody COVA309-22 Heteromer
P0DTC2;
333-527
NAG;
Assess
Crystal structure of neutralizing antibody D29 Fab in complex with SARS-CoV-2 spike receptor bindin… Heteromer
P0DTC2;
333-527
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody WRAIR… Heteromer
P0DTC2;
333-527
NAG;GOL;
Assess
Structure of SARS-CoV-2 spike receptor-binding domain F486L mutation complexed with American mink A… Heteromer
A0A8C7BTF2; P0DTC2;
333-527
ZN;
Assess
Cryo-EM structure of hACE2-bound SARS-CoV-2 Omicron spike protein with L371S, P373S and F375S mutat… Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;ZN;
Assess
Structure of SARS-CoV-2 XBB.1 spike RBD in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
332-526
NAG;NAG;NAG;NAG;
Assess
SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of t… Heteromer
P0DTC2;
333-527
NAG;
Assess
Locally refined region of SARS-CoV-2 spike in complex with antibody A19-46.1 Heteromer
P0DTC2;
332-526
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron RBD in complex with human ACE2 ectodomain (local refinement) Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;ZN;NAG;
Assess
SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2B04 (local refinement) Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of human ACE2 complexed with SARS-CoV-2 Omicron RBD Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;ZN;
Assess
Cryo-EM structure of Omicron RBD complexed with ACE2 and 304 Fab Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;ZN;
Assess
Cryo-EM structure of SARS-CoV-2 spike receptor-binding domain complexed with its receptor minke wha… Heteromer
A0A452CBT6; P0DTC2;
333-527
ZN;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with mouse ACE2 (local refinement) Heteromer
P0DTC2; Q8R0I0;
333-527
NAG;ZN;
Assess
Cryo-EM structure of SARS-CoV-2 D614G spike protein in complex with VH ab6 (focused refinement of N… Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of cat ACE2 and SARS-CoV-2 RBD Heteromer
P0DTC2; Q56H28;
333-527
ZN;
Assess
Cryo-EM structure of SARS-CoV-2 Delta RBD in complex with BA7208 and BA7125 fab (local refinement) Heteromer
P0DTC2;
334-528
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 (focused … Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of RBD/E77-Fab complex Heteromer
P0DTC2;
333-527
NAG;
Assess
Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab Heteromer
P0DTC2;
334-528
Assess
SARS-CoV-2 Omicron BA.2 RBD complexed with BD-604 and S304 Fab Heteromer
P0DTC2;
333-527
Assess
Cryo-EM structure of SARS-CoV-2 prototype spike protein receptor-binding domain in complex with whi… Heteromer
A0A6J0Z472; P0DTC2;
333-527
NAG;ZN;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron Prototype RBD in complex with fab L4.65 and L5.34 Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with human ACE2 (local refinement) Heteromer
P0DTC2; Q9BYF1;
333-527
ZN;NAG;
Assess
SARS-CoV-2 spike in complex with AHB2-2GS-SB175 (local refinement of the RBD and AHB2) Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with Fab30 (local refinement of the RBD and Fab… Heteromer
P0DTC2;
333-527
NAG;
Assess
Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REG… Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike receptor-binding domain in complex with sea lion ACE2 Heteromer
A0A6J2EID0; P0DTC2;
333-527
ZN;NAG;
Assess
G32Q4 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction) Heteromer
P0DTC2;
334-528
Assess
Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike protein in complex with VH domain F6 (focused … Heteromer
P0DTC2;
333-527
NAG;
Assess
Nanobody E bound to Spike-RBD in a localized reconstruction Heteromer
P0DTC2;
333-527
NAG;
Assess
C98C7 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction) Heteromer
P0DTC2;
334-528
Assess
Structure of RBD directed antibody DH1042 in complex with SARS-CoV-2 spike: Local refinement of RBD… Heteromer
P0DTC2;
333-527
NAG;
Assess
RBD in complex with Fab14 Heteromer
P0DOX5; P0DTC2;
333-527
NAG;
Assess
The complex structure of Omicron BA.1 RBD with BD604, S309,and S304 Heteromer
P0DTC2;
333-527
NAG;
Assess
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting no… Heteromer
P0DTC2;
334-528
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2.12.1 RBD in complex with human ACE2 (local refinement) Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;NAG;ZN;
Assess
Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike protein in complex with VH ab6 (focused ref… Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike receptor-binding domain in complex with mouse ACE2 Heteromer
P0DTC2; Q8R0I0;
333-527
ZN;NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with human ACE2 (local refinement) Heteromer
P0DTC2; Q9BYF1;
333-527
NAG;NAG;NAG;ZN;
Assess
SARS-CoV-2 BA.2.75 S Trimer in complex with ACE2(interface) Heteromer
P0DTC2; Q9BYF1;
334-528
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with rat ACE2 (local refinement) Heteromer
P0DTC2; Q5EGZ1;
333-527
ZN;NAG;
Assess
SARS-CoV-spike RBD bound to two neutralising nanobodies. Heteromer
P0DTC2;
334-528
NAG;
Assess
SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2H04 (local refinement) Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 receptor binding domain in complex with K202.B bispecific antibody Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with 35B5 Fab(state2, local refinement of the R… Heteromer
P0DTC2;
333-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 prototype spike protein receptor-binding domain in complex with hip… Heteromer
P0DTC2;
333-527
ZN;NAG;
Assess
Nanobody H11-H6 bound to RBD Heteromer
P0DTC2;
334-527
NAG;GOL;
Assess
Nanobody H11-H4 Q98R H100E bound to RBD Heteromer
P0DTC2;
334-527
NAG;GOL;NO3;
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with pT1611 scFV Heteromer
P0DTC2;
334-527
NAG;
Assess
Nanobody C5 bound to Kent variant RBD (N501Y) Heteromer
P0DTC2;
334-527
NAG;GOL;
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with pT1375 scFV Heteromer
P0DTC2;
334-527
NAG;
Assess
LY-CoV488 neutralizing antibody against SARS-CoV-2 Heteromer
P0DTC2;
334-527
NAG;GOL;PRO;
Assess
LY-CoV481 neutralizing antibody against SARS-CoV-2 Heteromer
P0DTC2;
334-527
GOL;NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
333-526
NAG; 13×GOL; 14×CL; 14×K;TAR;
Assess
SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 Heteromer
P0DTC2;
334-527
NAG; 14×GOL;PG4;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain N501Y mutant in complex with neutralizing n… Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
333-526
NAG;CL;
Assess
Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
P0DTC2;
334-527
NAG;GOL;PEG; 12×SO4;CIT;CL;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody K398.… Heteromer
P0DTC2;
334-527
NAG;EDO;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with neutralizing nanobody… Heteromer
P0DTC2;
334-527
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 42 Heteromer
P0DTC2;
334-527
NAG;GOL;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
P0DTC2;
334-527
NAG;PEG;GOL;SO4;CL;TRS;
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with pT1631 scFV Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1 Heteromer
P0DTC2;
334-527
NAG;NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody BIOLS56 Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with IS-9A Fab Heteromer
P0DTC2;
334-527
Assess
Structure of sybody SR4 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD) Heteromer
P0DTC2;
334-527
GOL;NAG;
Assess
Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P2S-2E9 Fab Heteromer
P0DTC2;
333-526
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with antibody CC12… Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2-Beta-RBD and BD-236-GWP/P-VK antibody complex Heteromer
P0DTC2;
333-526
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3… Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96 Heteromer
P0DTC2;
334-527
NAG;MPD;GOL;
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic… Heteromer
P0DTC2;
334-527
NAG;EDO;SO4;PGE;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody… Heteromer
P0DTC2;
334-527
NAG;GOL;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
P0DTC2;
334-527
NAG;NO3;CL;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with the neutralizing nanobody VHH-12 Heteromer
P0DTC2;
334-527
NAG;CL;GOL;SO4;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody K288.2 Heteromer
P0DTC2;
334-527
CAC;
Assess
SARS-CoV-2 Delta-RBD complexed with Omi-42 and Beta-49 Fabs Heteromer
P0DTC2;
333-526
NAG;GOL;SO4;CL;
Assess
Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-300 Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 delta variant spike receptor-binding domain (RBD) in complex with N… Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-CoV-2-Omicron-RBD and BD-236-GWP/P-VK antibody complex Heteromer
P0DTC2;
333-526
Assess
Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
P0DTC2;
334-527
10×SO4;GOL;NAG;PEG;CL;
Assess
Crystal structure of SARS-CoV-2 antibody P22A-1D1 with RBD Heteromer
P0DTC2;
333-526
NAG;
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-623 Fab Heteromer
P0DTC2;
333-526
Assess
Crystal structure of the SARS-Cov-2 RBD in complex with Fab 2303 Heteromer
P0DTC2;
334-527
NAG;
Assess
LY-CoV1404 neutralizing antibody against SARS-CoV-2 Heteromer
P0DTC2;
334-527
NAG;
Assess
The crystal structure of nanobody Nb4 in complex with receptor binding domain (RBD) of BA.1 Spike p… Heteromer
P0DTC2;
334-527
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain bound with ACE2 Heteromer
P0DTC2; Q9BYF1;
333-526
ZN;CL;NAG;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with the ridge-binding nAb EH8 isolated from a nonva… Heteromer
P0DTC2;
334-527
NAG;NAG;NA;
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 37 Heteromer
P0DTC2;
334-527
NAG;SO4;CL;GOL;
Assess
Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (T2… Heteromer
P0DTC2; Q9BYF1;
334-527
NAG;
Assess
Crystal structure of R14 bound to SARS-CoV-2 RBD Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… Heteromer
P0DTC2;
334-527
NAG;ACT;GOL;NAG;
Assess
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with neutralizing antibody W… Heteromer
P0DTC2;
334-527
GOL;NAG;
Assess
Crystal structure of SARS-CoV-2 antibody P5A-1D2 with RBD Heteromer
P0DTC2;
333-526
NAG;
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutr… Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 omicron RBD and human ACE2 Heteromer
P0DTC2; Q9BYF1;
333-526
NAG;ZN;CL;NAG;
Assess
SARS-CoV-2 Receptor-Binding Domain SPEEDesign Immunogen 3 Bound to P2B-2F6 Fab Heteromer
P0DTC2;
333-526
NAG;
Assess
Crystal structure of synthetic nanobody (Sb45+Sb68) complexes with SARS-CoV-2 receptor binding doma… Heteromer
P0DTC2;
334-527
Assess
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex wi… Heteromer
P0DTC2;
333-526
NAG;CL;MG;
Assess
SARS-CoV-2 RBD and Nb22 Heteromer
P0DTC2;
334-527
PG4;
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab Heteromer
P0DTC2;
333-526
Assess
Structure of SARS-CoV-2 spike receptor-binding domain in complex with high affinity ACE2 mutant (S1… Heteromer
P0DTC2; Q9BYF1;
334-527
NAG;
Assess
Structure of SARS-CoV-2 Gamma variant receptor-binding domain complexed with high affinity human AC… Heteromer
P0DTC2; Q9BYF1;
334-527
ZN;NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-… Heteromer
P0DTC2;
334-527
NAG;SO4;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH W and antibody … Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody ADG20 Heteromer
P0DTC2;
334-527
NAG;SO4;CIT;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibodi… Heteromer
P0DTC2;
334-527
GOL;NAG;
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with the human antibody CV2.6264 Heteromer
P0DTC2;
334-527
NAG;NAG;
Assess
Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-1H1 Fab Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with antibody CC12… Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with IY-2A Fab Heteromer
P0DTC2;
334-527
NAG;
Assess
crystal structure of SARS-CoV-2 antibody with RBD Heteromer
P0DTC2;
333-526
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody ADI-5… Heteromer
P0DTC2;
334-527
NAG;SO4;
Assess
Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizin… Heteromer
P0DTC2;
334-527
NAG; 13×SO4;EDO;
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with pT1511 scFV Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 RBD bound to neutralizing antibody Fab ICO-hu23 Heteromer
P0DTC2;
334-527
GOL;ZN;NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
333-526
NAG;SO4;
Assess
SARS-CoV-2 Delta RBD and Nb22 Heteromer
P0DTC2;
334-527
Assess
SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab Heteromer
P0DTC2;
333-526
Assess
Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD Heteromer
P0DTC2;
333-526
NAG;
Assess
Complex Structure of antibody BD-503 and RBD-E484K of COVID-19 Heteromer
P0DTC2;
334-527
NAG;
Assess
Complex Structure of antibody BD-503 and RBD-501Y.V2 of COVID-19 Heteromer
P0DTC2;
334-527
NAG;
Assess
Complex Structure of antibody BD-503 and RBD of COVID-19 Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with nanobody N19 Heteromer
P0DTC2;
334-527
Assess
Crystal structure of spike protein receptor binding domain of escape mutant SARS-CoV-2 from immunoc… Heteromer
P0DTC2; Q9BYF1;
333-526
NAG;NAG;NAG;NAG;NAG;ZN;CL;NAG;
Assess
SARS-CoV-2 Omicron RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 231 Heteromer
P0DTC2;
334-527
NAG;SO4;
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab Heteromer
P0DTC2;
333-526
Assess
SARS-CoV-2 Omicron RBD in complex with Omi-3 and EY6A Fabs Heteromer
P0DTC2;
333-526
GOL;IPA;
Assess
Crystal structure of antibody WRAIR-2134 in complex with SARS-CoV-2 receptor binding domain Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of antibody WRAIR-2134 in complex with SARS-CoV-2 receptor binding domain Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 Delta-RBD complexed with BA.4/5-2 and Beta-49 Fabs Heteromer
P0DTC2;
333-526
NAG;
Assess
Epitope-based selection of SARS-CoV-2 neutralizing antibodies from convalescent patients Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD complexed with Nanosota-1 Heteromer
P0DTC2;
333-526
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
333-526
NAG;NAG; 15×SO4;
Assess
SARS-CoV-2 Omicron BA.2 RBD in complex with COVOX-150 Fab (P21) Heteromer
P0DTC2;
333-526
NAG;
Assess
Crystal structure of the SARS-CoV-2 spike receptor-binding domain (RBD) with nanobody Nb20 Heteromer
P0DTC2;
334-527
CAC;
Assess
Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD Heteromer
P0DTC2;
333-526
NAG;
Assess
Bovine Fab SKD in complex with Sars COV-2 receptor binding domain Heteromer
P0DOX5; P0DOY2; P0DTC2;
334-527
NAG;
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab Heteromer
P0DTC2;
333-526
Assess
SARS-CoV-2 Omicron BA.2 RBD in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
334-527
NAG;ZN;
Assess
SARS-CoV-2 Receptor Binding Domain in Complex with Ab17 Heteromer
P0DTC2;
333-526
Assess
SARS-CoV-2 Delta-RBD complexed with BA.2-10 and EY6A Fabs Heteromer
P0DTC2;
334-527
Assess
Molecular basis for neutralizing antibody 2B11 targeting SARS-CoV-2 RBD Heteromer
P0DTC2;
333-526
Assess
Complex Structure of antibody BD-503 and RBD-S477N of COVID-19 Heteromer
P0DTC2;
334-527
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
333-526
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD with P2C-1F11 and P2B-1G5 Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-CoV-2 Omicron RBD in complex with Omi-9 Fab and nanobody F2 Heteromer
P0DTC2;
333-526
Assess
SARS-CoV-2 Omicron RBD in complex with Omi-6 and COVOX-150 Fabs Heteromer
P0DTC2;
333-526
Assess
SARS-CoV-2 Omicron RBD in complex with Omi-12 and Beta-54 Fabs Heteromer
P0DTC2;
333-526
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.4 RBD in complex with fab L4.65 and L5.34 Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 222 Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-COV-2 Spike RBDMACSp25 binding to hACE2 Heteromer
P0DTC2; Q9BYF1;
333-526
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 prototype RBD in complex with rabbit ACE2 (local refinement) Heteromer
G1TEF4; P0DTC2;
335-528
NAG;ZN;
Assess
Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs XMA01 and 3E2 (local refi… Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-CoV-2 Delta S-RBD-ACE2 Heteromer
P0DTC2; Q9BYF1;
333-526
Assess
SARS-COV-2 Spike RBDMACSp36 binding to hACE2 Heteromer
P0DTC2; Q9BYF1;
333-526
NAG;
Assess
SARS-COV-2 Spike RBDMACSp36 binding to mACE2 Heteromer
P0DTC2; Q8R0I0;
333-526
NAG;
Assess
Local refinement of the SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab and 58G6 Fab Heteromer
P0DTC2;
334-527
Assess
SARS-CoV-2 S bound to S2X259 Fab (local refinement of the RBD/S2X259 variable domains) Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 Omicron BA.1 Variant RBD with mouse ACE2 Bound Heteromer
P0DTC2; Q8R0I0;
335-528
NAG;ZN;NAG;
Assess
SARS-CoV-2 receptor binding domain in complex with AZ090 Fab Heteromer
P0DTC2;
334-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 BA.4/5 spike protein in complex with 1G11 (local refinement) Heteromer
P0DTC2;
333-526
Assess
CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb36 Heteromer
P0DTC2;
333-526
Assess
SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3) Heteromer
P0DTC2;
333-526
NAG;
Assess
Local refined cryo-EM structure of Omicron BA.5 RBD in complex with 8-9D Fab Heteromer
P0DTC2;
334-527
Assess
SARS-CoV-2 Omicron variant spike in complex with three human neutralizing antibodies Heteromer
A0A5C2G4I7; A0A5C2GTV1; A0A5C2GVU3; P0DTC2;
334-527
NAG;
Assess
Locally refined region of SARS-CoV-2 Spike in complex with IgG 553-15 Heteromer
P0DTC2;
334-527
NAG;
Assess
Locally refined region of SARS-CoV-2 Spike in complex with IgG 553-60 Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 Omicron BA.2 Variant RBD complexed with mouse ACE2 Heteromer
P0DTC2; Q8R0I0;
335-528
NAG;ZN;NAG;
Assess
Local refinement of SARS-CoV-2 Omicron BA.1 Spike glycoprotein in complex with rabbit monoclonal an… Heteromer
P0DTC2;
334-527
Assess
The structure of FC08 Fab-hA.CE2-RBD complex Heteromer
P0DTC2; Q9BYF1;
333-526
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs 8H12 and 3E2 (local refin… Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-CoV-2 BQ.1.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody F… Heteromer
P0DTC2; Q9BYF1;
334-527
NAG;NAG;ZN;
Assess
Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-CoV-2 Delta S-RBD-8D3 Heteromer
P0DTC2;
333-526
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
334-527
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs 8H12 and 1C4 (local refin… Heteromer
P0DTC2;
333-526
NAG;
Assess
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11 Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD) Heteromer
P0DTC2;
333-526
NAG;
Assess
Cryo-EM structure of the RBD-ACE2 interface of the SARS-CoV-2 trimeric spike protein bound to ACE2 … Heteromer
A0A7T0Q2W2; P0DTC2;
335-528
NAG;NAG;NAG;
Assess
SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD) Heteromer
P0DTC2;
333-526
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Delta variant spike protein in complex with three nAbs X01, X10 and… Heteromer
P0DTC2;
333-526
NAG;
Assess
Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies Heteromer
P0DTC2;
333-526
NAG;
Assess
Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A … Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-COV-2 Spike RBDMACSp6 binding to hACE2 Heteromer
P0DTC2; Q9BYF1;
333-526
NAG;
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 spike in complex with the Ab1 neutralizing antibody (focused refinement on Fab-RBD) Heteromer
P0DTC2;
333-526
NAG;
Assess
Cryo-EM structure of SARS-CoV2 RBD-ACE2 complex Heteromer
P0DTC2; Q9BYF1;
333-526
ZN;CL;NAG;
Assess
SARS-CoV-2 Delta S-RBD-ACE2 Heteromer
P0DTC2; Q9BYF1;
333-526
Assess
The interface of H014 Fab binds to SARS-CoV-2 S Heteromer
P0DTC2;
334-527
Assess
Interface of SARS-CoV-2 WT Spike in complex with R15 Fab and P14 Nanobody Heteromer
P0DTC2;
334-527
Assess
G32A4 Fab in complex with SARS-CoV-2 Spike 6P (RBD local reconstruction) Heteromer
P0DTC2;
334-527
Assess
cryoEM structure of a broadly neutralizing anti-SARS-CoV-2 antibody STI-9167 Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-CoV-2 RBD in complex with A5-10 Fab and A34-2 Fab Heteromer
P0DTC2;
333-526
NAG;MES;
Assess
SARS-CoV-2 spike protein RBD and P17 fab complex Heteromer
P0DTC2;
334-527
Assess
CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb105 Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-CoV-2 Omicron BA.1 spike protein receptor-binding domain in complex with white-tailed deer ACE2 Heteromer
A0A6J0Z472; P0DTC2;
333-526
NAG;NAG;NAG;ZN;
Assess
SARS-CoV-2 Delta-RBD complexed with Fabs BA.2-36, BA.2-23, EY6A and COVOX-45 Heteromer
P0DTC2;
333-526
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 spike protein receptor-binding domain in complex wit… Heteromer
A0A6J0Z472; P0DTC2;
333-526
NAG;ZN;
Assess
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8 Heteromer
P0DTC2;
333-526
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron spike protein with human ACE2 (focus refinement on RBD-1/AC… Heteromer
P0DTC2; Q9BYF1;
333-526
Assess
RBD of SARS-CoV-2 Spike protein in complex with pan-sarbecovirus nanobodies 2-10, 2-67, 2-62 and 1-… Heteromer
P0DTC2;
333-526
Assess
Cryo-EM structure of the RBD-ACE2 interface of the SARS-CoV-2 trimeric spike protein bound to ACE2 … Heteromer
A0A7T0Q2W2; P0DTC2;
335-528
Assess
SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of … Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 Delta S-RBD-ACE2 complex Heteromer
P0DTC2; Q9BYF1;
333-526
Assess
SARS-CoV-2 Spike RBD in complex with DMAbs 2130 and 2196 Heteromer
P0DTC2;
333-526
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike protein in complex with three nAbs X01, X10 and X17 Heteromer
P0DTC2;
333-526
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike protein in complex with double nAbs 3E2 and 1C4 (local refine… Heteromer
P0DTC2;
333-526
NAG;
Assess
SARS-CoV-2 spike protein in complex with three human neutralizing antibodies Heteromer
A0A5C2G4I7; A0A5C2GTV1; A0A5C2GVU3; P0DTC2;
334-527
NAG;
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
334-527
NAG;
Assess
Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27 Heteromer
P0DTC2;
334-527
Assess
CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb17 and Nb105 Heteromer
P0DTC2;
333-526
Assess
ACE2-RBD in SARS-CoV-2 Kappa variant S-ACE2 complex Heteromer
P0DTC2; Q9BYF1;
333-526
ZN;NAG;
Assess
Local refinement of the SARS-CoV-2 BA.1 Spike trimer in complex with 55A8 Fab Heteromer
P0DTC2;
334-527
Assess
SARS-CoV-2 spike in complex with LCB3 (local refinement of the RBD and LCB3) Heteromer
P0DTC2;
334-527
NAG;
Assess
SARS-CoV-2 Spike RBD in complex with DMAb 2196 Heteromer
P0DTC2;
333-526
NAG;
Assess
RBD/XG005 local refinement Heteromer
P0DTC2;
334-527
NAG;
Assess
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody… Heteromer
P0DTC2;
334-527
NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein in complex with the 10D12 heavy-chain-only antibody … Heteromer
P0DTC2;
333-526
Assess
Cryo-EM structure of SARS-CoV-2 BA.3 RBD in complex with golden hamster ACE2 (local refinement) Heteromer
A0A1U7QTA1; P0DTC2;
333-526
NAG;ZN;NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Delta RBD in complex with golden hamster ACE2 (local refinement) Heteromer
A0A1U7QTA1; P0DTC2;
333-526
NAG;ZN;NAG;
Assess
SARS-CoV-2 S RBD (C.37 Lambda variant) plus S309 Fab, local refinement Heteromer
P0DTC2;
334-527
NAG;
Assess
Cryo-EM structure of the Omicron RBD in complex with 35B5 Fab( local refinement of the RBD and 35B5… Heteromer
P0DTC2;
333-526
NAG;
Assess
ACE2-RBD in SARS-CoV-2 Beta variant S-ACE2 complex Heteromer
P0DTC2; Q9BYF1;
333-526
ZN;NAG;
Assess
Crystallographic structure of neutralizing antibody 10-40 in complex with SARS-CoV-2 spike receptor… Heteromer
P0DTC2;
335-527
NAG;
Assess
CRYSTAL STRUCTURE OF SARS-COV-2 RECEPTOR BINDING DOMAIN (RBD) in complex with 1D1 Fab Heteromer
P0DTC2;
335-527
NAG;GOL;TRS;
Assess
Crystal structure of SARS-CoV-2 S RBD in complex with a stapled peptide Heteromer
P0DTC2;
335-527
29N;
Assess
SARS-CoV-2 Receptor-Binding Domain SPEEDesign Immunogen 1 Bound to C144 scFv Heteromer
P0DTC2;
334-526
Assess
Crystal structure of SARS-CoV-2 spike receptor-binding domain in complex with neutralizing nanobody… Heteromer
P0DTC2;
335-527
NAG;
Assess
Crystal Structure of SARS-CoV-2 S receptor-binding domain (RBD) in complex CoV11 Fab Heteromer
P0DTC2;
334-526
NAG;SO4;ACT;
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with pT1580 scFV Heteromer
P0DTC2;
335-527
NAG;
Assess
LY-CoV555 neutralizing antibody against SARS-CoV-2 Heteromer
P0DTC2;
334-526
GOL;
Assess
Crystal structure of SARS-CoV-2 RBD and NIV-10 complex Heteromer
P0DTC2;
335-527
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv Heteromer
P0DTC2;
335-527
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
P0DTC2;
334-526
CL; 10×SO4;GOL;NAG;
Assess
Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
P0DTC2;
334-526
GOL;NAG; 13×SO4;CL;CIT;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2… Heteromer
P0DTC2;
334-526
NAG;
Assess
Crystal structure of chimeric omicron RBD (strain BA.2) complexed with human ACE2 Heteromer
P0DTC2; Q9BYF1;
334-526
NAG;ZN;CL;NAG;NA;
Assess
SARS-CoV-2 BA.2.12.1 RBD in complex with Beta-27 Fab and C1 nanobody Heteromer
P0DTC2;
333-525
NAG; 12×GOL;PO4;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
334-526
NAG;GOL;CL;IOD;PEG;
Assess
Crystal structure of nanobody Nb70 with antibody 1F11 fab and SARS-CoV-2 RBD Heteromer
P0DTC2;
334-526
NAG;
Assess
The co-crystal structure of BA.1-RBD with Fab-5549 Heteromer
P0DTC2;
334-526
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein i… Heteromer
P0DTC2;
334-526
19×SO4;GOL;NAG;PEG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in co… Heteromer
P0DTC2;
334-526
15×SO4;GOL;NAG;PEG;
Assess
Complex Structure of antibody BD-503 and RBD-N501Y of COVID-19 Heteromer
P0DTC2;
334-526
Assess
SARS-CoV-2 Delta-RBD complexed with BA.2-13 Fab and C1 nanobody Heteromer
P0DTC2;
333-525
NAG;GOL;PG0;
Assess
Crystal structure of chimeric omicron RBD (strain BA.2) complexed with chimeric mouse ACE2 Heteromer
P0DTC2; Q9BYF1;
334-526
NAG;ZN;CL;NAG;EDO;
Assess
SARS-CoV-2 Omicron BA.2.75 RBD in complex with ACE2 Heteromer
P0DTC2; Q9BYF1;
334-526
12×GOL;NAG;CL;PGE;
Assess
Crystal structure of SARS-CoV-2 spike receptor binding domain bound with P5S-2B10 Heteromer
P0DTC2;
334-526
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-508 Fab Heteromer
P0DTC2;
334-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with F… Heteromer
P0DTC2;
333-525
NAG;SO4;NO3;CL;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
333-525
NAG;GOL; 14×SO4;PEG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with F… Heteromer
P0DTC2;
334-526
NAG;
Assess
Crystal structure of SARS-CoV-2 Y453F-RBD bound to mink ACE2 Heteromer
A0A8C7BTF2; P0DTC2;
335-527
NAG;NAG;NAG;
Assess
Crystal structure of the SARS-COV-2 RBD with neutralizing-VHHs Re30H02 and Re21D01 Heteromer
P0DTC2;
334-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
334-526
NAG;
Assess
Crystal structure of FD20, a neutralizing single-chain variable fragment (scFv) in complex with SAR… Heteromer
P0DTC2;
334-526
NAG;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
333-525
NAG;NAG;
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab Heteromer
P0DTC2;
334-526
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with F… Heteromer
P0DTC2;
334-526
NAG;PO4;
Assess
Crystal structure of neutralizing antibody 10-28 in complex with SARS-CoV-2 spike receptor binding … Heteromer
P0DTC2;
335-527
NAG;
Assess
SARS-CoV-2 Delta-RBD complexed with BA.4/5-1 and EY6A Fabs Heteromer
P0DTC2;
334-526
NAG;
Assess
Crystal structure of affinity-enhancing and catalytically inactive ACE2 in complex with SARS-CoV-2 … Heteromer
P0DTC2; Q9BYF1;
334-526
NAG;ZN;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
334-526
Assess
BA.1 SARS-CoV-2 Spike bound to mouse ACE2 (local) Heteromer
P0DTC2; Q8R0I0;
333-525
NAG;NAG;
Assess
Local CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWA9 Fab Heteromer
P0DTC2;
334-526
Assess
BA.4/5 SARS-CoV-2 Spike bound to human ACE2 (local) Heteromer
P0DTC2; Q9BYF1;
333-525
NAG;ZN;
Assess
SARS-CoV-2 spike in complex with LCB1 (local refinement of the RBD and LCB1) Heteromer
P0DTC2;
334-526
NAG;
Assess
Beta SARS-CoV-2 Spike bound to mouse ACE2 (local) Heteromer
P0DTC2; Q8R0I0;
333-525
NAG;NAG;
Assess
BA.2.12.1 SARS-CoV-2 Spike bound to mouse ACE2 (local) Heteromer
P0DTC2; Q8R0I0;
333-525
NAG;NAG;
Assess
Structure of SARS-CoV-2 spike with antibody Fabs 2A10 and 1H2 (Local refinement of the RBD and Fabs… Heteromer
P0DTC2;
335-527
NAG;
Assess
SARS-CoV-2 Spike (6P) in complex with 3 R1-32 Fabs and 3 ACE2, focused refinement of RBD region Heteromer
P0DTC2; Q9BYF1;
334-526
ZN;NAG;
Assess
Local structure of BD55-3500 and omicron RBD complex Heteromer
P0DTC2;
334-526
NAG;
Assess
SARS-CoV-2 BN.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody Fab… Heteromer
P0DTC2; Q9BYF1;
334-526
NAG;NAG;
Assess
Local CryoEM structure of the SARS-CoV-2 S6P(B.1.1.529) in complex with BD55-4637 Fab Heteromer
P0DTC2;
334-526
NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH272 Fab Heteromer
P0DTC2;
334-526
Assess
Local structure of BD55-1239 Fab and SARS-COV2 Omicron RBD complex Heteromer
P0DTC2;
334-526
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 RBD in complex with fab L4.65 and L5.34 Heteromer
P0DTC2;
335-527
NAG;
Assess
Structure of SARS-CoV-2 spike receptor-binding domain Y453F mutation complexed with American mink A… Heteromer
A0A8C7BTF2; P0DTC2;
335-527
NAG;ZN;
Assess
Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH027 Fab Heteromer
P0DTC2;
334-526
Assess
Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH236 Fab Heteromer
P0DTC2;
334-526
Assess
SARS-CoV-2 spike in complex with the S2D106 neutralizing antibody Fab fragment (local refinement of… Heteromer
P0DTC2;
335-527
NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH272 Fab Heteromer
P0DTC2;
334-526
Assess
Local CryoEM structure of the SARS-CoV-2 S6P(B.1.617.2) in complex with SWC11 Fab Heteromer
P0DTC2;
334-526
Assess
Local CryoEM structure of the SARS-CoV-2 S6P(B.1.1.529) in complex with BD55-3152 Fab Heteromer
P0DTC2;
334-526
NAG;
Assess
Omicron BA.4/5 SARS-CoV-2 S RBD in complex with TH132 Fab Heteromer
P0DTC2;
334-526
Assess
BA.4/5 SARS-CoV-2 Spike bound to mouse ACE2 (local) Heteromer
P0DTC2; Q8R0I0;
333-525
NAG;NAG;
Assess
Local structure of BD55-3546 Fab and SARS-COV2 Delta RBD complex Heteromer
P0DTC2;
334-526
NAG;
Assess
SARS-CoV-2 receptor binding domain bound to Fab PDI 215 Heteromer
P0DTC2;
334-525
NAG;IPA;
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a highly pote… Heteromer
P0DTC2;
336-527
NAG;GOL;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH V and antibody … Heteromer
P0DTC2;
334-525
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC25.… Heteromer
P0DTC2;
334-525
NAG;
Assess
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with antibody CC12… Heteromer
P0DTC2;
334-525
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193 Heteromer
P0DTC2;
334-525
NAG;
Assess
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies Heteromer
P0DTC2;
334-525
NAG;CL;
Assess
Cryo-EM structure of SARS-CoV-2 RBD in complex with anti-SARS-CoV-2 DARPin,SR22, and two antibody F… Heteromer
P0DTC2;
335-526
NAG;
Assess
Local resolution of BD55-5840 Fab and SARS-COV2 Omicron RBD Heteromer
P0DTC2;
335-526
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 RBD in complex with anti-SARS-CoV-2 DARPin,SR16m, and two antibody … Heteromer
P0DTC2;
335-526
NAG;
Assess
Local structure of BD55-5514 and BD55-5840 Fab and Omicron BA.1 RBD complex Heteromer
P0DTC2;
335-526
NAG;
Assess
SARS-CoV-2 spike in complex with the S2K146 neutralizing antibody Fab fragment (local refinement of… Heteromer
P0DTC2;
335-526
NAG;
Assess
ACE2-RBD Focused Refinement Using Symmetry Expansion of Applied C3 for Triple ACE2-bound SARS-CoV-2… Heteromer
P0DTC2; Q9BYF1;
335-526
NAG;NAG;
Assess
Cryo-EM structure of SARS-CoV-2 spike in complex with FSR22, an anti-SARS-CoV-2 DARPin (Local refin… Heteromer
P0DTC2;
335-526
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with pT1610 scFV Heteromer
P0DTC2;
335-525
NAG;
Assess
CRYSTAL STRUCTURE OF SARS-COV-2 RECEPTOR BINDING DOMAIN (RBD-beta variant) in complex with 3D2 Fab Heteromer
P0DTC2;
336-526
NAG;GOL;
Assess
Crystal Structure of SARS-CoV-2 S delta variant receptor-binding domain (RBD) in complex CoV11 Fab … Heteromer
P0DTC2;
336-526
NAG;PO4;MPD;
Assess
Crystal structure of Omicron BA.4/5 RBD in complex with a neutralizing antibody scFv Heteromer
P0DTC2;
336-526
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with MW07 Fab Heteromer
P0DTC2;
336-526
NAG;
Assess
Crystal structure of SARS-CoV-2 delta variant spike receptor-binding domain (RBD) in complex with N… Heteromer
P0DTC2;
335-525
Assess
SARS-CoV-2 Beta RBD in complex with nanobody C1, Omi-18 and Omi-31 Fabs Heteromer
P0DTC2;
333-523
NAG;
Assess
SARS-CoV-2 Omicron RBD in complex with Omi-25 Fab Heteromer
P0DTC2;
335-525
Assess
Crystal structure of SARS-CoV-2 antibody P5A-3C8 with RBD Heteromer
P0DTC2;
333-522
NAG;
Assess
XBB 1.0 RBD bound to P4J15 (Local) Heteromer
P0DTC2;
336-525
NAG;
Assess
S-RBD (Omicron XBB.1) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
336-525
NAG;NAG;
Assess
S-RBD (Omicron BF.7) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
336-525
NAG;NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV6… Heteromer
P0DTC2;
337-525
Assess
SARS-CoV-2 S protein in complex with pT1696 Fab Heteromer
P0DTC2;
330-518
NAG;
Assess
Structure of SARS-CoV-2 spike receptor-binding domain complexed with its receptor equine ACE2 Heteromer
F6V9L3; P0DTC2;
336-523
ZN;NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 20A7 Heteromer
P0DTC2;
335-522
NAG;
Assess
Crystal structure of the SARS-CoV-2 RBD (Wuhan) with neutralizing VHHs Ma6F06 and Re21H01 Heteromer
P0DTC2;
334-521
P4G;EDO;
Assess
SARS-CoV-2 Spike RBD in complex with neutralizing Fab SARS2-38 (local refinement) Heteromer
P0DTC2;
333-520
NAG;
Assess
Crystal structure of SARS-CoV-2 Beta RBD complexed with P36-5D2 Fab Heteromer
P0DTC2;
333-519
NAG;
Assess
Crystal structure of SARS-CoV-2 Spike RBD in complex with the D27 neutralizing antibody Fab fragment Heteromer
P0DTC2;
336-521
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with C… Heteromer
P0DTC2;
334-519
NAG;GOL;CL;PO4;PRO;
Assess
SARS-CoV-2 Omicron BA.1 spike trimer (6P) in complex with YB13-292 Fab, focused refinement of Fab r… Heteromer
P0DTC2;
332-517
NAG;
Assess
Ternary Crystal Complex Structure of RBD with NB1B5 and NB1C6 Heteromer
P0DTC2;
333-517
Assess
Crystallographic structure of two neutralizing antibodies in complex with SARS-CoV-2 spike receptor… Heteromer
P0DTC2;
334-518
TRS;NAG;GOL;
Assess
The receptor binding domain of SARS-CoV-2 spike glycoprotein in complex with Beta-55 and EY6A Fabs Heteromer
P0DTC2;
333-517
NAG;
Assess
Delta-RBD complex with BA.2-07 fab, SARS1-34 fab and C1 nanobody Heteromer
P0DTC2;
333-517
NAG;
Assess
Crystal structure of the SARS-CoV-2 BA.1 RBD with neutralizing-VHHs Ma16B06 and Ma3F05 Heteromer
P0DTC2;
334-517
Assess
Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
P0DTC2;
333-516
NAG;NAG;GOL;PEG;CL;TRS;PO4;
Assess
Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody… Heteromer
P0DTC2;
334-517
NAG;
Assess
SARS-CoV-2 Delta-RBD complexed with BA.4/5-35 Fab Heteromer
P0DTC2;
334-517
NAG;
Assess
SARS-CoV-2 spike RBD in complex with neutralizing antibody UT28K Heteromer
P0DTC2;
334-517
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.4/5 RBD in complex with rabbit ACE2 (local refinement) Heteromer
G1TEF4; P0DTC2;
335-518
ZN;NAG;
Assess
Cryo-EM map of SARS-CoV-2 Omicron BA.2 spike in complex with 2130-1-0114-112 Heteromer
P0DTC2;
333-516
NAG;
Assess
Structure Determination of the RBD-NB1A7 Heteromer
P0DTC2;
333-515
NAG;
Assess
Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab Heteromer
P0DTC2;
335-517
NAG;
Assess
Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in c… Heteromer
P0DTC2;
334-516
NAG;GOL;SO4;
Assess
A SARS-CoV-2 neutralizing antibody Heteromer
P0DTC2;
334-516
NAG;
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab Heteromer
P0DTC2;
334-516
Assess
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab Heteromer
P0DTC2;
334-516
Assess
A SARS-CoV-2 neutralizing antibody Heteromer
P0DTC2;
334-516
Assess
The receptor binding domain of SARS-CoV-2 spike glycoprotein in complex with COVOX-58 and COVOX-158… Heteromer
P0DTC2;
334-516
GOL;NAG;NA;
Assess
Crystallographic structure of neutralizing antibody 2-15 in complex with SARS-CoV-2 spike receptor-… Heteromer
P0DTC2;
336-518
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… Heteromer
P0DTC2;
334-516
NAG;NAG;GOL;ACT;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron S6P trimer in complex with neutralizing antibody VacW-209 (… Heteromer
A0A5C2GQT9; P0DTC2;
336-518
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 recombinant spike protein STFK in complex with three neutralizing a… Heteromer
P0DTC2;
336-518
NAG;NAG;
Assess
local structure of hu33 and spike Heteromer
P0DTC2;
334-516
NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Delta S6P trimer in complex with neutralizing antibody VacW-209 (lo… Heteromer
A0A5C2GQT9; P0DTC2;
336-518
NAG;
Assess
local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-812 Fab and BD-836 Fab Heteromer
P0DTC2;
334-516
Assess
Cryo-EM structure of SARS-CoV-2 recombinant spike protein STFK1628x in complex with three neutraliz… Heteromer
P0DTC2;
336-518
NAG;NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S2P trimer in complex with neutralizing antibody VacW-209 (local re… Heteromer
A0A5C2GQT9; P0DTC2;
336-518
NAG;
Assess
Cryo-EM structure of human ACE2 receptor bound to protein encoded by vaccine candidate BNT162b1 Heteromer
P0DTC2; Q9BYF1;
336-518
Assess
Local structure of BD55-3372 and delta spike Heteromer
P0DTC2;
334-516
Assess
Cryo-EM structure of SARS-CoV-2 Mu S6P trimer in complex with neutralizing antibody VacW-209 (local… Heteromer
A0A5C2GQT9; P0DTC2;
336-518
NAG;
Assess
CC6.30 fragment antigen binding in complex with SARS-CoV-2-6P-Mut7 S protein (RBD/Fv local refineme… Heteromer
P0DTC2;
333-515
NAG;NAG;
Assess
Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-771 Fab and BD-821 Fab Heteromer
P0DTC2;
334-516
Assess
The 2019-nCoV RBD/ACE2-B0AT1 complex Heteromer
P0DTC2; Q695T7; Q9BYF1;
336-518
14×NAG;NAG; 10×NAG;LEU;ZN;
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 beta variant spike glycoprotein in c… Heteromer
P0DTC2;
334-515
NAG;PG0;GOL;PEG;CL;
Assess
Crystal structure of The SARS-COV-2 BA.2.75 RBD with neutralizing-VHHs Re32D03 and Ma3B12 Heteromer
P0DTC2;
336-517
Assess
A SARS-CoV-2 neutralizing antibody Heteromer
P0DTC2;
334-515
NAG;
Assess
SARS-CoV-2 S protein RBD in complex with A8-1 Fab Heteromer
P0DTC2;
334-515
Assess
SARS-CoV-2 Omicron RBD in complex with Omi-32 Fab and nanobody C1 Heteromer
P0DTC2;
335-516
Assess
Cryo-EM structure of SARS-CoV-2 C.1.2 S6P trimer in complex with neutralizing antibody VacW-209 (lo… Heteromer
A0A5C2GQT9; P0DTC2;
337-518
NAG;
Assess
SARS-CoV-2 S protein in complex with pT1644 Fab Heteromer
P0DTC2;
335-516
NAG;
Assess
Crystal structure of the SARS-CoV-2 RBD with neutralizing-VHHs Re5D06 and Re9F06 Heteromer
P0DTC2;
335-515
DMX;SO4;
Assess
SARS-CoV-2 RBD in complex with a Fab fragment of a neutralising antibody mRBD2 Heteromer
P0DTC2;
335-515
SO4;
Assess
Structure Determination of the NB1B11-RBD Complex Heteromer
P0DTC2;
335-515
ZN;
Assess
Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody Heteromer
P0DTC2;
335-515
Assess
Crystal structure of neutralizing antibody P1D9 Fab in complex with SARS-CoV-2 spike receptor bindi… Heteromer
P0DTC2;
335-515
NAG;
Assess
Crystal structure of SARS-CoV-2 RBD Q498Y complexed with human ACE2 Heteromer
P0DTC2; Q9BYF1;
339-519
NAG;ZN;EDO;CL;
Assess
Crystal structure of SARS-CoV-2 Alpha RBD in complex with the D27LEY neutralizing antibody Fab frag… Heteromer
P0DTC2;
336-516
Assess
SARS-CoV-2 XBB.1 spike RBD bound to the human ACE2 ectodomain and the S309 neutralizing antibody Fa… Heteromer
P0DTC2; Q9BYF1;
335-515
NAG;NAG;
Assess
SARS-CoV-2 BA.2 spike RBD in complex bound with VacBB-551 Heteromer
P0DTC2;
337-517
Assess
CryoEM structure of RBD domain of COVID-19 in complex with Legobody Heteromer
P06654; P0DTC2; P99134;
335-515
GLC;
Assess
SARS-CoV-2 spike glycoprotein trimer complexed with Fab fragment of anti-RBD antibody E7 (focused r… Heteromer
P0DTC2;
335-515
Assess
Antibody N3-1 bound to RBD in the up conformation Heteromer
P0DTC2;
337-517
Assess
Antibody N3-1 bound to RBDs in the up and down conformations Heteromer
P0DTC2;
337-517
Assess
Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary comp… Heteromer
P0DTC2;
337-516
NAG;IMD;GOL;BR;PG6;
Assess
Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-360 Heteromer
P0DTC2;
337-516
NAG;
Assess
SARS-COV-2 BA.1 Spike incomplex with VacBB-665 Heteromer
P0DTC2;
338-517
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2… Heteromer
P0DTC2;
338-516
NAG;
Assess
S-RBD(Omicron BA.3) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
338-516
NAG;NAG;
Assess
S-RBD (Omicron BA.2.75) in complex with PD of ACE2 Heteromer
P0DTC2; Q9BYF1;
338-516
NAG;NAG;
Assess
SARS-CoV-2 RBD in complex with 1F Fab Heteromer
P0DTC2;
336-514
Assess
Cryo-EM structure of Human ACE2 bound to a high-affinity SARS CoV-2 mutant Heteromer
P0DTC2; Q9BYF1;
338-515
NAG;
Assess
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-… Heteromer
P0DTC2;
338-514
NAG;
Assess
Structure of P4A2 Fab in complex with Spike-RBD from SARS-CoV-2 Heteromer
P0DTC2;
337-513
Assess
The structure of ZCB11 Fab against SARS-CoV-2 Omicron Spike Heteromer
P0DTC2;
338-514
Assess
SARS-CoV-2 RBD-62 in complex with ACE2 peptidase domain Heteromer
P0DTC2; Q9BYF1;
341-514
ZN;NAG;
Assess
Structure of SARS-CoV-2 chimeric receptor-binding domain complexed with its receptor human ACE2 Heteromer
P0DTC2; P59594; Q9BYF1;
455-518
NAG;NAG;ZN;CL;EDO;NAG;
Assess
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of … Heteromer
P0DTC2;
443-501
Assess
Cryo-EM structure of the SARS-CoV-2 HR1HR2 fusion core complex with N969K mutation Heteromer
A0A8B6RKS7; P0DTC2;
1159-1200
Assess
SARS-CoV2 spike glycoprotein N-terminal heptad repeat domain + SARS-CoV2(QEYKKEKE) Heteromer
A0A6C0RQ44; P0DTC2;
1168-1203
Assess
Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody CC40… Heteromer
P0DTC2;
1140-1161
ACT;SO4;GOL;
Assess
Crystal structure of human neutralizing mAb CV3-25 binding to SARS-CoV-2 S MPER peptide 1140-1165 Heteromer
P0DTC2;
1146-1165
10×NA;
Assess
fp.006 Fab in complex with SARS-CoV-2 Fusion Peptide Heteromer
P0DTC2;
813-830
PEG;EDO;
Assess
Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody COV3… Heteromer
P0DTC2;
1145-1159
Assess
Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody COV8… Heteromer
P0DTC2;
1145-1159
Assess
Crystal structure of CV3-25 Fab bound to SARS-CoV-2 spike stem helix peptide Heteromer
P0DTC2;
1152-1166
GOL;SO4;
Assess
Antibody DH1058 Fab fragment bound to SARS-CoV-2 fusion peptide Heteromer
P0DTC2;
812-826
CA;PO4;
Assess
Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Spike peptide S761-775 Heteromer
D7RIG0; P01903; P0DTC2;
761-775
EDO;
Assess
Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Omicron (BA.1) Spike peptide S7… Heteromer
D7RIG0; P01903; P0DTC2;
761-775
EDO;SO4;
Assess
Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Spike peptide S511-530 Heteromer
D7RIG0; P01903; P0DTC2;
512-525
15×EDO;SO4;MES;
Assess
Crystal structure of SARS-CoV-2 fusion peptide in complex with neutralizing antibody COV44-62 Heteromer
P0DTC2;
812-825
Assess
Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Omicron (BA.1) Spike peptide S4… Heteromer
D7RIG0; P01903; P0DTC2;
486-499
30×EDO;SO4;DHL;
Assess
Human Leukocyte Antigen class II allotype DR1 presenting SARS-CoV-2 Spike peptide S486-505 Heteromer
D7RIG0; P01903; P0DTC2;
486-499
10×EDO;DHL;
Assess
Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with Fab of broadly neutralizin… Heteromer
P0DTC2;
1145-1158
GOL;
Assess
Crystal Structure of VP12E7 Fab in complex with SARS-CoV-2 S fusion peptide Heteromer
P0DTC2;
812-825
Assess
S2P6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide Heteromer
P0DTC2;
1146-1159
SO4;
Assess
Crystal structure of SARS-CoV-2 spike stem helix peptide in complex with neutralizing antibody COV9… Heteromer
P0DTC2;
1148-1160
Assess
Crystal structure of the 76E1 Fab in complex with a SARS-CoV-2 spike peptide Heteromer
P0DTC2;
813-825
Assess
Crystal Structure of VN01H1 Fab in complex with SARS-CoV-2 S fusion peptide Heteromer
P0DTC2;
813-824
Assess
Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV… Heteromer
P01834; P0DOX5; P0DTC2;
812-823
Assess
Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV… Heteromer
P0DTC2;
813-823
Assess
B6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide Heteromer
P0DTC2;
1147-1156
GOL;
Assess
SARS-CoV-2 S stem helix peptide bound to Fab22 Heteromer
P0DTC2;
1147-1156
Assess
Crystal structure of SARS-CoV-2 neutralizing antibody WS6 in complex with spike S2 peptide Heteromer
P0DTC2;
1148-1157
11×SO4;PEG;
Assess
SARS-CoV-2 Spike-derived peptide S1215-1224 (YIWLGFIAGL) presented by HLA-A*02:01 Heteromer
P0DTC2; P61769; Q53Z42;
1215-1224
Assess
Crystal Structure of HLA-A*02:01 in complex with KLNDLCFTNV, an 10-mer epitope from SARS-CoV-2 Spik… Heteromer
A0A140T913; P0DTC2; P61769;
386-395
GOL;
Assess
Crystal Structure of HLA-B*35:01 in complex with IPFAMQMAY, an 9-mer epitope from SARS-CoV-2 spike … Heteromer
P0DTC2; P61769; Q546I9;
896-904
PO4;NA;
Assess
Crystal Structure of HLA-A*11:01 in complex with NSASFSTFK, an 9-mer epitope from SARS-CoV-2 spike … Heteromer
P0DTC2; P61769; U5YJK1;
370-378
GOL;SO4;NA;CL;CA;
Assess
MHC I A02 Allele presenting YLQPRTFLL Heteromer
A0A140T913; P0DTC2; P61769;
269-277
EDO;ACT;CA;
Assess
SARS-CoV-2 Spike-derived peptide S1185-1193 K1191N mutant (RLNEVANNL) presented by HLA-A*02:01 Heteromer
P0DTC2; P61769; Q53Z42;
1185-1193
CD;ZN;NA;ACT;CL;
Assess
Crystal Structure of HLA-B*15:01 in complex with spike derived peptide NQKLIANQF from SARS-CoV-2 vi… Heteromer
P0DTC2; P61769;
919-927
ACT;PEG;
Assess
SARS-CoV-2 spike-derived peptide S1060-1068 (VVFLHVTYV) presented by HLA-A*02:01 Heteromer
A0A140T913; P0DTC2; P61769;
1060-1068
CD;NA;
Assess
Complex Structure of HLA-A*2402 with the Peptide from HCoV(CoV-2) spike protein Heteromer
A0A5H2UYS3; P0DTC2; P61769;
1208-1216
Assess
Human leukocyte antigen A*0201 in complex with SARS-CoV-2 epitope YLQPRTFLL Heteromer
A0A140T913; P0DTC2; P61769;
269-277
GOL;
Assess
SARS-CoV-2 Spike-derived peptide S976-984 (VLNDILSRL) presented by HLA-A*02:01 Heteromer
P0DTC2; P61769; Q861F7;
976-984
ACT;CD;ZN;
Assess
MHC I A02 Allele presenting YLQLRTFLL Heteromer
A0A140T913; P0DTC2; P61769;
269-277
12×IOD;PEG;
Assess
SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-A*02:01 Heteromer
P0DTC2; P61769; Q53Z42;
269-277
Assess
SARS-CoV-2 YLQ peptide binds to HLA-A2 Heteromer
A0A140T913; P0DTC2; P61769;
269-277
PG4;
Assess
CRYSTAL STRUCTURE OF A MUTANT MYLU-B-67 FOR 2.2 ANGSTROM, 52M 53Q 54Q 55P 56W DELETED Heteromer
G1PNR4; L5K3Y9; P0DTC2;
1052-1060
Assess
CRYSTAL STRUCTURE OF BAT MHC CLASS I MYLU-B-67 Heteromer
G1PNR4; L5K3Y9; P0DTC2;
1052-1060
Assess
SARS-CoV-2 Spike-derived peptide S489-497 (YFPLQSYGF) presented by HLA-A*29:02 Heteromer
B0UXQ0; P0DTC2; P61769;
489-497
SO4;MG;NA;
Assess
HLA peptide complex Heteromer
A0A140T913; P0DTC2; P61769;
269-277
EDO;
Assess
SARS-CoV-2 RLQ peptide-specific TCR pRLQ3 binds to RLQ-HLA-A2 Heteromer
A0A140T913; P0DTC2; P61769;
1000-1008
Assess
SARS-CoV-2 YLQ peptide-specific TCR pYLQ7 binds to YLQ-HLA-A2 Heteromer
A0A140T913; P0DTC2; P61769;
269-277
Assess
Complex structure of HLA2402 with recognizing SARS-CoV-2 Y453F epitope NYNYLFRLF Heteromer
D9UAY1; P0DTC2; P61769;
448-456
Assess
YLQ-SG3 TCR in complex with SARS-CoV-2 Spike-derived peptide S269-277 (YLQPRTFLL) presented by HLA-… Heteromer
P0DTC2; P61769; Q53Z42;
269-277
NA;
Assess
SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-T1006I-HLA-A2 Heteromer
A0A140T913; P0DTC2; P61769;
1000-1008
PG4;
Assess
The structure of FLA-K*00701/KP-CoV-9 Heteromer
C6ZK69; P0DTC2; Q5MGS7;
815-823
Assess
SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-HLA-A2 Heteromer
A0A140T913; P0DTC2; P61769;
1000-1008
PG4;
Assess
Complex structure of HLA0201 with recognizing SARS-CoV-2 epitope S1 Heteromer
A0A5H2UU57; P0DTC2; P61769;
417-425
Assess
SARS-CoV-2 RLQ peptide binds to HLA-A2 Heteromer
A0A140T913; P0DTC2; P61769;
1000-1008
Assess
Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope QYIKWPWYI Heteromer
F6IR24; P0DTC2; P61769;
1208-1216
Assess
Complex structure of HLA2402 with recognizing SARS-CoV-2 epitope pep4 Heteromer
D9UAY1; P0DTC2; P61769;
448-456
Assess
Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope Heteromer
A0A140T913; P0DTC2; P61769;
269-277
PEG;SO4;
Assess
TCR peptide HLA-A2 complex Heteromer
A0A140T913; P0DTC2; P61769;
269-277
Assess
SARS-CoV-2 Spike-derived peptide S417-425 K417T mutant (TIADYNYKL) presented by HLA-A*02:01 Heteromer
P0DTC2; P61769; Q53Z42;
418-425
ZN;CD;NA;
Assess
CRYSTAL STRUCTURE OF BAT MHC CLASS I MYLU-B-67 FOR 2.1 ANGSTROM Heteromer
G1PNR4; L5K3Y9; P0DTC2;
1053-1060
Assess
CRYSTAL STRUCTURE OF BAT MHC CLASS I MYLU-B-67 FOR 2.2 ANGSTROM Heteromer
G1PNR4; L5K3Y9; P0DTC2;
1053-1060
Assess
Epitope-directed anti-SARS CoV 2 scFv engineered against the key spike protein region. Heteromer
P0DTC2;
816-823
Assess
CRYSTAL STRUCTURE OF A MUTANT MYLU-B-67 FOR 2.4 ANGSTROM, 52M 53Q 54Q 55P 56W DELETED Heteromer
G1PNR4; L5K3Y9; P0DTC2;
1053-1060
Assess
3D1 in complex with 6-mer HR1 peptide from SARS-CoV-2 Heteromer
P0DTC2;
950-955
Assess
The complex structure of COPI cargo sorting module with SARS-CoV-2 Spike KxHxx sorting motif Heteromer
P0DTC2; P41811;
1268-1273
Assess
Crystal structure of neuropilin-1 b1 domain in complex with SARS-CoV-2 S1 C-end rule (CendR) peptide Heteromer
O14786; P0DTC2;
683-685
PEG;
Assess
Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484I spike proteinhomo-6-mer14-1147
36×NAG; 48×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike proteinhomo-6-mer14-1147
36×NAG; 48×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), dimer of S trimer conformation 2homo-6-mer14-1146
66×NAG;NAG; 24×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), dimer of S trimer conformation 3homo-6-mer14-1146
66×NAG;NAG; 24×NAG;
Assess
Structure of SARS-CoV-2 3Q-2P full-length dimers of spike trimershomo-6-mer14-1146
76×NAG;NAG;NAG; 16×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), dimer of S trimer conformation 1homo-6-mer14-1146
66×NAG;NAG; 24×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484I spike protein (focused refinement of RBD)homo-6-mer322-589
12×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein (focused refinement of RBD)homo-6-mer322-589
12×NAG;
Assess
Structure of the 2019-nCoV HR2 Domainhomo-4-mer1169-1203
Assess
Structure of coiled-coil tetramer from SARS-CoV-2 spike stalk regionhomo-4-mer1177-1203
EDO;ZN;
Assess
SARS-CoV-2 Mu variant spike(close state)homo-3-mer14-1162
Assess
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantshomo-3-mer14-1162
20×NAG;NAG;NAG; 28×NAG;
Assess
Middle state of SARS-CoV-2 BA.2 variant spike proteinhomo-3-mer14-1162
18×NAG;NAG;NAG; 20×NAG;
Assess
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantshomo-3-mer14-1162
24×NAG;NAG;NAG; 24×NAG;
Assess
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantshomo-3-mer14-1162
16×NAG;NAG;NAG; 32×NAG;
Assess
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantshomo-3-mer14-1162
20×NAG;NAG;NAG; 28×NAG;
Assess
Closed state of SARS-CoV-2 BA.2 variant spike proteinhomo-3-mer14-1162
21×NAG;NAG;NAG; 21×NAG;
Assess
Distinct conformational states of SARS-CoV-2 spike proteinhomo-3-mer14-1162
21×NAG;NAG;NAG;NAG; 21×NAG;
Assess
Acidic Omicron Spike Trimerhomo-3-mer14-1162
14×NAG;NAG; 30×NAG;
Assess
Structural and functional impact by SARS-CoV-2 Omicron spike mutationshomo-3-mer14-1162
11×NAG;NAG; 15×NAG; 25×NAG;
Assess
Structural and functional impact by SARS-CoV-2 Omicron spike mutationshomo-3-mer14-1162
NAG; 21×NAG;NAG; 21×NAG;
Assess
SARS-CoV-2 C.1.2 variant spike (Close state)homo-3-mer14-1162
NAG; 21×NAG;NAG; 24×NAG;
Assess
Structural impact on SARS-CoV-2 spike protein by D614G substitutionhomo-3-mer14-1162
30×NAG;NAG;NAG; 21×NAG;
Assess
Neutral Omicron Spike Trimerhomo-3-mer14-1162
16×NAG;NAG; 24×NAG;
Assess
One RBD-up 1 of pre-fusion SARS-CoV-2 Delta variant spike proteinhomo-3-mer14-1162
10×NAG; 16×NAG;NAG; 25×NAG;
Assess
Closed state of pre-fusion SARS-CoV-2 Kappa variant spike proteinhomo-3-mer14-1162
NAG; 27×NAG;NAG; 21×NAG;
Assess
Structural impact on SARS-CoV-2 spike protein by D614G substitutionhomo-3-mer14-1162
NAG; 21×NAG;NAG; 24×NAG;
Assess
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantshomo-3-mer14-1162
NAG; 21×NAG;NAG; 24×NAG;
Assess
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantshomo-3-mer14-1162
19×NAG;NAG;NAG; 29×NAG;
Assess
One RBD-up 2 of pre-fusion SARS-CoV-2 Delta variant spike proteinhomo-3-mer14-1162
10×NAG; 17×NAG;NAG; 24×NAG;
Assess
SARS-CoV-2 lambda variant spikehomo-3-mer14-1162
15×NAG; 15×NAG;NAG; 17×NAG;
Assess
Structural impact on SARS-CoV-2 spike protein by D614G substitutionhomo-3-mer14-1162
20×NAG;NAG;NAG; 28×NAG;
Assess
One RBD-up 1 of pre-fusion SARS-CoV-2 Gamma variant spike proteinhomo-3-mer14-1162
19×NAG;NAG;NAG; 29×NAG;
Assess
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variantshomo-3-mer14-1162
20×NAG;NAG;NAG; 28×NAG;
Assess
One RBD-up 1 of pre-fusion SARS-CoV-2 Kappa variant spike proteinhomo-3-mer14-1162
19×NAG;NAG; 11×NAG; 24×NAG;
Assess
One RBD-up 2 of pre-fusion SARS-CoV-2 Gamma variant spike proteinhomo-3-mer14-1162
17×NAG;NAG;NAG; 28×NAG;
Assess
One RBD-up 2 of pre-fusion SARS-CoV-2 Kappa variant spike proteinhomo-3-mer14-1162
19×NAG;NAG; 11×NAG; 24×NAG;
Assess
SARS-CoV-2 B.1.620 variant spike (close state)homo-3-mer14-1162
NAG; 21×NAG;NAG; 22×NAG;
Assess
SARS-COV-2 BETA VARIANT SPIKE PROTEIN IN TRANSITION STATEhomo-3-mer14-1162
Assess
SARS-CoV-2 C.1.2 variant spike (Open state)homo-3-mer14-1162
Assess
SARS-CoV-2 B.1.620 variant spike (open state)homo-3-mer14-1162
19×NAG;NAG;NAG; 26×NAG;
Assess
SARS-CoV-2 Mu variant spike (open state)homo-3-mer14-1162
20×NAG;NAG;NAG; 28×NAG;
Assess
SARS-CoV-2 Beta variant spike protein in open statehomo-3-mer14-1161
Assess
One RBD-up state of SARS-CoV-2 BA.2 variant spike proteinhomo-3-mer14-1160
18×NAG;NAG;NAG; 21×NAG;
Assess
Closed state of pre-fusion SARS-CoV-2 Delta variant spike proteinhomo-3-mer14-1160
27×NAG;NAG;NAG; 21×NAG;
Assess
BANAL-20-52 Spike trimerhomo-3-mer14-1150
24×NAG; 33×NAG;
Assess
Prototypic SARS-CoV-2 spike (containing V417) in the open conformationhomo-3-mer14-1149
NAG; 15×NAG;MAN;
Assess
Prototypic SARS-CoV-2 spike (containing K417) in the open conformationhomo-3-mer14-1149
NAG;MAN; 21×NAG;
Assess
Prototypic SARS-CoV-2 G614 spike (open form)homo-3-mer14-1149
NAG; 23×NAG;MAN;
Assess
Delta variant of SARS-CoV-2 Spike proteinhomo-3-mer14-1148
12×NAG; 35×NAG;
Assess
Delta Spike Trimer(1 RBD Up)homo-3-mer14-1148
13×NAG; 35×NAG;
Assess
Spike of SARS-CoV-2 spike protein(1 up)homo-3-mer14-1148
31×NAG;
Assess
Delta Spike Trimer(3 RBD Down)homo-3-mer14-1148
NAG; 39×NAG;
Assess
SARS-CoV-2 Kappa variant spike protein in transition statehomo-3-mer14-1148
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417T mutant spike protein ectodomainhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
Transition state of SARS-CoV-2 Delta variant spike proteinhomo-3-mer14-1147
Assess
SARS-CoV-2 (D614G) Spike trimerhomo-3-mer14-1147
34×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K mutant spike protein ectodomainhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Epsilon (B.1.429) spike proteinhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
SARS-Cov2 S protein at close statehomo-3-mer14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 Omicron spike proteinhomo-3-mer14-1147
18×NAG; 22×NAG;
Assess
SARS-Cov2 S protein at open statehomo-3-mer14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,L452R mutant spike protein ectodomainhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y mutant spike protein ectodomainhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G,N501Y,E484K,K417N mutant spike protein ectodomainhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
SARS-CoV-2 Omicron S-openhomo-3-mer14-1147
Assess
SARS-CoV-2 S trimer, S-closedhomo-3-mer14-1147
24×NAG; 30×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484A spike proteinhomo-3-mer14-1147
18×NAG; 20×NAG;
Assess
SARS-CoV-2 S trimer, S-openhomo-3-mer14-1147
Assess
Double deletion S-2P trimer(1 Up)homo-3-mer14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Gamma (P.1) spike proteinhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 D614G mutant spike protein ectodomainhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Beta (B.1.351) spike proteinhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
Double deletion S-2P trimer(3 down)homo-3-mer14-1147
Assess
Cryo-EM structure of the SARS-CoV-2 furin site mutant S-Trimer from a subunit vaccine candidatehomo-3-mer14-1147
39×NAG; 15×NAG;ELA;VCG;
Assess
Locked Wuhan SARS-CoV2 Prefusion Spike ectodomain with lipid boundhomo-3-mer14-1147
15×NAG; 36×NAG;STE;
Assess
SARS-CoV-2 Kappa variant spike protein in open statehomo-3-mer14-1147
Assess
SARS-CoV-2 Omicron S-openhomo-3-mer14-1147
Assess
SARS-CoV-2 Omicron S-open-2homo-3-mer14-1147
Assess
SARS-CoV-2 Omicron S-closehomo-3-mer14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike proteinhomo-3-mer14-1147
18×NAG; 20×NAG;
Assess
SARS-CoV-2-6P-Mut7 S protein (asymmetric)homo-3-mer14-1147
14×NAG; 34×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Alpha (B.1.1.7) spike proteinhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
Open state of SARS-CoV-2 Delta variant spike proteinhomo-3-mer14-1147
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike proteinhomo-3-mer14-1147
18×NAG; 19×NAG;
Assess
SARS-CoV-2 spike glycoprotein trimer in closed statehomo-3-mer14-1147
15×NAG; 33×NAG;EIC;BLR;
Assess
Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomainhomo-3-mer14-1147
18×NAG; 24×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 XBB.1.5 spike proteinhomo-3-mer14-1147
18×NAG; 20×NAG;
Assess
Spike/Nb2 complex with 1 RBD uphomo-3-mer14-1147
11×NAG; 23×NAG;
Assess
SARS-CoV-2-6P-Mut7 S protein (C3 symmetry)homo-3-mer14-1147
12×NAG; 30×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 wild-type S-Trimer from a subunit vaccine candidatehomo-3-mer14-1147
32×NAG; 19×NAG;ELA;
Assess
Furin Cleaved Spike Protein of SARS-CoV-2 in Intermediate Conformationhomo-3-mer14-1146
Assess
Trimeric SARS-CoV-2 spike ectodomain in complex with biliverdin (one RBD erect)homo-3-mer14-1146
25×NAG;BLA; 27×NAG;
Assess
Mink Variant SARS-CoV-2 Spike in Closed conformationhomo-3-mer14-1146
NAG;NAG; 39×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1), one RBD-up conformation 1homo-3-mer14-1146
34×NAG;NAG; 19×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), two RBD-up conformationhomo-3-mer14-1146
33×NAG; 15×NAG;
Assess
Structure of the SARS-CoV-2 A372T spike glycoprotein (open)homo-3-mer14-1146
35×NAG;
Assess
Furin Cleaved Spike Protein of SARS-CoV-2 in Closed Conformationhomo-3-mer14-1146
27×NAG; 24×NAG;
Assess
Structure of SARS-CoV-2 3Q-2P full-length prefusion spike trimer (C3 symmetry)homo-3-mer14-1146
45×NAG;NAG;VCG;EIC;
Assess
Mink Variant SARS-CoV-2 Spike with 2 Erect RBDshomo-3-mer14-1146
NAG; 30×NAG;
Assess
Open conformation of D614G SARS-CoV-2 spike with 1 Erect RBDhomo-3-mer14-1146
NAG;NAG; 33×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), one RBD-up conformation 2homo-3-mer14-1146
36×NAG; 12×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351), uncleavable form, two RBD-up conformationhomo-3-mer14-1146
30×NAG; 17×NAG;
Assess
Mink Variant SARS-CoV-2 Spike with 1 Erect RBDhomo-3-mer14-1146
NAG; 26×NAG;
Assess
Prototypic SARS-CoV-2 spike (containing V417) in the closed conformationhomo-3-mer14-1146
NAG; 19×NAG;
Assess
Open conformation of D614G SARS-CoV-2 spike with 2 Erect RBDshomo-3-mer14-1146
NAG; 31×NAG;
Assess
SARS-CoV-2 spike protein in complex with sybody no68 in a 1up/2down conformationhomo-3-mer14-1146
Assess
Trimeric SARS-CoV-2 spike ectodomain in complex with biliverdin (closed conformation)homo-3-mer14-1146
30×NAG;BLA; 24×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), two RBD-up conformation 2homo-3-mer14-1146
35×NAG; 13×NAG;
Assess
Prototypic SARS-CoV-2 spike (containing K417) in the closed conformationhomo-3-mer14-1146
NAG; 19×NAG;
Assess
Closed conformation of D614G SARS-CoV-2 spike proteinhomo-3-mer14-1146
15×NAG; 33×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 5homo-3-mer14-1146
33×NAG; 15×NAG;
Assess
Cryo-EM structure of apo SARS-CoV-2 Omicron spike protein (S-2P-GSAS)homo-3-mer15-1147
16×NAG; 21×NAG;
Assess
Prototypic SARS-CoV-2 G614 spike (closed form)homo-3-mer14-1146
NAG; 24×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1), one RBD-up conformation 2homo-3-mer14-1146
33×NAG;NAG; 20×NAG;
Assess
Structure of the SARS-CoV-2 A372T spike glycoprotein (closed)homo-3-mer14-1146
27×NAG; 24×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), all RBD-down conformationhomo-3-mer14-1146
NAG; 35×NAG; 12×NAG;
Assess
Uncleavable Spike Protein of SARS-CoV-2 in Closed Conformationhomo-3-mer14-1146
30×NAG; 21×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), all RBD-down conformationhomo-3-mer14-1146
34×NAG; 14×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 1homo-3-mer14-1146
35×NAG; 13×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 3homo-3-mer14-1146
36×NAG; 12×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Gamma variant (P.1), two RBD-up conformationhomo-3-mer14-1146
NAG; 31×NAG; 21×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), two RBD-up conformation 1homo-3-mer14-1146
35×NAG; 13×NAG;
Assess
Omicron spike at 3.0 A (open form)homo-3-mer14-1146
12×NAG; 21×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), two RBD-up conformation 3homo-3-mer14-1146
36×NAG; 12×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Kappa variant (B.1.617.1), one RBD-up conformation 1homo-3-mer14-1146
34×NAG; 14×NAG;
Assess
SARS-CoV-2 Delta variant spike proteinhomo-3-mer15-1147
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 4homo-3-mer14-1146
36×NAG; 12×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351), uncleavable form, one RBD-up conformationhomo-3-mer14-1146
31×NAG; 15×NAG;
Assess
SARS-CoV-2 Spike Glycoprotein with 2 RBDs Erecthomo-3-mer14-1146
Assess
S protein of SARS-CoV-2 in the locked conformationhomo-3-mer14-1146
11×NAG; 59×NAG;EIC;
Assess
Structure of Covid Spike variant deltaN25 with one erect RBDhomo-3-mer14-1146
38×NAG;
Assess
SARS-CoV-2-6P-Mut2 S proteinhomo-3-mer15-1147
18×NAG; 30×NAG;
Assess
Furin Cleaved Spike Protein of SARS-CoV-2 with One RBD Erecthomo-3-mer14-1146
Assess
Cryo-EM structure of SARS-CoV-2 S-Beta variant (B.1.351), Cleavable form, one RBD-up conformationhomo-3-mer14-1146
29×NAG; 17×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-Delta variant (B.1.617.2), one RBD-up conformation 2homo-3-mer14-1146
36×NAG; 12×NAG;
Assess
SARS-CoV-2 Delta variant spike proteinhomo-3-mer15-1147
Assess
SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations…homo-3-mer16-1147
NAG; 28×NAG;
Assess
SARS-CoV-2 Omicron-BA.2 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations…homo-3-mer16-1147
10×NAG; 30×NAG;
Assess
Cryo-EM structure of the spike of SARS-CoV-2 Omicron variant of concernhomo-3-mer14-1145
15×NAG; 29×NAG;
Assess
SARS-CoV-2 spike glycoprotein trimer in closed state after treatment with Cathepsin Lhomo-3-mer14-1145
15×NAG; 27×NAG;BLR;
Assess
SARS-CoV-2 S protein S:A222V + S:D614G mutant 1-uphomo-3-mer15-1146
10×NAG;NDG; 25×NAG;
Assess
SARS-CoV-2 S-protein:D614G mutant in 1-up conformationhomo-3-mer15-1146
10×NAG; 24×NAG;
Assess
SARS-CoV-2 S protein S:D614G mutant 1-uphomo-3-mer15-1146
10×NAG; 24×NAG;
Assess
SARS-CoV-2 S protein S:D614G mutant in 3-down with binding site of an entry inhibitorhomo-3-mer15-1146
10×NAG; 24×NAG;NA;XIO;
Assess
Structure of the Ancestral Scaffold Antigen-5 of Coronavirus Spike proteinhomo-3-mer16-1146
NAG; 39×NAG;
Assess
Structure of the Ancestral Scaffold Antigen-6 of Coronavirus Spike proteinhomo-3-mer16-1146
NAG; 45×NAG;
Assess
SARS-CoV-2 Omicron Variant SPIKE trimer, all RBDs downhomo-3-mer17-1147
NAG; 14×NAG;
Assess
Alpha Variant SARS-CoV-2 Spike with 2 Erect RBDshomo-3-mer16-1146
NAG; 37×NAG;
Assess
Cryo-EM structure of S glycoprotein encoded by the Covid-19 mRNA vaccine candidate RQ3013 (Prefusio…homo-3-mer16-1146
12×NAG; 21×NAG;
Assess
SARS-CoV-2 S Omicron Spike B.1.1.529homo-3-mer19-1147
NAG;NAG; 18×NAG;NAG; 14×NAG;
Assess
SARS-CoV-2 Omicron BA.2.13 variant spikehomo-3-mer22-1150
15×NAG; 27×NAG;
Assess
SARS-CoV-2 Omicron BA.2 variant spike (state 2)homo-3-mer22-1150
18×NAG; 30×NAG;
Assess
SARS-CoV-2 Omicron BA.4 variant spikehomo-3-mer22-1150
18×NAG; 30×NAG;
Assess
SARS-CoV-2 Omicron BA.2 variant spike (state 1)homo-3-mer22-1150
13×NAG; 30×NAG;
Assess
Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg…homo-3-mer14-1141
14×NAG; 38×NAG;EIC;BLA;
Assess
Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg…homo-3-mer14-1141
15×NAG; 39×NAG;BLA;EIC;
Assess
SARS-CoV-2 XBB 1.0 closed conformation.homo-3-mer19-1146
36×NAG;
Assess
Structure of SARS-CoV-2 Spike Protein Trimer (K986P, V987P, single Arg S1/S2 cleavage site) in Lock…homo-3-mer14-1141
15×NAG;BLA; 39×NAG;EIC;
Assess
Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg…homo-3-mer14-1141
13×NAG; 37×NAG;BLA;EIC;
Assess
Structure of SARS-CoV-2 D614G Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and sing…homo-3-mer14-1140
12×NAG; 39×NAG;BLA;EIC;
Assess
Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg…homo-3-mer14-1140
12×NAG; 36×NAG;BLA;EIC;
Assess
Beta Variant SARS-CoV-2 Spike with 1 Erect RBDhomo-3-mer20-1146
NAG; 28×NAG;
Assess
Structure of the SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 1)homo-3-mer14-1139
NAG; 31×NAG;
Assess
SARS-CoV-2 Spike, C3 symmetryhomo-3-mer14-1139
NAG;NAG; 36×NAG;EIC;
Assess
Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x1 disulphide-bond mutant, S383…homo-3-mer15-1140
12×NAG; 39×NAG;BLA;
Assess
SARS-CoV-2 Spike with ethylbenzamide-tri-iodo Siallyllactose, C3 symmetryhomo-3-mer14-1139
NAG;NAG; 36×NAG;GE9;SIA;EIC;
Assess
Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (RBDs down)homo-3-mer27-1152
12×NAG; 36×NAG;
Assess
Gaussian mixture model based single particle refinement - SARS (SARS-CoV-2 Spike Proteins on intact…homo-3-mer27-1151
15×NAG; 33×NAG;
Assess
SARS CoV-2 Spike protein, Closed conformation, C3 symmetryhomo-3-mer15-1139
NAG; 20×NAG;EIC;
Assess
Cryo-EM structure of SARS-CoV-2 Spike Proteins on intact virions: 3 Closed RBDshomo-3-mer27-1151
15×NAG; 33×NAG;
Assess
SARS CoV-2 Spike protein, Closed conformation, C1 symmetryhomo-3-mer15-1139
NAG; 25×NAG;EIC;
Assess
Cryo-EM structure of SARS-CoV-2 Delta variant spike proteins on intact virions: 3 Closed RBDhomo-3-mer27-1151
15×NAG; 33×NAG;
Assess
SARS-CoV-2 spike protein in one-RBD open statehomo-3-mer23-1146
Assess
Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-2 state)homo-3-mer16-1139
NAG; 36×NAG;
Assess
SARS-CoV-2 Omicron Spike trimerhomo-3-mer24-1147
28×NAG;
Assess
SARS-CoV-2 S (Spike Glycoprotein) D614G with One(1) RBD Uphomo-3-mer26-1149
NAG; 45×NAG;
Assess
SARS-CoV-2 spike protein in two-RBD weak state after CTSL-treatmenthomo-3-mer23-1146
Assess
Cryo-EM structure of bat RaTG13 spike glycoproteinhomo-3-mer14-1137
NAG; 36×NAG;
Assess
Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg…homo-3-mer17-1140
12×NAG; 39×NAG;BLA;
Assess
SARS-CoV-2 spike protein in one-RBD weak state after CTSL-treatmenthomo-3-mer23-1146
Assess
Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state)homo-3-mer16-1139
NAG; 36×NAG;
Assess
SARS-CoV-2 BA.2.75 S Trimer (1 RBD Up)homo-3-mer22-1144
NAG; 45×NAG;
Assess
pH 5.5 SARS-CoV-2 BA.2.75 S Trimer (1 RBD Up)homo-3-mer22-1144
NAG; 45×NAG;
Assess
Structure of Covid Spike variant deltaN135 in fully closed formhomo-3-mer24-1146
48×NAG;
Assess
Alpha Variant SARS-CoV-2 Spike in Closed conformationhomo-3-mer24-1146
NAG; 39×NAG;
Assess
Prefusion-stabilized SARS-CoV-2 spike proteinhomo-3-mer25-1147
Assess
Structure of Covid Spike variant deltaN135 with one erect RBDhomo-3-mer24-1146
48×NAG;
Assess
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibodyhomo-3-mer25-1147
15×NAG; 30×NAG;
Assess
SARS-CoV-2 BA.2.75 S Trimer (3 RBD Down)homo-3-mer22-1144
NAG; 36×NAG;
Assess
SARS-CoV-2 BA.2.75 S Trimer (3 RBD Down)homo-3-mer22-1144
NAG;NAG; 33×NAG;
Assess
SARS-CoV-2 spike in prefusion state (flexibility analysis, 1-up closed conformation)homo-3-mer27-1148
16×NAG;NAG;NAG; 18×NAG;MAN;DMS;
Assess
Cryo-EM structure of prefusion SARS-CoV-2 spike omicron B.1.1.529 varianthomo-3-mer26-1147
38×NAG;
Assess
SARS-CoV-2 spike in prefusion state (flexibility analysis, 1-up open conformation)homo-3-mer27-1148
16×NAG;NAG;NAG; 18×NAG;MAN;DMS;
Assess
SARS-CoV-2 Omicron BA.4 variant spikehomo-3-mer29-1150
18×NAG; 33×NAG;
Assess
Alpha Variant SARS-CoV-2 Spike with 1 Erect RBDhomo-3-mer25-1146
NAG;NAG; 33×NAG;
Assess
SARS-CoV-2 Omicron BA.3 variant spikehomo-3-mer29-1150
12×NAG; 23×NAG;
Assess
SARS-CoV-2 spike glycoprotein trimer in Intermediate statehomo-3-mer26-1147
NAG; 15×NAG;
Assess
Beta Variant SARS-CoV-2 Spike with 2 Erect RBDshomo-3-mer25-1146
NAG; 20×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; c…homo-3-mer27-1147
14×NAG; 33×NAG;
Assess
Cryo-EM structure of a prefusion stabilized SARS-CoV-2 Spike (D614N, R682S, R685G, A892P, A942P and…homo-3-mer27-1147
10×NAG; 10×NAG;
Assess
Structure of SARS-CoV-2 Spike Protein Trimer (single Arg S1/S2 cleavage site) in Closed Statehomo-3-mer27-1147
12×NAG; 36×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), one RBD-up conformation 3homo-3-mer27-1147
29×NAG;NAG; 16×NAG;
Assess
SARS-CoV-2 RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS)homo-3-mer27-1147
58×NAG;
Assess
Triple mutant (K417N-E484K-N501Y) SARS-CoV-2 spike protein in the 1-RBD-up conformation (S-GSAS-D61…homo-3-mer27-1147
12×NAG; 26×NAG;
Assess
Structure of SARS-CoV-2 spike at pH 5.5, all RBDs downhomo-3-mer27-1147
16×NAG; 26×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; con…homo-3-mer27-1147
12×NAG; 34×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S…homo-3-mer27-1147
14×NAG; 33×NAG;
Assess
SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-…homo-3-mer27-1147
12×NAG; 35×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), two RBD-up conformationhomo-3-mer27-1147
31×NAG; 16×NAG;
Assess
SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer fully cleaved by furin without the P986-P987 stabi…homo-3-mer27-1147
15×NAG; 33×NAG;
Assess
S1-S2 deletion S-2P trimer(3 down)homo-3-mer27-1147
Assess
SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA…homo-3-mer27-1147
15×NAG; 33×NAG;
Assess
SARS-CoV-2 Omicron 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA…homo-3-mer27-1147
15×NAG;NAG;NAG; 21×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub…homo-3-mer27-1147
12×NAG; 34×NAG;
Assess
UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformationhomo-3-mer27-1147
35×NAG;
Assess
Consensus structure of SARS-CoV-2 spike at pH 5.5homo-3-mer27-1147
14×NAG; 28×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S…homo-3-mer27-1147
14×NAG; 33×NAG;
Assess
SARS-CoV-2 spike ectodomain structure (open state)homo-3-mer27-1147
12×NAG; 35×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S…homo-3-mer27-1147
14×NAG; 32×NAG;
Assess
SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-…homo-3-mer27-1147
12×NAG; 34×NAG;
Assess
SARS-CoV-2 Omicron 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA…homo-3-mer27-1147
11×NAG;NAG; 14×NAG; 15×NAG;
Assess
SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer fully cleaved by furin without the P986-P987 stabili…homo-3-mer27-1147
12×NAG; 35×NAG;
Assess
SARS-CoV-2 rS2d Down State Spike Protein Trimerhomo-3-mer27-1147
Assess
UK (B.1.1.7) SARS-CoV-2 S-GSAS-D614G variant spike protein in the 3-RBD-down conformationhomo-3-mer27-1147
18×NAG; 27×NAG;
Assess
UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformationhomo-3-mer27-1147
NAG; 30×NAG;
Assess
Structure of the SARS-CoV-2 spike glycoprotein (closed state)homo-3-mer27-1147
15×NAG; 33×NAG;
Assess
UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up conformationhomo-3-mer27-1147
34×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub…homo-3-mer27-1147
12×NAG; 34×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub…homo-3-mer27-1147
12×NAG; 34×NAG;
Assess
Cryo-EM structure of a biotinylated SARS-CoV-2 spike probe in the prefusion state (1 RBD up)homo-3-mer27-1147
12×NAG; 35×NAG;
Assess
SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA…homo-3-mer27-1147
15×NAG; 33×NAG;
Assess
Down-state locked rS2d SARS-CoV-2 spike ectodomain in the RBD-down conformation, State 2homo-3-mer27-1147
Assess
SARS-CoV-2 u1S2q 1-RBD Up Spike Protein Trimerhomo-3-mer27-1147
Assess
SARS-CoV-2 D614G 1-RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-…homo-3-mer27-1147
12×NAG; 35×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub…homo-3-mer27-1147
12×NAG; 34×NAG;
Assess
South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformat…homo-3-mer27-1147
38×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Spike trimer S2D14 with two RBDs in the open conformationhomo-3-mer27-1147
NAG;NAG;NAG; 24×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Spike trimer S2D14 with two RBDs exposedhomo-3-mer27-1147
11×NAG;NAG; 32×NAG;
Assess
Cryo-EM structure of the SARS-CoV-2 spike glycoprotein in complex with all-trans retinoic acidhomo-3-mer27-1147
27×NAG;REA;
Assess
SARS-CoV-2 D614G 1-RBD-up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-…homo-3-mer27-1147
12×NAG; 33×NAG;
Assess
SARS-CoV-2 spike protein in closed statehomo-3-mer27-1147
Assess
SARS-CoV-2 Spike H655Y variant, One RBD Openhomo-3-mer27-1147
Assess
Structure of formaldehyde cross-linked SARS-CoV-2 S glycoproteinhomo-3-mer27-1147
15×NAG; 33×NAG;
Assess
Structure of the prefusion SARS-CoV-2 spike glycoproteinhomo-3-mer27-1147
11×NAG; 27×NAG;
Assess
SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA…homo-3-mer27-1147
15×NAG; 33×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 2-RBD-up conformation - D3homo-3-mer27-1147
NAG; 36×NAG;
Assess
SARS-CoV-2 u1S2q 2-RBD Up Spike Protein Trimerhomo-3-mer27-1147
Assess
South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformat…homo-3-mer27-1147
40×NAG;
Assess
Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 2homo-3-mer27-1147
18×NAG; 25×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Spike trimer S2D14 in the 3-RBD Down conformationhomo-3-mer27-1147
18×NAG; 15×NAG; 15×NAG;
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 2-RBD up conformationhomo-3-mer27-1147
31×NAG;
Assess
South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformat…homo-3-mer27-1147
28×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub…homo-3-mer27-1147
12×NAG; 34×NAG;
Assess
SARS-CoV-2 D614G 3 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA…homo-3-mer27-1147
15×NAG; 33×NAG;
Assess
Apo spike protein from SARS-CoV2homo-3-mer27-1147
Assess
Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), one RBD-up conformation 2homo-3-mer27-1147
29×NAG;NAG; 18×NAG;
Assess
SARS-CoV-2 RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS)homo-3-mer27-1147
15×NAG; 33×NAG;
Assess
SARS-CoV-2 u1S2q All Down RBD State Spike Protein Trimerhomo-3-mer27-1147
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub…homo-3-mer27-1147
12×NAG; 34×NAG;
Assess
Down-state locked rS2d SARS-CoV-2 spike ectodomain in the RBD-down conformation, State 1homo-3-mer27-1147
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformat…homo-3-mer27-1147
30×NAG;
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 1-RBD up conformationhomo-3-mer27-1147
NAG; 27×NAG;
Assess
South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 1-RBD-up conformat…homo-3-mer27-1147
38×NAG;
Assess
SARS-CoV-2 Spike Glycoprotein, prefusion with one RBD up conformationhomo-3-mer27-1147
12×NAG; 35×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 1-RBD-up conformation; Sub…homo-3-mer27-1147
12×NAG; 34×NAG;
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 1-RBD up conformationhomo-3-mer27-1147
NAG; 30×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S…homo-3-mer27-1147
14×NAG; 33×NAG;
Assess
SARS-CoV-2 spike glycoprotein trimer in open statehomo-3-mer27-1147
NAG; 15×NAG;
Assess
SARS-CoV-2 Omicron 1-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-G…homo-3-mer27-1147
NAG; 22×NAG;
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformat…homo-3-mer27-1147
30×NAG;
Assess
South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the RBD-down conformat…homo-3-mer27-1147
28×NAG;
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 1-RBD up conformationhomo-3-mer27-1147
NAG; 31×NAG;
Assess
South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the RBD-down conformat…homo-3-mer27-1147
33×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S…homo-3-mer27-1147
14×NAG; 33×NAG;
Assess
Delta (B.1.617.2) SARS-CoV-2 variant spike protein (S-GSAS-Delta) in the 3-RBD-down conformation; S…homo-3-mer27-1147
14×NAG; 33×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 S-UK variant (B.1.1.7), one RBD-up conformation 1homo-3-mer27-1147
32×NAG;NAG; 15×NAG;
Assess
Structure of SARS-CoV-2 spike at pH 5.5, single RBD up, conformation 1homo-3-mer27-1147
17×NAG; 26×NAG;
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformat…homo-3-mer27-1147
30×NAG;
Assess
SARS-CoV-2 D614G 3-RBD-down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSA…homo-3-mer27-1147
15×NAG; 33×NAG;
Assess
South African (B.1.351) SARS-CoV-2 spike protein variant (S-GSAS-B.1.351) in the 2-RBD-up conformat…homo-3-mer27-1147
25×NAG;
Assess
Mink Cluster 5-associated SARS-CoV-2 spike protein (S-GSAS-D614G-delFV) in the 3-RBD down conformat…homo-3-mer27-1147
30×NAG;
Assess
Cryo-EM structure of a prefusion stabilized SARS-CoV-2 Spike (D614N, R682S, R685G, A892P, A942P and…homo-3-mer27-1147
NAG; 15×NAG;
Assess
Down-state locked, S2 stabilized rS2d-HexaPro SARS-CoV-2 spike ectodomain in the RBD-down conformat…homo-3-mer27-1147
Assess
Structure of SARS-CoV-2 spike at pH 4.0homo-3-mer27-1147
15×NAG; 32×NAG;
Assess
SARS-CoV-2 Omicron 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-G…homo-3-mer27-1147
NAG;NAG; 26×NAG;
Assess
SARS-CoV-2 B.1.1.7 Spike Glycoprotein trimerhomo-3-mer27-1147
NAG; 23×NAG;
Assess
Structure of SARS-CoV-2 spike at pH 4.5homo-3-mer27-1147
17×NAG; 30×NAG;
Assess
SARS-CoV-2 D614G 1RBD up Spike Protein Trimer without the P986-P987 stabilizing mutations (S-GSAS-D…homo-3-mer27-1147
12×NAG; 35×NAG;
Assess
SARS-CoV-2 Omicron 3-RBD down Spike Protein Trimer without the P986-P987 stabilizing mutations (S-G…homo-3-mer27-1147
NAG;NAG;NAG;NAG; 25×NAG;
Assess
Cryo-EM structure of Brazil (P.1) SARS-CoV-2 spike glycoprotein variant in the prefusion state (1 R…homo-3-mer27-1147
11×NAG; 29×NAG;
Assess
SARS-CoV-2 u1S2q All Down RBD State Spike Protein Trimer - asymmetric refinementhomo-3-mer27-1147
Assess
Down-state locked, S2 stabilized rS2d-HexaPro SARS-CoV-2 spike ectodomain in the RBD-down conformat…homo-3-mer27-1147
Assess
Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic A…homo-3-mer27-1147
12×NAG; 33×NAG;
Assess
Triple mutant (K417N-E484K-N501Y) SARS-CoV-2 spike protein in the 3-RBD-Down conformation (S-GSAS-D…homo-3-mer27-1147
Assess
VAS5 Spike (3 RBD down)homo-3-mer27-1147
14×NAG; 29×NAG;
Assess
Trypsin-digested S protein of SARS-CoV-2 D614G mutanthomo-3-mer27-1146
22×NAG; 27×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Spike D614G variant, two RBD-up conformation 2homo-3-mer27-1146
27×NAG; 20×NAG;
Assess
Prefusion 2019-nCoV spike glycoprotein with a single receptor-binding domain uphomo-3-mer27-1146
17×NAG; 27×NAG;
Assess
S protein of SARS-CoV-2 bound with PD of ACE2 in the conformation 1 (1 up RBD and no PD bound)homo-3-mer27-1146
22×NAG; 27×NAG;
Assess
S protein of SARS-CoV-2 in the active conformationhomo-3-mer27-1146
22×NAG; 27×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Spike D614G variant, one RBD-up conformation 2homo-3-mer27-1146
NAG; 26×NAG; 19×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Spike D614G variant, two RBD-up conformation 1homo-3-mer27-1146
NAG; 28×NAG; 16×NAG;
Assess
SARS-CoV-2 HexaPro S One RBD uphomo-3-mer27-1146
11×NAG; 28×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Spike D614G variant, one RBD-up conformation 1homo-3-mer27-1146
NAG; 30×NAG; 16×NAG;
Assess
CryoEM structure of del68-76/del679-688 prefusion-stabilized spikehomo-3-mer27-1146
NAG; 28×NAG;
Assess
Trypsin-digested S protein of SARS-CoV-2homo-3-mer27-1146
22×NAG; 27×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Spike D614G variant, one RBD-up conformation 3homo-3-mer27-1146
NAG; 29×NAG; 18×NAG;
Assess
Cryo-EM structure of protein encoded by vaccine candidate BNT162b2homo-3-mer27-1146
Assess
S protein of SARS-CoV-2 D614G mutanthomo-3-mer27-1146
22×NAG; 27×NAG;
Assess
SARS-CoV-2 E406W mutant Spike ectodomainhomo-3-mer27-1145
NAG; 42×NAG;
Assess
Structure of SARS-CoV-2 S2P spike at pH 7.4 refolded by low-pH treatmenthomo-3-mer27-1144
14×NAG; 14×NAG;
Assess
Structure of freshly purified SARS-CoV-2 S2P spike at pH 7.4homo-3-mer27-1144
14×NAG; 14×NAG;
Assess
Structure of aged SARS-CoV-2 S2P spike at pH 7.4homo-3-mer27-1144
14×NAG; 13×NAG;
Assess
Structure of apo SARS-CoV-2 spike protein with one RBD uphomo-3-mer27-1144
13×NAG;
Assess
Complex structure of a small molecule (SPC-14) bound SARS-CoV-2 spike protein, closed statehomo-3-mer27-1144
Q83; 15×NAG;
Assess
Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x2 disulphide-bond mutant, G413…homo-3-mer27-1140
15×NAG; 33×NAG;
Assess
Cryo-EM structure of SARS-CoV-2 Spike ectodomainhomo-3-mer27-1140
NAG;NAG;NAG;NAG; 23×NAG;
Assess
Structure of SARS-CoV-2 Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and single Arg…homo-3-mer27-1140
NAG;BLA; 27×NAG;
Assess
Structure of SARS-CoV-2 D614G Spike Protein with Engineered x3 Disulfide (x3(D427C, V987C) and sing…homo-3-mer27-1140
NAG;BLA; 30×NAG;
Assess
Prefusion SARS-CoV-2 S ectodomain trimer covalently stabilized in the closed conformationhomo-3-mer27-1140
NAG; 33×NAG;
Assess
Structure of SARS-CoV-2 Spike Protein Trimer (K986P, V987P, single Arg S1/S2 cleavage site) in Clos…homo-3-mer27-1140
15×NAG; 33×NAG;
Assess
Structure of Disulphide-stabilized SARS-CoV-2 Spike Protein Trimer (x1 disulphide-bond mutant, S383…homo-3-mer27-1140
12×NAG; 36×NAG;
Assess
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutraliz…homo-3-mer27-1140
35×NAG;
Assess
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutraliz…homo-3-mer27-1140
NAG; 27×NAG;
Assess
SARS CoV-2 Spike protein, Bristol UK Deletion variant, Closed conformation, C1 symmetryhomo-3-mer27-1139
EIC; 30×NAG;
Assess
SARS CoV-2 Spike protein, Bristol UK Deletion variant, Closed conformation, C3 symmetryhomo-3-mer27-1139
EIC; 33×NAG;
Assess
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 2)homo-3-mer28-1139
NAG; 36×NAG;
Assess
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 1)homo-3-mer28-1139
NAG; 36×NAG;
Assess
SARS-CoV-2 Spike D614G variant, minus RBDhomo-3-mer27-1137
Assess
Cryo-EM structure of SARS-CoV-2 postfusion spike in membranehomo-3-mer695-1249
NAG;NAG;NAG;MAN;NAG;
Assess
Nanometer resolution in situ structure of SARS-CoV-2 post-fusion spikehomo-3-mer703-1234
NAG;NAG;NAG;
Assess
Distinct conformational states of SARS-CoV-2 spike proteinhomo-3-mer703-1197
NAG;NAG;NAG;NAG;MAN;
Assess
Cryo-EM structure of S glycoprotein encoded by the Covid-19 mRNA vaccine candidate RQ3013 (Postfusi…homo-3-mer703-1197
NAG;NAG;NAG;NAG;MAN;
Assess
Structure of the SARS-CoV-2 spike glycoprotein S2 subunithomo-3-mer705-1150
18×NAG;
Assess
Prefusion-stabilized SARS-CoV-2 S2 subunithomo-3-mer704-1140
Assess
Structure of post fusion core of SARS-CoV-2 S2 subunithomo-3-mer912-1180
Assess
Structure of post fusion core of 2019-nCoV S2 subunithomo-3-mer912-1031
PG4;ZN;
Assess
Crystal structure of post fusion core of 2019-nCoV S2 subunithomo-3-mer918-1032
Assess
Crystal Structure of SARS-CoV-2 HR1 motif in complex with pan-CoVs inhibitor EK1homo-3-mer911-975
Assess
SARS-CoV-2 spike Protein TM domainhomo-3-mer1217-1237
Assess
Crystal structure of the recombinant protein HR121 from the S2 protein of SARS-CoV-2homo-2-mer912-1180
Assess
Cryo-EM structure of S protein trimer of SARS-CoV2monomer27-1140
Assess
Crystal structure of SARS-CoV-2 spike protein N-terminal domain in complex with biliverdinmonomer14-311
BLA;NAG;PG4;PEG;PGE;1PE;
Assess
Cryo-EM structure of SARS-CoV-2 Omicron BA.2 spike protein (focused refinement of NTD)monomer14-293
NAG;NAG;
Assess
Local CryoEM structure del68-76/del679-688 prefusion-stabilized spikemonomer14-290
Assess
SARS-CoV-2 Omicron BA.3 variant spike (local)monomer323-589
NAG;
Assess
Crystal structure of SARS-CoV-2 S RBD in complex with a stapled peptidemonomer333-527
GOL;KZ0;
Assess
Crystal structure of the SARS-CoV-2 receptor binding domainmonomer333-527
NAG;NAG;FUC;GOL;
Assess
SARS-CoV-2 E406W mutant RBD - Local Refinementmonomer333-526
NAG;
Assess
Membrane bound structure of HR1 domain of SARS-CoV-2 spike proteinmonomer919-965
Assess
Fusion Peptide of SARS-CoV-2 Spike Rearranges into a Wedge Inserted in Bilayered Micellesmonomer816-857
Assess
NMR structure of a peptide deriving from SARS-CoV-2 S RBD 482-506 fragment in HFIP/H2Omonomer482-506
Assess
NMR structure of a peptide deriving from SARS-CoV-2 Lineage B.1.1.7 S RBD 482-506 fragment in HFIP/…monomer482-506
Assess
NMR structure of a peptide deriving from SARS-CoV-2 Lineages P.1 and B.1.351 S RBD 482-506 fragment…monomer482-506
Assess

3 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
7mjm.1 Heteromer
P0DTC2; Q9BYF1;
0.7714-1147
99.45
Assess
6xr8.1.Ahomo-3-mer0.7414-1162
NAG;NAG;NAG;NAG;100.00
Assess
7kj2.1 Heteromer
P0DTC2; Q9BYF1;
0.7227-1147
NAG; 10×NAG;99.67
Assess